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ABSTRACT
The experiments described in this thesis concern the
study, in rat and human blood vessels, of the production,
and basal and stimulated release of prostaglandins (PGs).
The PGs have potent effects on vascular smooth muscle and
may be involved in the control of blood flow and blood
pressure.
The profile of PG production in homogenates from blood
vessels of male and female rats has been characterised.
PGF2k and PGE2 were found to be produced in substantial
amounts in addition to the PG more usually measured,
PGI2. There was a difference in the profile of PG
production between male and female rats, with the aorta
from female rats producing significantly more PGF2K than
the aorta from male rats. Also, the basal output of
6-keto-PGFia was greater from the perfused aorta of male
than female rats. However, no difference was observed in
PG production by the aorta and vena cava of female rats
between Day 1 (oestrus) and Day 4 (prooestrus) of the
oestrous cycle. Also, short-term ovariectomy and 2 days
of oestrogen and progesterone treatment did not affect PG
production by the aorta and vena cava of treated compared
to control female rats.
PGs have been implicated in the control of vascular tone,
therefore PG production by homogenates of aorta and vena
cava from male and female New Zealand genetically
hypertensive (GH) rats was investigated. 6-keto-PGFlK and
PGE2 production by either blood vessel did not differ in
normotensive compared to GH male rats. However, PGF2K
production was significantly greater by the aorta of male
GH rats than of male normotensives. The smooth muscle
and endothelial cell layers of GH male rats were found to
produce significantly more PGF2CC than that of male
normotensives. The smooth muscle layer from male GH rats
also produced less 6-keto-PGF10C than controls. The
isolated, perfused aorta of male GH rats released
significantly greater amounts of PGF2K, but not of
6-keto-PGF4K or PGE2 than the aorta from normotensives.
The smooth muscle and endothelial cell layers of aorta
from female GH rats produced significantly less
6-keto-PGFla and PGF20C than those from normotensives.
Conversely, the release of all 3 PGs was greater from the
isolated, perfused aorta of GH females compared to
normotensives. Thus, male GH rats have an increased
capacity for the synthesis of the vasoconstrictor PG,
PGF2cc and show an increased release of PGF2CC from the
perfused aorta. Female GH rats however, have an increased
capacity for the synthesis of PGE2 and show an increase
in the release of 6-keto-PGF i a , PGF20C and PGE2 from the
perfused aorta.
PGs may modulate the act
noradrenaline (NA) and angio
the release of PGs after st
determined in the isolated,
bed from male and female,
male rats, NA caused a
ions of the pressor hormones
tensin II (All), therefore
imulation with NA and All was
perfused mesenteric arterial
normotensive and GH rats. In
significant increase in
6-keto-PGFiK release in GH and control rats. All caused a
significant increase in 6-keto-PGF10C release in
normotensive but not in GH rats. There was a greater
pressor response to both NA and All in the mesenteric bed
from GH rats suggesting that PGI2 alone is not
attenuating the response to NA. The absence of any
increase in PGI2 release after All may reflect a
deficiency in this proposed aspect of the control of
vascular tone in the GH male rat. In female normotensive
and GH rats only the higher dose of NA and All caused a
significant increase in PGI2 release, with no difference
observed in the pressor response between the two groups.
Blood pressure increases with age, consequently blood
vessel PG production was measured in aged male and female
rats, established to have higher blood pressures than
similar young rats. The amounts of 6—keto—PGF loc produced
by homogenates of smooth muscle were considerably greater
in old, compared to young male and female rats. However,
the basal output of 6-keto-PGFta from the perfused aorta
did not change significantly with age, but did tend to be
greater in old male and female rats. The production of
PGF2k by homogenates, and PGF20C output from perfused
aorta was significantly greater in old compared to young
rats. The responses to NA and All in the mesenteric bed
did not differ markedly between old and young rats.












subjects. 6-Keto-PGF 1<x production by homogenates of
saphenous vein was lower in male, but not female, smokers
and ex-smokers, although this was significant only for
ex-smokers. However, the basal outputs of PGs,
particularly 6-keto-PGF10C from the saphenous vein were
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1.1 An introduction to prostaglandin biochemistry
1.1.1 Historical
In 1966, the first prostaglandin (PG) symposium was held
in Stockholm. There were 76 participants and 35 papers
were read over 2 days. In his opening address, von Euler
said " we have indeed in prostaglandin a unique
hormone its scope of action is still wider,
however, and it may well be that the prostaglandins
represent a group of compounds which are involved in a
variety of actions ranging from effects on the central
nervous system to intricate metabolic actions, thus
justifying their very special chemical configuration".
This prophetic statement was easily fulfilled within 10
years, culminating in 1982 with the presentation of the
Nobel Prize for Medicine to two of the founding fathers
of the PG field, Bengt Samuelsson and Sune Bergstrom, and
one of its most respected workers, John Vane. The
predicted scope of action and impact of arachidonic acid
metabolites on all areas of biology is evident from a
consideration of the proceedings of the sixth
international prostaglandin conference held in Florence
in 1986.
1.1.2 Prostaglandins and their origin
PGs are a group of structurally related compounds
implicated in the majority of vital physiological
processes such as blood-pressure regulation, haemostasis,
inflammation, immune regulation and reproduction. They
are produced by almost every cell in the body, with the
exception of the red blood cell, and because PGE2 and
PGF2k are metabolised during one passage through the
lungs they most closely resemble autocoids, or local
hormones. PGI2 and PGD2, however, are not metabolised to
any great extent by the lung and therefore are
potentially able to act as circulating hormones
(Armstrong, Lattimer, Moncada and Vane, 1978).
Structurally, PGs are derivatives of the hypothetical
compound prostanoic acid, which is characterised by 20
carbon (C) atoms, arranged in a cyclopentane ring with
two side chains, one of which is terminated by a carboxyl
group the other by a methyl group. Thus PGs are 20-C
cyclic fatty acids and depending on the structure of the
cyclopentane ring are divided into families indicated by
the letters A-I. Each family consists of a 1-, 2- and 3-
series depending on the number of double bonds in the
side chains. PGIt cannot be produced biosynthetically and
consequently must lack a physiological role.
Before any further discussion of PGs and their many
actions in the body is possible, it is neccessary to
consider the ultimate origins and biosynthesis of these
compounds. Dietary fats consist mainly of fatty acids
esterified to glycerol. For a long time fats have been
considered solely as a source of energy but this way of
thinking has changed completely since the structural and
metabolic functions of fatty acids have been recognised,
in particular their role as PG precursors. The majority
of fatty acids consist of an aliphatic chain of C- atoms
with a terminal carboxyl group. In some fatty acids not
all free C-bonds are saturated with hydrogen (H) atoms,
resulting in a double bond between two adjacent C-atoms
(HC=CH); these are called unsaturated fatty acids.
Polyunsaturated fatty acids (PUFAs) contain two or more
double bonds, normally in the cis configuration.
Starting mainly from stearic acid (18:0) the body can
produce a considerable number of long-chain PUFAs by the
alternating action of a desaturase enzyme complex and an
elongase enzyme system. These are liver microsomal enzyme
complexes allowing the introduction of double bonds into
fatty acid molecules. They require reduced pyridine
nucleotide and molecular oxygen. They act only on
activated fatty acids (acyl-CoA) according to the
following reaction.
R, - CH2 - CH2 - R2 - CoA + NAD(P)H + H+ + 02
Rj - CH = CH - R2 - CoA + NAD (P)+ + 2H20
Endogenously formed PUFAs are members of the n-9 or n-7
families and since the introduction of double bonds and
chain length addition occur at the carboxyl end of the
fatty acid molecule there can be no interconversions
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between the n-9 and n-7, and the n-3 and the n-6 families
of fatty acids (although these interconversions occur
readily in plants).
1.1.3 Essential fatty acid precursors
Saturated fatty acids and PUFAs of the n-9 and n-7
families are, on their own, insufficient to maintain
normal life in mammals. In 1929, Burr and Burr observed
that rats fed a rigidly fat-free diet, developed severe
deficiency symptoms and ultimately died. This deficiency
syndrome could be cured only by the administration of
oils containing PUFAs of the n-3 and n-6 families.
Similar results have been obtained in a variety of
species including man. Mammals have an absolute
requirement for n-3 and n-6 fatty acids because they lack
^12 and ^15 desaturases (present in plants) and therefore
depend on dietary intake for these fatty acids, now
termed essential fatty acids (EFAs).
In general, the EFAs are all cis C-20 unsaturated fatty
acids with 3, 4 or 5 double bonds interrupted by
methylene groups. Fatty acids are usually designated as
a:b(n-c), where a is the total number of C-atoms, b is
the number of double bonds and c is the position of the
first double bond from the terminal methyl group. Three
EFAs, dihomo-gamma-1inolenic acid (DHLA) 20:3(n-6) ;
arachidonic acid (AA), 20:4(n-6) and eicosapentaenoic
acid (EPA), 20:5(n-3) are classical substrates for the
biosynthesis of PGs of the 1, 2 and 3 series
respectively, as shown in Fig. 1.1. These EFAs are
obtained from the meat and fish constituents of the diet.
In animal tissues, these PG precursors can also be
derived from linoleic acid (18:2(n-6)) and
gamma-linolenic acid (18:3(n-6)) commonly found in the
seeds and leaves of plants. First 18:2(n-6) is
desaturated to 18:3(n-6) (also found in rare plant oils
such as evening primrose oil), then 18:3(n-6) is rapidly
chain elongated to 20:3(n-6) probably explaining why
18:3(n-6) is virtually undetectable in animal tissues.
20:3(n-6) is then avidly taken up into membrane and other
phospholipid pools where it may then be liberated to
serve as substrate for the synthesis of PGs. In most
species including man, tissue phospholipid content of
20:3(n-6) is one third to one fiftieth that of
arachidonic acid (20:4(n-6)) and since 20:4(n-6) and
20:3(n-£) are the precursors of the 2-series PGs and the
1-series PGs respectively, this probably explains why PGs
of the 2- series predominate over PGs of the 1-series
(Willis, 1981).
1.1.4 Structural lipids
Under normal circumstances, tissue free fatty acid levels
are found at very small concentrations. Most fatty acids
are present as triglycerides acting as a general reserve
in adipose tissue or as membrane phospholipids performing
a structural, or a metabolic function by providing PG
precursors. Phospholipids have a glycerol backbone












-»■Eicosafetraenoic 20:4(n-3) Eicosapentaenoic 20:5(n-3)
and 2 positions are found hydrocarbon groups; at the 2
position largely a PUFA and at the 1 position generally a
saturated fatty acid. The phosphoric acid groups form
diesters with choline, ethanolamine, serine or inositol.
For practical purposes sphyngomyelin is also considered
as a phospholipid although it is in fact a sphyngosine
derivative containing one amide-linked (mainly saturated
or monounsaturated) long-chain fatty acid and a
phosphorylcholine group attached to the terminal hydroxyl
group of sphyngosine. Phospholipids can be hydrolysed by
specific enzymes, phospholipase A,, A2, C or D, so-called
depending on their site of action.
1.1.5 An historical coincidence
At about the same time as Burr and Burr discovered the
essentiality of certain of the PUFAs, Kuzrok and Lieb
(1930), who were studying artificial insemination, found
that human semen produced both relaxation and potent
contraction of the isolated human uterine strip. Later,
Goldblatt (1933) and von Euler (1934) independently found
that human seminal plasma and sheep seminal vesicle
contain a potent lipid substance with smooth
muscle-stimulating and vasodepressor activity, and which
von Euler termed "prostaglandin" in the mistaken belief
that it came from the prostate gland. Thereafter little
definitive information on PGs was obtained until
Bergstroin and associates (Bergstrom and Sjovall, 1957;
Bergstrom, Eliasson, von Euler and Sjovall, 1959)
isolated and synthesised pure PGs. As greater quantities
of pure PGs became available considerable progress was
made towards elucidating the pharmacodynamic and
biochemical action of each PG. Quite separately,
information on the EFAs increased and it was only when
the striking similarity in the molecular shapes of AA and
PGE2 was noted that it was discovered that PGs are
synthesised from EFAs (Van Dorp, Beerthuis, Nugteren and
Vonkeman, 1964; Bergstrom, Danielsson and Samuelsson,
1964).
1.2 PG synthesis
1.2.1 Source of precursor fatty acids.
PGs are not stored in cells but must be synthesised
immediately prior to their release (Piper and Vane,
1971). The precursor fatty acids must be in a
non-esterified form and are therefore not immediately
available for PG synthesis but must be released from an
intracellular lipid pool. The possible sources of
precursor fatty acids are mono-, di- or tri-glycerides,
cholesterol esters or phospholipids. Triglyceride fatty
acids, particularly in adipose tissue, can be released by
the action of a triglyceride lipase (Boyer, LePetit and
Giudicelli, 1970) and in the ovary where there is a high
concentration of cholesterol arachidonate, cholesterol
esterase activity can be stimulated by luteinising
hormone resulting in PG synthesis (Kuehl, 1974).
1.2.2 Phospholipases
The phospholipid fraction appears to be the major source
of PG precursor fatty acids and most of the work on
precursor release has concentrated on these lipids. The
hydrolytic enzymes responsible for cleaving fatty acids
are known as phospholipases. Phospholipases A, and A2
(PLAt and PLA2) release the fatty acids esterified in
positions 1 and 2, respectively of the phospholipid
molecule and phospholipase C hydrolyses the
glyceryl-phosphate bond to liberate a phosphorylated base
and a diglyceride. Phospholipase D is found mainly in
plants and removes the base from the phospholipid to give
phosphatidic acid (Fig. 1.2). As an unsaturated fatty
acid is generally esterified in the 2 position of the
phospholipid molecule, PLA2 is an important enzyme in the
regulation of PG synthesis. A phosphatidylinositol
specific phospholipase C (in combination with a
diglyceride lipase) may be one of the pathways
responsible for AA release in response to platelet
stimulation (Bell, Kennerly, Stanford and Majerus, 1979;
Rittenhouse-Simmons, 1980).
1.2.3 Stimulus inhibition and turnover
A number of diverse stimuli, including mechanical
stimulation, distension and tissue damage will initiate
PG production via stimulation of phospholipases.
Hormonal and other stimuli including antigen challenge,
thrombin and collagen cause AA release from phospholipids































Fig. 1.2 Structure of phospholipid molecule. Rj and R2 fatty acid
residues; R^-alcohol group. C and D - site of
action of respective phospholipases.
particularly PLA2 , provide the first possible target for
controlling PG synthesis. Indeed, compounds such as
mepacrine and chlorpromazine inhibit PLA2 by forming
complexes with phospholipids and preventing enzymic
attack (Lullmann and Wehling, 1979). Polyamines such as
putrescine and spermidine bind to the lipid surface of
micelles and produce an identical effect to
chlorpromazine. The activity of PLA2 is dependent on
Ca2+, thus depriving the enzyme of Ca2+ is a very
effective means of inhibition. It has been postulated
that the calcium-binding protein calmodulin may be
involved in phospholipase activation. Purified PLA2 from
snake venom, in the presence of Ca2+ was found to be
stimulated by calmodulin (Moskowitz, Shapiro, Schook and
Puszkin, 1983). In cultured porcine aortic endothelial
cells, the stimulation of PGI2 synthesis by bradykinin
and the calcium ionophore A23187 was inhibited by TMB-8,
an antagonist of intracellular calcium mobilisation, by
the calcium channel blocker, methoxyverapami1, and by the
calmodulin antagonists, W7 and trifluoperazine (Whorton,
Willis, Kent and Young, 1984; Seid, MacNeil and
Tomlinson, 1983). Calmodulin was found to stimulate the
conversion of AA to TXB2 in platelets and interestingly,
was also found to inhibit the action of bovine lung
15-hydroxyprostaglandin dehydrogenase on 3H-PGE2 (Wong,
1981). Glucocorticoids have been known to interfere with
PG generation for a number of years. These drugs have
been found to act by inhibition of PLA2 activity thus
preventing the release of AA from membrane phospholipids
(Gryglewski, Panczenko, Korbut, Grodzinska and
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Ocetkiewicz, 1975; Hong and Levine, 1976; Blackwell,
Flower, Nijkamp and Vane, 1978). Glucocorticoids have no
direct effect on PLA2 but appear to act by induction of
proteins that possess anti-phospholipase properties
(Danon and Assouline, 1978; Flower and Blackwell, 1979).
A protein called macrocortin, with a molecular weight of
1500 daltons has been isolated from guinea-pig lungs and
rat peritoneal macrophages and may be present in a
pre-formed store in some cells. Rabbit neutrophils
produce another protein, lipomodulin, (40000 daltons)
which appears not to be stored and probably has to be
synthesised de novo (Hirata et al, 1981; Blackwell,
Carnuccio, Di Rosa, Flower, Langham, Parente, Persico,
Russell-Smith and Stone, 1982). These inhibitory proteins
are probably formed from the same precursor, and are now
called lipocortins.
1.2.4 The cyclooxygenase pathway.
The next step in the synthesis of PGs is the insertion of
molecular oxygen into AA. This reaction is catalysed by
the enzyme cyclooxygenase (CO) and results in the
formation of the PG endoperoxide, PGG2 which is
immediately converted by a peroxidase to PGH2, with a
sufficient amount of PGG2 remaining at steady state to
fully activate the CO under most conditions. The
importance of hydroperoxides in PG biosynthesis was
appreciated from early studies showing a decreased
synthesis of PGs in the presence of glutathione and
glutathione peroxidase (Lands, Lee and Smith, 1971).
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Thus, in an autocatalytic reaction the CO activity forms
the activating hydroperoxide, PGG2. The work of Lands
and colleagues (Lands, 1984) suggests that the
self-limiting nature of the CO-catalysed reaction is due
to enzyme self-inactivation rather than product
inhibition. PGH2 has a very short half-life because it
is converted by various membrane bound enzymes into the
different PGs and thromboxanes, a series of compounds
characterised by an oxane instead of a cyclopentane ring.
The activities of the different PG synthetases show
quantitative differences in various tissues resulting in
a different profile of products depending on which tissue
is considered. The profile of possible AA products,
usually known as the AA cascade is shown in Figure 1.3. A
PGH2-PGE2 isomerase enzyme has been isolated (Ogino,
Miyamoto, Yamamoto and Hayaishi, 1977) and very recently
an enzyme catalysing the reduction of 9,11-endoperoxide
PGH2 to PGF20t has been isolated from bovine lung
(Watanabe, Yoshida, Shimizu and Hayaishi, 1985). The
production of PGF20C was previously believed to be largely
a non-enzymic process. An enzyme, 9-keto-prostaglandin
reductase, catalysing the reduction of PGE2 to PGF2a has
been identified (Lands, 1979) and an enzyme,
9-hydroxyprostaglandin dehydrogenase, catalysing the
reverse reaction has also been found (Pace-Asciak, 1975).
The enzymes for the synthesis of TXA2 and PGI2,
thromboxane synthetase and prostacyclin synthetase have
been well characterised. The primary PGs, E and F are
relatively stable and PGE t and PGF1(X were isolated in














field. However, the introduction of a modification of
bioassay methods, the superfusion system, by Ferriera and
Vane in 1967 was neccessary for the detection and
subsequent characterisation of the labile and
biologically active metabolites of arachidonic acid, such
as TXA2 and PGI2• The PG endoperoxides, PGG2 and PGH2
were shown to induce platelet aggregation through the
action of PGH2 itself and also by its conversion to an
unstable vasoconstrictor substance identified as TXA2
(Hamberg and Samuelsson, 1974; Hamberg, Svensson and
Samuelsson, 1975). However, TXA2 was first described by
Piper and Vane (1969) when they detected the release of
an unstable substance, that contracted rabbit aorta, from
sensitised guinea-pig lung challenged with antigen. This
substance was called rabbit aorta contracting substance
(RCS) and as its release was inhibited by indomethacin it
was considered to be an arachidonic acid metabolite. It
was later established that most of the activity of RCS
could be ascribed to TXA2. TXA2 has a half-life at body
pH and temperature of 30 seconds. The enzyme which
synthesises TXA2 from PG endoperoxides, thromboxane
synthetase, was identified in the high-speed particulate
fraction of human and horse platelets and has since been
studied in some detail in human and bovine platelets
(White and Glassman, 1976; Sun, 1977). TXA2 is hydrolysed
rapidly to TXB2 which is considerably more stable than
the parent compound and is the index of TXA2 production
most frequently measured. Prostacyclin, or PGI2 was
discovered in a similar manner to TXA2 when the
generation of an unstable substance with potent
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anti-aggregatory properties was described in blood vessel
microsomes stimulated with PGH2 (Moncada, Gryglewski,
Bunting and Vane, 1976). PGI2 has a half-life of 2-3
minutes at body temperature and pH, becoming hydrolysed
to 6-keto-PGF lcc, a stable product.
1.2.5 The lipoxygenase pathway.
Another possible pathway from arachidonic acid is the
lipoxygenase pathway producing hydroxy fatty acids from
platelets, leukocytes and mast cells (Nugteren, 1975;
Borgeat, Hamberg and Samuelsson, 1976) and leukotrienes,
products with three conjugated double bonds and the major
metabolites of AA in rabbit polymorphonuclear leukocytes
(p.m.n.) (Borgeat and Samuelsson, 1979). In platelets, a
hydroperoxy compound, 12 - hydroperoxy-5, 8, 10, 14-
eicosatetraenoic acid (12-HPETE) is formed which
is then converted to the hydroxy compound (12-HETE)
Additional platelet lipoxygenase products are formed but
their biological functions are not yet known.
Leukotrienes are formed from arachidonic acid by the
5-1ipoxygenase pathway (Fig. 1.3). They have been found
in lung tissue where they act as potent
bronchoconstrictors and are thought to be involved in
asthma and other hypersensitivity reactions (Walker,
1980; Hamberg, 1976). Leukotriene C has been identified
as the smooth muscle contracting substance, first
described by Feldberg and Kellaway (1938) and called
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"slow reacting substance of anaphylaxis" (SRS-A),
(Samuelsson, Borgeat, Hamraarstrom and Murphy, 1980).
Leukotriene B4 is a potent chemotactic factor for human
peripheral p.m.n. and rat peritoneal p.in.n. It is
generated and released by various inflammatory cells
after both physiological and pharmacological stimuli in
vitro. LTB4 is present in vivo, associated with acute,
neutrophi1-rich inflammatory lesions and it may be
associated with certain pathological inflammatory states
(for review see Bray, 1983).
1.2.6 PGs and cyclic nucleotides
Some effects of PGs are mediated through changes in the
intracellular level of adenosine-3'-5'-monophosphate
(cAMP), following binding of the PG to specific receptors
at the surface of the target cells (Miller and Gorman,
1979). PGI2 is a potent stimulator of platelet cAMP,
considerably more potent than PGKj and also stimulates
adenylate cyclase in isolated platelet membrane
preparations (Gorman, Bunting and Miller, 1977). PGI2
increases cAMP levels in cells other than platelets,
including cultured human fibroblasts (Gorman, Hamilton
and Hopkins, 1979) and guinea-pig lung homogenates
(MacDermot, Barnes, 1980). PGI2 and PGs of the E series
have also been reported to increase intracellular cAMP
levels in arterial smooth muscle in a dose-related manner
by specific activation of adenylate cyclase (Beatty,
Bocek and Young, 1973; Dembinska-Kiec, Rucker and
Schonhofer, 1980). PGI2 and PGs of the E series are
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potent vasodilators in most vascular beds and relax the
majority of vascular preparations in vitro (Vane, Bunting
and Moncada, 1982). Increases in the intracellular
levels of cyclic GMP (cGMP) or in the ratio of cGMP to
cAMP have been associated with PGF2K-induced contraction
of smooth muscle from dog lobar pulmonary and lateral
saphenous veins (Kadowitz, Joiner, Hyman and George,
1975). Although the precise role for cGMP in smooth
muscle contraction by PGs is not clear, there is evidence
that unsaturated fatty acid peroxides contract smooth
muscle concurrent with increased levels of cGMP (Gruetter
and Ignarro, 1979; Asano and Hikada, 1979). Moreover,
bradykinin-induced contractions of blood vessels were
shown to be associated with increased levels of cGMP
(Clyman, Sandler, Manganiello and Vaughan, 1975).
Bradykinin may induce vasoconstriction in isolated bovine
mesenteric veins by causing the accumulation of cGMP,
which has been shown to increase the activity of
9-keto-prostaglandin-reductase, thus promoting the
formation of PGF20C from PGE2 (Wong, McGiff and Terragno,
1977). From these findings it is possible to formulate
the hypothesis that increased levels of cGMP are
associated with constriction of blood vessels, and that
the biological activities of the F series are related to
the guanylate cyclase system. This is in contrast to the
vasodilator actions of PGs of the E and I series which
are related to the adenylate cyclase system.
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1.2.7 Inhibition of cyclooxygenase
Vane (1971) and Smith and Willis (1971), independently
and simultaneously reported that aspirin and indomethacin
could inhibit PG synthesis in cell-free homogenates of
lung tissue and human platelets, respectively. Vane
(1971) showed that this effect was directly on the
enzymatic conversion of AA to PGs. This observation led
to an adequate explanation for the mode of action of such
drugs in reducing inflammation, fever, hyperalgesia and
platelet aggregation. This group of agents, the
non-steroidal anti-inflammatory (NSAID) drugs provided a
powerful research tool for the study of PGs. Several
classes of inhibitor have now been identified (for review
see Flower, 1974). Three types of inhibition are
recognised; reversible competitive, reversible and
irreversible non-competitive (Lands, 1981). Examples of
reversible competitive inhibitors are fatty acids,
closely related to the substrate with a comparable
affinity, but not converted to oxygenated products. The
precursor of the 3 series of PGs, EPA (20:5 (n-3)) is a
poor substrate for CO and exerts an aspirin-like
inhibitory effect on platelets (Needleman, Wyche, Le Due,
Sankarappe, Jakschik and Sprecher, 1981). The
anti-inflammatory drug, ibuprofen, shows a similar
binding for CO as AA (Rome and Lands, 1975). Aspirin
covalently acetylates a lysine residue in the active site
of the CO enzyme (Roth, Stanford and Majerus, 1975).
Aspirin therefore inhibits the enzyme in platelets for
the lifespan of these cells as platelets are unable to
synthesise new protein (Steiner, 1970). Inhibition of
vascular CO may persist for a much shorter period as new
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enzyme may be generated. Also, the CO of human skin
fibroblasts, arterial smooth muscle cells and human aorta
appear to be less sensitive to inhibition by aspirin than
human platelets (Baenzinger, Dillender and Majerus, 1977;
Burch, Baenzinger, Stanford and Majerus, 1978).
1.3 Metabolism
1.3.1 General PG metabolism
There is no appreciable storage of PGs in tissues and the
level of any PG released by a tissue will depend on a
balance between synthesis and catabolism. Several enzyme
systems which metabolise PGs have been isolated from
different tissue preparations in vitro. The enzyme
15-prostaglandin hydroxydehydrogenase (15-PGHD) catalyses
the oxidation of PGs at C-15 and is found in highest
concentrations in lung, spleen and kidney (Larsson and
Anggard, 1970) where it converts PGs to the 15-keto
compound. Prostaglandin 13,14-reductase catalyses
reduction of the 13 double bond of PGs and is found in
highest concentrations in liver, spleen, small intestine
and kidney although fairly high concentrations are found
elsewhere in the body (Larsson and Anggard, 1970). PGs
are also metabolised by ^-oxidation of the carboxylic
acid side chain and this has been demonstrated in rat
liver mitochondria (Hamberg, 1968) and in homogenates of
rat liver and kidney (Nakano and Morsy, 1971).
oxidation results in the formation of dinor- and
tetranor-derivatives of PGs. Enzymes catalysing
/^oxidation of the PG side chain are found in human
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seminal plasma (Hamberg and Samuelsson, 1966) and
guinea-pig and human liver microsomes (Israelsson,
Hamberg and Samuelsson, 1969). Although thse early
studies were carried out on the classical PGs more recent
studies have shown that similar metabolic pathways exist
for PGI2 . Namely that in rat, rabbit and monkey PGI2 is
metabolised via the 15-PGHD pathway to give the inactive
or weakly active metabolites, 15-keto-PGI2,
6,15-diketo-PGF1K and 13 ,14-dihydro-6, 15-diketo-PGF loc.
PGI2 is also metabolised by ^-oxidation and
13,14-reductase pathways (Sun, Taylor, McGuire, Wong,
Malik and McGiff, 1979). Similarly, in the cat an
injection of PGI2 resulted in a prominent peak of
13 ,14-dihydro-6,15-diketo-PGF loc in plasma suggesting that
metabolism is via the 15-PGHD, 13,14-reductase pathway
(Machleidt, Foerstermann, Henning and Hertting, 1981).
1.3.2 Synthesis and metabolism of PGs by blood vessels
The enzyme 15-prostaglandin hydroxydehydrogenase
(15-PGHD) is responsible for the catabolism of PGE2 and
PGF2oc and has been shown to be present in both arteries
and veins (Wong and McGiff, 1977). PGI2 can be
metabolised by the 15-PGHD of bovine mesenteric arteries
and veins, veins being more active than arteries, and is
converted to 6,15 di-keto-PGF loc (Wong, Sun and McGiff,
1978). In these tissues, 6,15 di-keto-PGF loc was the only
product recovered, probably reflecting the low levels of
13,14-reductase present.
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I-3.3 Profile of PG metabolites in plasma and urine
In order to determine the possible physiological or
pathological roles of PGs in humans and other species it
is neccessary to have a reliable index of the production
of each PG in either plasma or urine. For many years the
13,14, dihydro-15-keto PGs have been considered to be the
optimal PG parameters in peripheral plasma. In the human,
however, it was shown that after i.v. injection of [3H]
labelled PGF20C, the pattern of metabolites appearing with
time in the circulation began to resemble the metabolic
profile of products in the urine (Granstrom, Kindahl and
Swahn, 1982). The major compound measured, the
II-ketotetranor metabolite, appeared to be present in the
circulation for several hours, considerably longer than
the 13,14, dihydro-15-keto metabolite. In a further
study, Granstrom and Kindahl (1982) established that
although the initial PGF20C metabolite in cattle, rat and
guinea-pig was 13,14, dihydro-15-keto PGF20(, the
11-ketotetranor product was the dominant plasma
metabolite, whereas highly polar dicarboxylic acids
dominated the metabolic profile in sheep and rabbit
circulation. Five urinary metabolites of prostacyclin
were identified by gas chromatography-mass spectrometry
(GC-MS) in humans; the major compounds being the dinor
metabolites of 6-keto-PGF loc (Rosencranz, Fischer, Weimer
and Frolich, 1980). A later study by Brash and co-workers
showed that 82% of an administered dose of radio-labelled
PGI2 could be recovered in the urine and, in contrast to
other species, only 4% in faeces. A number of metabolites
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were identified by GC-MS, all retaining the 6-keto-PGF 10c
structure and 6-keto-PGFla itself accounted for 6% of the
administered dose (Brash, Jackson, Saggese, Lawson, Oates
and Fitzgerald, 1983).
1.3.4 A metabolite of PGI2 with biological activity,
6-keto-PGE t.
In the last few years a considerable amount of interest
has been shown in the synthesis and biological activity
of 6-keto-PGE i, a novel metabolite of PGI2. 6-keto-PGEt
was identified as a metabolite of PGI2 in the Tyrode's
perfused rabbit liver and its in vitro conversion from
PGI2 was demonstrated in cell-free homogenates of rabbit
liver (Wong, Malik, Desiderio, McGiff and Sun, 1980;
Wong, Lee, Quilley and McGiff, 1981). 6-keto-PGE4 can be
generated from PGI2 or its hydrolysis product,
6-keto-PGFlK by the action of 9-hydroxyprostaglandin
dehydrogenase, an enzyme detected some years previously
in rat kidney where it converts PGF2K to PGE2
(Pace-Asciak, 1975). 6-Keto-PGE! is produced by human
platelets (Hoult, Lofts and Moore, 1981) and inhibits
platelet aggregation in man and other species although
its potency relative to PGI2 varies from one study to the
next. Originally reported as being equally as potent as
PGI2 (Wong, McGiff, Sun and Lee, 1979) other studies have
shown it to be from 5 to 20 times less potent than the
parent PG in inhibiting platelet aggregation (Lofts and
Moore, 1982; Miller, Aiken, Shebuski and Gorman, 1980).
Like PGI2, 6-keto-PGE! appears to have identical
- 24 -
vasodepressor activity in rat or dog following either
intravenous or intraarterial injection (Quilley, Wong and
McGiff, 1979; Van Dam, Fitzpatrick, Friedman, Ramwell,
Rose and Kot, 1981) suggesting that it also escapes
pulmonary degradation in vivo. 6-keto-PGEt has potent
effects on the cardiovascular system and is vasodepressor
in all species studied, but again its potency relative to
PGI2 varies from one species to another and from one
study to another. Its effect on blood pressure has been
established in rat, rabbit, dog and cat and it is likely
that this effect is on a number of vascular beds (Quilley
et al., 1979; Van Dam et al., 1981; Hyman and Kadowitz,
1981). The discrepancies in potency of 6-keto-PGEi may
reflect genuine species differences or perhaps a
difference in the half life of 6-keto-PGE4 in the
circulation compared to PGI2. The formation of
6-keto-PGE , from PGI2 may be an important determinant of
the actions of PGI2 in vivo and may explain some of the
discrepancies between the in vitro and in vivo actions of
PGI2; the apparently longer half-life of PGI2 in plasma
may be due to the greater stability of 6-keto-PGEt at
physiological pH. However, the possibility of 6-keto-PGEj
contributing to the actions of PGI2 in man seems unlikely
because studies of the metabolic disposition of PGI2 have
failed to detect metabolites with the 6-keto-PGE
structure, and infusion of synthetic PGI2 in volunteers
does not result in accumulation of 6-keto-PGEj in plasma
(Brash et al., 1983; Jackson, Goodman, Fitzgerald, Oates
and Branch, 1982).
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1.4 Platelet / vessel wall interaction
1.4.1 Vascular actions of the PGs
PGE2 and PGF20C have been shown to be produced by bovine
aorta, mesenteric arteries and veins (Terragno, Crowshaw,
Terragno and McGiff, 1975) and by bovine pulmonary artery
and mesenteric artery of foetal and maternal origin
(Terragno, McGiff, Smigel and Terragno, 1978). However,
since the discovery of PGI2 production by rabbit aorta
microsomes (Moncada, Gryglewski, Bunting and Vane, 1976),
PGI2 has been presumed to be the major PG produced by
blood vessels and the other PGs have been either ignored
or assigned relatively minor roles in blood vessel
function. There is evidence that in certain blood
vessels, namely foetal ductus arteriosus, PGI2 is not the
principal product of AA metabolism (Terragno, Terragno,
McGiff and Rodriguez, 1977) and in the microcirculation
of the heart and brain, the major products of AA
metabolism have been reported to be PGE2 and PGD2
respectively (Gerritzen and Printz, 1981). As mentioned
above one of the first known actions of a PG was the
potent vasodepressor effect of von Euler's lipid extract.
Similar to vasoactive peptides and biogenic amines, PGs
show considerable species and tissue differences in their
pharmacological responses. It is well-established that
PGs of the E-series are powerful vasodilators in many
species of mammal, whereas PGF20C is a moderately potent
vasoconstrictor and/or pressor substance in dogs, rats
and monkeys (Pike, Kupiecki and Weeks, 1967; Nakano and
McCurdy, 1968; Du Charme, Weeks and Montgomery, 1968;
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Weeks, Sekhar and Du Charme, 1969) but a vasodepressor in
cats and rabbits (Anggard and Bergstrom, 1963; Horton and
Main, 1963). PGI2 is vasodepressor in dogs, rats and
rabbits (Armstrong, Chappie, Dusting, Hughes, Moncada and
Vane, 1977) and is considerably more potent than PGE2.
PGI2 is a strong vasodilator in the mesenteric, hind-limb
and pulmonary circulations of the dog (Dusting, Moncada
and Vane, 1978; Kadowitz, Chapnick, Feigen, Hyman, Nelson
and Spannhake, 1978).
1.4.2 PGs as circulating hormones.
These early studies on the systemic cardiovascular
actions of PGs have provided the fundamental basis for
the suggestion that these biologically active substances
could be important in the regulation of blood pressure
and blood flow. However, the investigations into the
pulmonary metabolism of PGs by Vane and colleagues has
neccessitated the modification of this hypothesis.
Studies of the metabolism of PGs in the pulmonary
circulation in vivo, showed that almost all of an
infusion of PGE , , PGE2 or PGF20C was inactivated in one
passage through the lungs (Ferriera and Vane, 1967;
Piper, Vane and Wyllie, 1970), but PGA, and PGA2 survived
passage through dog lung without being metabolised
(McGiff, Terragno, Strand, Lee, Ng, 1969). The
inactivation process for PGs was therefore very
selective. Also, because the criterion for a circulating
hormone required that a substance had to pass unchanged
or even enhanced through the pulmonary circulation e.g.
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angiotensin, (Ng and Vane, 1967) it was apparent that
PGE J , PGE2 and PGF20C could not be acting as circulating
hormones. However, because PGA2 was not destroyed by the
lungs and a PGA compound was found to dilate blood
vessels, lowering blood pressure and promoting salt and
water excretion, it was suggested that PGA2 could be the
circulating renal anti-hypertensive substance
counteracting those forces elevating blood pressure (Lee,
McGiff, Kannegeisser, Aykent, Mudd, and Frawley, 1971).
Using RIA, Zusman, Caldwell, Speroff and Behrman (1972)
concluded that levels of PGA2 in the plasma of normal man
were greater than 1 ng/ml but other studies using
mass-spectrometry, capable of detecting as little as 5
pg/ml of PGA2, were unable to substantiate the presence
of PGA2 in plasma (Granstrom and Samuelsson, 1978). The
material in plasma which cross-reacted with
PGA-antibodies probably arose from non-enzymic
degradation of PGE2 during storage and sample
preparation.
1.4.3 Is PGI2 a circulating vasodepressor hormone?
Bioassay experiments suggested that PGI2 produced by the
lung acted as a circulating platelet inhibitory factor
and a vasodepressor agent in rabbits and cats (Moncada,
Korbut, Bunting and Vane, 1978; Gryglewski, Korbut,
Ocetkiewcz, 1978). Using gas chromatography-mass
spectrometry (GC-MS) measurements of plasma 6-keto-PGF loc
concentrations were made in patients undergoing cardiac
catheterisation, the results suggesting that PGI2 was
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released from the lungs at a rate of 5ng/kg/min (Hensby,
Barnes, Dollery and Dargie, 1979), strongly suggesting a
role for PGI2 as a circulating hormone in man. However,
in another study by Fitzgerald, Brash, Falardeau and
Oates (1981), the rate of PGI2 secretion into the
circulation was estimated by measurement (GC-MS) of 2
urinary metabolites of PGI2 and was found to be
approximately 0.1 ng/kg/min. Another study using GC-MS
found that plasma levels of 6-keto-PGFla were less than 3
pg/ml (Blair, Barrow, Waddell, Lewis and Dollery, 1982).
Similarly, neither human peripheral plasma, whole blood
nor blood drawn directly from the heart contained any
detectable PGI2 (<20 pg/ml) as measured by gas
chromatography with electron-capture detection of the
pentaf luorobenzyl derivative of 6-keto-PGF loc
(Christ-Hazelhof and Nugteren, 1981). Generally, RIA
gives elevated levels of PGs compared with levels
measured by GC-MS due to cross-reactions but two studies
using RIA found systemic arterial and venous plasma
levels of 6-keto-PGF loc of < 50 pg/ml and approx. 7 pg/ml
respectively (Bdlund, Bonifin, Kaijser, Olin, Patrono,
Pinca and Wennmalm, 1981; Forder and Carey, 1982)
agreeing with the findings from GC-MS. Using a different
approach, Steer, Maclntyre, Levine and Salzman (1980)
established that addition of PGI2 binding antibodies to
platelet rich plasma (PRP) shortly after blood collection
had no effect on platelet aggregation, and concluded that
the circulating concentration of PGI2 in humans was below
that required for inhibition of aggregation. Pace-Asciak,
Carrara and Levine (1981), using rats found that although
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PGI2 specific antibodies could sequester an administered
dose of PGI2, resting arterial blood pressure in
normotensive and hypertensive rats was not significantly
altered by anti-PGI2 antibodies. Thus the evidence to
date strongly suggests that PGI2 is not acting as a
circulating anti-platelet factor or as a circulating
vasodepressor agent.
1.4.4 Platelet PGs and thromboxanes.
Kloeze (1967) showed that PGs had powerful effects on
platelet aggregation in vitro; PGEt being strongly
inhibitory whereas PGE2 was slightly stimulatory. Later
studies showed that PGD2 and PGI2 were potent
antiaggregants. Smith and Willis (1970) demonstrated that
stimulated platelets produce PGs themselves, in
particular PGE2. However, exogenous PGE2 did not induce
the platelet release reaction and aggregation, therefore
a short-lived intermediate of AA conversion into PGE2 was
proposed. Indeed, two intermediates were found, the
cyclic endoperoxides PGG2 and PGH2. Although the
endoperoxides were able to aggregate platelets these
studies suggested the presence of a highly unstable,
potent endoperoxide derivative, which was confirmed in
later studies and named thromboxane A2 (Hamberg et al.,
1975). The major effect of TXA2 is the induction of
platelet aggregation which can occur independently of the
platelet release reaction (Kinlough-Rathbone, Reimers,
Mustard and Packham, 1976; Meyers, Seachord, Holmsen,
Smith and Prieur, 1979). TXA2 is also a potent
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vasoconstrictor and is probably involved in primary
haemostasis (Mestel, Oetliker, Beck, Felix, Imback and
Wagner, 1980).
1.4.5 Vascular PG synthesis
PGI2 was first discovered in blood vessels (Moncada et
al., 1976) and although it appears to be the major
product of AA metabolism in vascular tissues, PGE2 and
PGF2oc are also produced by rabbit blood vessels and by
porcine endothelial cells in culture (Foerstermann,
Hertting and Neufang, 1984; Boeynams and Galand, 1983;
Ody, Seillan, Russo-Marie and Duval, 1983). TXA2 is
produced in small amounts by human umbilical artery, by
the pulmonary artery of the rabbit and by slices of
piglet aorta and vena cava, although it is possible that
TXA2 is being produced by platelets contaminating these
tissues. (Tuvemo,Strandberg, Hamberg and Samuelsson,
1976; Salzman, Salmon and Moncada, 1980; Siess, Dray,
Seillan, Ody and Russo-Marie, 1981). However, TXA2 has
also been shown to be produced by vascular endothelial
cells in culture (Ingerman, Aharony, Silver, Smith,
Nissenbaum, Sedar and Macarak, 1980; Goldsmith and
Needleman, 1982).
The actions of PGI2 are largely the converse of TXA2 in
that it causes vasodilation, inhibits platelet
aggregation and adhesion and stimulates platelet
adenylate cyclase resulting in a marked increase in cAMP
levels. The striking opposite effects of TXA2 and PGI2 on
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platelet aggregation and blood vessel tone led to the
hypothesis that a balance between the two compounds would
regulate platelet aggregability and therefore determine
arterial thrombosis tendency (Moncada and Vane, 1976).
This hypothesis requires that vascular PGI2 is able to
reach the platelets and the initial studies on the
possibility of PGI2 as a circulating hormone seemed to
validate this hypothesis.
1.4.6 Role of the endothelium in PGI2 generation
The ability of the aorta to synthesise PGI2 from
exogenous PGH2 is greatest at the endothelium and
decreases progressively towards the adventitia (Moncada,
Herman, Higgs and Vane, 1977). Studies using cultured
vascular cells have also shown that endothelial cells are
the most active producers of PGI2 with smooth muscle
cells in culture producing mainly PGE2, although smooth
muscle cells from rabbits and humans have been found to
produce PGI2 (Weksler, Marcus and Jaffe, 1977; Maclntyre,
Pearson and Gordon, 1978; Ody and Duval, 1983; Siess et
al., 1981; Larrue, Dorian, Demond-Henri and Bricaud,
1981; Baenzinger, Becherer and Majerus, 1979). Arteries
appear to have a greater capacity for PG synthesis than
veins as shown in rats and dogs (Skidgel and Printz,
1978; Eldor, Hoover, Pett, Gay, Alonso and Weksler,
1981). Cultured cells from human pulmonary arteries also
produced greater amounts of PGI2 than those from
pulmonary veins, although this finding was not
substantiated using fresh human arteries and veins
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(Johnson, 1980; Moncada, Higgs and Vane, 1977). The
possible importance of endothelial PGI2 generation can be
appreciated from studies where the endothelial cell layer
has been removed. Following balloon de-endothelialisation
of rabbit aorta the aortic surface was 87% covered by
platelets. Infusion of PGI2 completely inhibited platelet
aggregation and reduced surface coverage by 84% (Adelman,
Stemerman, Mennell and Handin, 1981). Tschopp and
Baumgartner (1981) studied the effect of removing the
aortic endothelium of different species and found that
the degree of adhesion and aggregation of platelets to
the sub-endothelium correlated negatively with the
generation of PGI2 in vitro by aortic segments of rat,
rabbit and guinea-pig. PGI2 synthetic capacity (from
exogenous AA) was assayed at the surface of
de-endothelialised rabbit aorta and was found to increase
with time after injury, the increase in PGI2 production
correlating with the formation of a neointima (Eldor,
Falcone, Hajjar, Minick and Weksler, 1981).
De-endothelialisation of a small area of a branch of rat
mesenteric artery, and subsequent superfusion with ADP,
induced the formation of a thrombus which was markedly
enhanced by the prostacyclin synthetase inhibitor,
tranylcypromine (Bourgain, Andries, Biagi and Finne,
1981).
1.4.7 Endoperoxide steal hypothesis
Studies have shown that fresh vascular tissue can use
both AA and PG endoperoxides for PGI2 synthesis but that
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the endoperoxides are the better substrate (Bunting,
Gryglewski, Moncada and Vane, 1976). Also, vascular cells
or endothelial cells treated with indomethacin incubated
in platelet-rich plasma could generate a substance with
PGI2-like activity (Bunting et al., 1976; Gryglewski,
Bunting, Moncada, Flower and Vane, 1976). From these
studies it was concluded that the vessel wall is able to
synthesise PGI2 not only from endogenous precursors but
also from PG endoperoxides released by platelets,
implying that vessel wall PGI2 synthesis may limit the
extent of platelet reactions. Moncada and Vane (1978)
proposed that this biochemical interaction between
platelets and the vessel wall would continually prevent
arterial thrombosis.
The hypothesis was challenged by several authors
Needleman, Bronson, Wyche, Sivakoff and Nicolaou,
(1978) showed that arachidonic acid was rapidly
converted to PGI2 by perfused rabbit heart and kidneys
but that PGH2 was not readily converted. Similarly,
Hornstra, Haddeman and Don (1979) failed to find a
significant difference in PGI2 production of rat aorta
incubated in platelet-rich (PRP) or platelet-poor plasma
(PPP). Indomethacin-treated tissue did not produce any
detectable amounts of PGI2. However, it has been shown
that when the platelet number is similar to normal blood
levels, feeding of endoperoxides to endothelial cells
suspended in platelet-rich plasma does occur (Marcus,
Broekman, Weksler, Jaffe, Safier, Ullman and
Tack-Goldman, 1981), although the relevance of such in
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vitro experiments to in vivo events could be questioned.
Of interest is the demonstration by Schafer, Crawford and
Gimbrone (1984) that endoperoxides from uninhibited
platelets were efficiently utilised by aspirin-pretreated
bovine aortic endothelial cells for the formation of
6-keto-PGF,K, but that there was no evidence for the
reverse transfer of endoperoxides from endothelial cells
to platelets. More recent experiments have indicated an
area in which "endoperoxide steal" could be of
importance. Using selective thromboxane synthetase
inhibitors several workers have shown a reduction in TXB2
concentrations with concomitant increases in PGE2 and
PGF20C (Smith and Gubiz, 1981), and PGI2 concentrations
(Randall, Parry, Hawkeswood, Cross, and Dickinson, 1981;
Defryn, Deckmyn and Vermylen, 1982). More significantly,
administration of thromboxane synthetase inhibitors to
rats caused the redirection of PG production from TXB2 to
PGI2 in an in vivo model when platelets were stimulated
with collagen (Maguire and Wallis, 1984). Therefore the
antithrombotic potential of thromboxane synthetase
inhibitors is two-fold, reduction of TXB2 production and
the enhancement of vascular PGI2 production.
As mentioned previously, it now seems unlikely that PGI2
functions as a circulating hormone, and the phenomenon of
agonist-specific desensitization of PGs on platelet
adenylate cyclase would also preclude PGI2 acting in the
general circulation to prevent platelet aggregation
(Miller and Gorman, 1979). However, it seems likely that
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PGI2 acts locally in the vasculature particularly where
there is damage to the endothelium and therefore where
there is platelet activation, thus limiting the extent of
platelet aggregation. It is possible that in this
situation platelet endoperoxides might provide an
additional substrate for endothelial PGI2 formation.
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1.4.8 Aspirin as an antithrombotic agent
Early in vitro studies suggested that platelet CO was
more sensitive to aspirin than that of vascular tissue
and that, because of new enzyme synthesis by endothelium,
vascular PGI2 synthesis was restored more quickly than
platelet TXA2 synthesis (Burch et al., 1978; Jaffe and
Weksler, 1979). Aspirin, therefore has the potential of
being a valuable anti-thrombotic agent. However, segments
of human vein incubated in vitro after patients had taken
aspirin in vivo were inhibited from producing PGI2 for at
least 48 hr after doses of greater than 40 mg aspirin.
TXA2 production by platelets was inhibited 75% by a 40 mg
dose of aspirin, additional doses producing a cumulative
inhibitory effect on TXA2 production (Weksler, Pett,
Alonso, Richter, Stelzer, Subramanian, Tack-Goldman and
Gay, 1983; Preston, Greaves and Stoddard, 1982).
Recently, it has been shown that repeated very low doses
of aspirin (20 mg daily for 1 week) inhibit platelet
TXA2 formation by 93% and vascular PGI2 production by
50%, indicating that there is also a cumulative effect of
repeated small doses of aspirin (Weksler, Tack-Goldman,
Karwande, Gay, 1983). These findings suggest that PG
production by human vascular tissue is very sensitive to
inhibition by conventional, fairly low doses of aspirin.
Patrignani, Filabozzi and Patrono (1982) showed that 0.45
mg/kg per day of aspirin inhibited TXA2 production by
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platelets by >95% without any effect on urinary
6-keto-PGF loc levels. Similarly, doses of aspirin of <160
mg/day were found to totally inhibit the urinary
excretion of TXB2 metabolites, while PGI2 metabolites
persisted at 25-40% of uninhibited values (Fitzgerald,
Oates, Hawiger, Maas, Roberts, Lawson and Brash, 1983).
These excretion studies are difficult to interpret as the
precise origin of urinary PGs is not certain; an
alternative interpretation of these findings could be
that renal PG synthesis recovers more quickly from
aspirin inhibition than vascular tissue from other sites.
The clinical trials on the efficacy of aspirin in the
prevention of myocardial infarctions and stroke have all
been carried out using doses of 0.3 g/day or greater
(lg/day as average). When the results of six randomised
trials of aspirin in men who had survived a myocardial
infarction were pooled, it appeared that aspirin was of
modest benefit, reducing deaths by 16% and recurrent
infarction by 21% (Prescott and Majerus, 1983). It now
seems possible that similar results could be obtained
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1.5 Factors stimulating vascular PGI2 production
1.5.1 Plasma factors
In 1978, Maclntyre, Pearson and Gordon observed that pig
aortic endothelial cells were stimulated to produce PGI2
by a factor present in cell free plasma. Similarly, a
serum factor derived from human PRP or PPP stimulated
6-keto-PGFJK release from rat aortic rings (Ritter,
Orchard and Lewis, 1982). The stimulatory activity was
heat-stable and was not inhibited by cycloheximide
suggesting that its mechanism of action is not dependent
on de novo protein synthesis. Seid, Jones and Russell
(1983) established that both human plasma and serum could
stimulate 6-keto-PGFjK production by porcine aortic
endothelial cells and that serum caused a significantly
greater stimulation than plasma from the same individual.
The supernatants from platelets stimulated with collagen
also stimulated endothelial cell 6-keto-PGF 10c production.
It is likely therefore that the plasma and serum
stimulatory factor is derived from platelets.
1.5.2 ATP and ADP stimulation of PGI2 production
Extracellular ATP is a potent vasoactive agent
(Burnstock, 1981) requiring the presence of endothelial
cells to exert its vasodilator effects (De Mey and
Vanhoutte, 1981). Prostaglandins are released in
biologically active concentrations from vascular beds
perfused with ATP (Needleman, Minkes and Douglas, 1974)
and it has since been shown that ATP and ADP dose
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dependently stimulate the release of PGI2 from cultured
endothelial cell layers at concentrations (0.2-10.0 Jim)
that cause platelet aggregation, and which are reached in
whole blood when platelets are activated (Pearson, Slakey
and Gordon, 1983; Van Coevorden and Boeynaems, 1984;
Ingerman-Wojenski, Smith and Silver, 1983).
Extracellular ADP and ATP also stimulated the release of
6-keto-PGFja from rings of rat and rabbit aorta and rings
of rabbit pulmonary artery (Boeynams and Galand, 1983).
1.5.3 Thrombin stimulation of PGI2 production
Thrombin was found to stimulate the release of PGI2 into
the medium of human umbilical vein endothelial cells and
bovine smooth muscle cells in culture (Weksler, Ley and
Jaffe, 1978; Dejana, Balconi, Castellarnau, Barbieri,
Vergara-Dauden and De Gaetano, 1983). However, although
thrombin caused an endothelium-dependent relaxation of
canine femoral artery rings, the relaxation was not
affected by aspirin, indomethacin or the prostacyclin
synthetase inhibitor, tranylcypromine (De Mey and
Vanhoutte, 1981). Therefore the endothelium-dependent
relaxation of canine femoral artery induced by thrombin
is not mediated by PGI2. In addition, the importance of
the site of origin of endothelial cells used in these
studies has been stressed. Goldsmith and Kisker (1982)
demonstrated that in contrast to superfused umbilical
veins where thrombin produced a 10-fold stimulation in
the stimulation of 6-keto-PGFi^, sheep aortic vascular
segments failed to release 6-keto-PGFxa in response to
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thrombin. Therefore, the demonstration that thrombin
induces the release of PGI2 from umbilical vein
endothelial cells may not be representative of the
responses of other parts of the vasculature. The
production of thrombin at a site of vascular injury
could, by stimulating PGI2 synthesis by endothelial cells
adjacent to the injured area limit the extent of the
platelet response and help to localise thrombus
formation.
1.5.4 Angiotensin stimulation of PGI2 production
Several authors have described a stimulatory effect of
the potent vasoactive agent, angiotensin II (All) on the
release of PG-like material either in vivo or in perfused
organs (McGiff, Crowshaw, Terragno and Lonigro, 1970;
Dusting, Mullins and Nolan, 1981). Grodzinska and
Gryglewski (1980) showed that All perfused through rabbit
mesenteric artery and guinea-pig lungs induced the
release of prostacyclin and that this effect was mediated
through All receptors. Nolan, Dusting and Martin (1981),
found that the release of PGI2 in response to All in the
isolated rat mesenteric bed was reduced by dexamethasone
and mepacrine, compounds both reported to inhibit
phospholipase A2. Stimulation of PGE-like material by
All has also been reported for human umbilical vein
endothelial cells in culture (Gimbrone and Alexander,
1975), although a later study was unable to demonstrate
any effect of All on PG formation in human umbilical
artery or vein endothelial cells (Alhenc-Gelas, Tsai,
Callahan, Campbell and Johnson, 1982).
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1.5.5 Bradykinin stimulation of PGI2 production
Bradykinin is a potent vasodilator and hypotensive agent
although it has opposing effects on arteries and veins,
dilating arteries and constricting veins (Bobbin and
Guth, 1968). Its activity may be mediated, at least in
part, by PGs. Early studies demonstrated that bradykinin
could induce the release of PGs (specifically PGE2 and
PGI2) from isolated, perfused rabbit kidneys, hearts and
mesenteric blood vessels, and in vivo, from the rabbit
ear artery (Isakson, Raz, Denny, Wyche and Needleman,
1977; Blumberg, Denny, Marshall and Needleman, 1977;
Simmet and Herting, 1980; Sametz and Juan, 1982). In the
anaesthetised dog, PGI2 release induced by bradykinin was
mainly of renal origin. The sustained hypotensive effect
of bradykinin was reduced after inhibition of PG
synthesis with indomethacin, suggesting that PGI2
released in response to bradykinin was involved in the
blood pressure response (Mullane and Moncada, 1980).
However, the venoconstrictor action of bradykinin may
depend on the capacity of the vein to increase its
production of PGF2<X, as shown by abolition of the
bradykinin-induced contraction of bovine mesenteric vein
after indomethacin treatment (Wong, Terragno, Terragno
and McGiff, 1977). Later studies have established that
bradykinin can stimulate the release of [3H] AA from
labelled porcine aortic endothelial cells in culture
(Whorton, Young, Data, Barchowsky and Kent, 1982), and
can stimulate the release of PGI2 from endogenous AA in
these cells (Pearson, Carleton and Hutchings, 1983).
Bradykinin selectively stimulated the release of
6-keto-PGF!K from human umbilical vein endothelial cells
in culture without significantly affecting the release of
PGE2 , PGF2a or TXB2 ; but bradykinin stimulated the
release of both 6—keto—PGF 10c and PGE2 from umbilical
artery endothelial cells (Alhenc-Gelas et al., 1982) In
addition, bradykinin enhanced the release of PGE2 (as
well as PGI2) in pulmonary artery. The release of PGI2
from bovine pulmonary artery endothelial cells stimulated
by bradykinin was abolished by the Ca2+ chelator, EGTA,
by the slow calcium channel antagonists, verapamil and
nifedipine and by the calmodulin inhibitor,
trifluoperazine, suggesting that bradykinin mediates its
effects on PGI2 formation by activation of a
phospholipase via a Ca2+-calmodulin dependent pathway
(Crutchley, Ryan, Ryan and Fisher, 1983).
1.5.6 Histamine stimulation of PGI2 production
An injection of histamine into the isolated perfused
rabbit ear dose-dependently stimulated the release of
PGE2 and PGI2. In arteries pre-labelled with [14C] AA
histamine stimulated the release of radioactive AA and
increased the release of PGI, , PGE2 , PGF20C and PGD2 . The
Ht receptor antagonist mepyramine abolished the
histamine-stimulated release of PGs (Juan and Sametz,
1980). Histamine also stimulated PGI2 formation in
cultured human umbilical vein endothelial cells
(Baenzinger, Force and Becherer, 1980) but did not have a
significant effect on venous and arterial smooth muscle
cells or skin fibroblasts (Baenzinger, Fogerty, Mertz and
Chernuta, 1981). Another study by Alhenc-Gelas, Tsai,
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Callaghan, Campbell and Johnson (1982) has shown that
human arterial and venous umbilical endothelial cells in
culture synthesise PGF2K and PGE2 as well as PGI2 and
that histamine stimulates not only PGI2 release but also
PGF20C and PGE2 release from venous cells. The release of
PGs induced by histamine was inhibited by the Hj receptor
antagonist, pyrilamine but not by the H2 receptor
antagonist, cimetidine.
1.6 Other factors influencing vascular PG production
1.6.1 Nutritional factors
If a deficiency of vasodilatory PGs initiates or
aggravates hypertension, then inhibition of PG production
by dietary deprivation of precursor fatty acids should
result in elevated blood pressure. The importance of the
availability of PG precursors such as linoleic acid can
be appreciated from several studies. Dyerberg and
co-workers (Dyerberg, Bang, Stofferson, Moncada and Vane,
1978) were the first to suggest that the low incidence of
coronary heart disease among Eskimos may be due, at least
in part, to their high intake of EPA leading to an
anti-thrombotic state in which an active PGI3 and an
inactive TXA3 are formed. Thus EPA could act in two ways
to reduce platelet aggregability; it competes with AA for
platelet cyclooxygenase but is itself a poor substrate
for the enzyme, reducing TXA2 formation; TXA3 formed is
not aggregatory (Fischer and Weber, 1983). PGI3 (
417-PGI2), has been synthesised from PGH3 by aortic
microsomes and has been shown to have properties very
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similar to PGI2, although it has not been shown that
vessel wall can convert EPA to PGI3 (Needleman, Raz,
Minkes, Ferrendelli and Sprecher, 1979). In 1974,
Rosenthal, Simone and Silbergleit first described an
increase in systolic blood pressure in the rat during
dietary deprivation of PG precursors and although this
finding was later confirmed by other workers (Triebe,
Block and Forster, 1976), the mechanism of the increase
in blood pressure was not clear. These studies did show
however, that a linoleic acid-deficient diet augments the
development of hypertension in rats with a high salt
intake while a linoleic acid-enriched diet attenuates the
hypertension. Further studies established that the
linoleic acid content of the diet had little effect on
the development of salt-induced hypertension in the rat
if the salt load was excessively high, but if the
salt-load was more moderate then a low linoleic acid
content exaggerated the hypertension (Box and Mogenson,
1980; MacDonald, Kline and Mogenson, 1981). In contrast,
in the spontaneously hypertensive rat (SHR) a high level
of dietary linoleic acid was associated with higher blood
pressures than a low level of linoleic acid in the diet
(Box and Mogenson, 1982). A more detailed study
established that blood pressure increased significantly
in rats fed a linoleic acid-deficient diet and that
generation of PGI2-like activity from segments of aorta
in vitro was suppressed compared to rats fed a 5 or 9 en%
linoleic acid diet (Dusing, Scherhag, Glanzer, Budde and
Kramer, 1983). In comparison with diets rich in linoleic
acid which might be expected to enhance PG synthesis, the
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feeding of diets rich in n-3 fatty acids such as
linolenic acid and EPA decreases PG production (Ten Hoor,
deDeckere, Haddeman, Hornstra and Quadt, 1980) and is
associated with an increase in blood pressure of normal
rats (Scherhag, Kramer and Dusing, 1982).
1.6.2 Gender differences in PG production
The mortality and morbidity from cardiovascular diseases
is much greater in males than in pre-menopausal females
(Kuller, 1976). Male and female differences in the
production of PGs have been reported, with male rats
having been found to release more 6-keto-PGF10c from
aortic rings than female rats (Pomerantz, Maddox, Maggi,
Ramey, Ramwell, 1980). Furthermore, male lungs converted
AA into 6-keto-PGF10C more readily than female lungs
(Maggi, Tyrell, Maddox, Watkins and Ramey, 1980) and
microsomes of kidney medulla from male rats produced
greater amounts of PGD2 , PGE2 and PGF20C than those from
female rats (Gesce, Ottlecz, Schaffer, Bujdosc and
Telegdy, 1979). The sex steroids have been implicated in
these differences in AA metabolism in blood vessels.
Experimentally-induced arterial thrombosis is markedly
enhanced by testosterone treatment in male and female
rats, whereas oestradiol significantly increased the
obstruction time and decreased the thrombus weight in
male, but not female rats (Uzonova, Ramey, Ramwell,1976).
If vascular PGI2 were involved in these effects on
thrombosis via its anti-platelet actions, as suggested by
the work of Ohtsu and colleagues (Ohtsu, Saitoh, Okada,
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Chang and Murota, 1983) where oestrogen treatment was
shown to inhibit artificially induced thrombus formation
with the concomitant stimulation of PGI2 synthesis in the
aorta, then females might be expected to show a greater
production of PGI2 than males. However, this is not the
case as evidenced from the findings of Maggi et al.
(1980) and Pomerantz et al. (1980). In vitroy oestrogen
has been shown to stimulate PGI2 production in cultured
rat aortic smooth muscle cells (Chang, Nakao, Orimo,
Murota, 1980) and cultured porcine endothelial cells
(Seillan, Ody, Russo-Marie and Duval, 1983). A combined
oestrogen/progestagen treatment stimulated PGI2 release
from aortic rings and from segments of aorta, vena cava,
heart and lung (Karpati, Chow, Woollard, Hutton and
Dandona, 1980; Roncaglioni, de Minno, Rayers, de Gaetano
and Donati, 1979). In contrast, testosterone treatment of
male rats significantly inhibited the production of PGI2
by rings of aorta (Chang, Nakao, Tai and Murota, 1982)
and either inhibited (Nakao, Chang, Murota and Orimo,
1981) or had no effect on PGI2 production by rat or pig
aortic smooth muscle cells in culture (Pomerantz et al.,
1980; Seillan et al., 1983). There was no effect of
testosterone treatment on the release of 6-keto-PGFtK
from aortic rings of adult rats castrated at birth (Wey,
Skjaerlund and Subbiah, 1983).
1.6.3 Effects of age on PG production
A complex interrelationship exists between blood pressure
and arterial disease, hypertension increasing the
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susceptibility of blood vessels to arteriosclerosis. It
is generally accepted that in humans, blood pressure
increases with age as does the incidence of coronary
heart disease and thrombosis. Studies to date do not
show unequivocally that these increases in blood pressure
and thrombotic tendency with increasing age are related
to PG mediated effects. It has been shown that
15-hydroperoxyarachidonic acid (15-HPAA), a lipid
peroxide, is a potent and selective inhibitor of PGI2
generation by porcine vessel wall microsomes or by fresh
vascular tissue (Moncada et al., 1976). Other fatty acid
peroxides and their methyl esters show similar effects
(Salmon et al., 1978). Lipid peroxidation induced by free
radical formation is known to occur in the ageing process
(Slater, 1972) and it is reasonable to suggest that PGI2
generation could be reduced in aged blood vessels because
of the effects of greater concentrations of lipid
peroxides.
Pace-Asciak and Carrara (1979) and Panganamala and
co-workers (Panganamala, Hanumaiah and Merola, 1981) have
shown that PGI2 formation by aortic homogenates or intact
aorta increases with age in the rat. However, these
authors were studying a very limited age range using rats
of up to 20 weeks of age and were not looking at the
situation in the old animal. Aortic smooth muscle cells
from old rats produced less PGI2 in culture than those
obtained from young rats and this was due to a specific
decrease in PGI2 synthetase activity. These cells from
old rats were found to produce more PGE2 than PGI2 (Chang
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et al., 1980). Using bovine smooth muscle and endothelial
cells in vitro (Ager et al., 1982) it was observed that
during sub-culture the ability to generate PGI2 decreased
while PGE2 formation increased. It is not known if these
changes are due to specific effects of lipid peroxides on
PGI2 synthetase.
1.6.4 PG production in disease states
A number of diseases have now been related to an
imbalance in the PGI2/TXA2 system. Platelets from
patients with arterial thrombosis or deep vein thrombosis
produce greater amounts of PG endoperoxides and TXA2 than
healthy controls and have a shortened survival time
(Lagarde and Dechavanne, 1977). Platelets from rabbits
made atherosclerotic by feeding a high cholesterol diet
and from patients who have survived myocardial infarction
are abnormally sensitive to aggregating agents and
produce more TXA2 than controls (Shimamoto, Kobayashi,
Takahashi, Takashima, Sakomoto and Morooka, 1978;
Szczeklik, Gryglewski, Musial, Grodzinska, Serwonska and
Marcinkiewicz, 1978). Diabetic patients are highly
susceptible to microvascular complications,
atherosclerosis and thrombosis and it has been shown that
platelets from rats made diabetic by streptozotocin
released more TXA2 than controls, whereas the aorta from
these rats showed a reduced release of PGI2 (Harrison,
fieece and Johnson, 1978). Similarly, vascular PGI2
production in diabetic patients was depressed and
circulating levels of 6-keto-PGFtK were reduced in
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diabetic patients with proliferative retinopathy,
although there did not appear to be an association
between reduced PGI2 production and diabetic retinopathy
(Johnson, Harrison, Raftery andd Elder, 1979; Dollery,
Friedman, Hensby, Kohner, Lewis, Porta and Webster, 1979;
Davis, Brown, Finch, Mitchell and Turner, 1981).
PGI2 generation is reduced in arteries from rabbits with
experimental atherosclerosis and in human atherosclerotic
plaques (Dembinska-Kiec, Gryglewska, Zmuda and
Gryglewski, 1977; D'Angelo, Villa, Mysliwiec, Donati and
de Gaetano, 1978). In early experimental atherosclerosis
in rabbits it has been found that platelets have an
increased sensitivity to the antiaggregatory effect of
PGI2, an increased sensitivity to ADP and increased TXA2
formation (Gryglewski, Dembinska-Kiec, Zmuda and
Gryglewska, 1978; Dembinska-Kiec, Rucker and Schonhofer,
1979). This probably reflects a decreased in vivo PGI2
concentration resulting in an increased sensitivity of
the platelets to PGI2. Cultured smooth muscle cells from
atherosclerotic rabbit aorta also produce decreased
amounts of PGI2 (Larrue, Rigaud, Daret, Demond, Durand
and Bricaud, 1980).
1.7 Hypertension
An exhaustive review of the possible causes of
hypertension and its attendant pathologies is beyond the
scope of this discussion, but the basic findings will be
outlined and in particular the possible involvement of
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PGs in the aetiology of the disease. In both clinical
and experimental hypertension the final common pathway
leading to an elevated arterial pressure is an increased
total peripheral resistance. Structural abnormalities in
the vasculature that characterise the hypertensive
process are (1) changes in the vascular media, (2)
rarefication of the resistance vessels, (3)lesions of the
intimal surface. These structural changes result in an
altered physical state on which hormones, such as
noradrenaline and angiotensin II, can act. Hypertension
is a multifactorial disorder in which a number of
physiological mechanisms participate to elevate arterial
pressure; these include intravascular volume changes
involving the kidney, steroid hormones, sodium and water
balance and other pressor mechanisms such as the
renin-angiotensin-aldosterone system; altered
catecholamine metabolism and neural function; other
hormonal influences and possibly the two depressor
mechanisms, the kallikrein-kinin and prostaglandin
systems. A variety of clinical and experimental forms of
hypertension have been described and intensively studied
involving renal pathology, excessive production of
hormones or altered catecholamine metabolism. However,
probably over 95% of patients with hypertension have
essential hypertension, i.e. hypertension of undetermined
cause which seems to have a genetic predisposition and is
slowly progressive with regard to the vascular and organ
involvement. Therefore, an experimental model mimicking
this condition must also be naturally occuring,
predisposed genetically aiid slowly progressive. There are
v d1
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now available several experimental models of essential
hypertension and these will be discussed in greater
detai1.
1.7.1 Animal models of hypertension - the genetically
hypertensive rat
Hypertension can be induced in animals by several methods
and there are now available a number of models of
hypertension, using the rat. Experimentally, hypertension
can be induced by clipping the renal artery to produce
two forms of renovascular hypertension (Goldblatt
hypertension); one form, consisting of one clipped kidney
with the opposite kidney intact, is associated with high
renin levels and relatively reduced intravascular volumes
whereas the second form, consisting of one clipped kidney
with the opposite kidney removed is associated with
higher volumes and consequently relatively lower renin
levels. Hypertension can also be induced by salt-loading
animals treated with the mineralocorticoid,
deoxycorticosterone acetate. However, for an animal
model to represent the most common form of human
hypertension, essential hypertension, it is required to
be polygenic in origin and influenced by environmental
factors. Two strains of rat fulfilling these criteria
have been bred through brother to sister mating, the
spontaneously hypertensive rat (SHR) of Okamoto (Okamoto
and Aoki, 1963) and the New Zealand genetically
hypertensive (GH) strain of Smirk (Smirk and Hall, 1958).
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(For comprehensive reviews on the validity of using
genetically hypertensive rats in the study of
hypertension see McGiff and Quilley, (1981) and Trippodo
and Frolich, (1981)).
Other hypertensive strains are now available but appear
to involve primarily alterations in renal, sodium and
water metabolism (Milan strain), high sensitivity to
sodium intake (Dahl strain) and the Lyon strain (Vincent,
Bornet, Berthezene, Dupont and Sassard, 1978). The New
Zealand GH strain appears to be most similar to the
Japanese SHR but has not been studied in as great detail.
The relevance of using a genetic model of hypertension in
the rat will be discussed largely with reference to the
SHR as the majority of studies have been conducted using
this animal. It is probable that many of these findings
also apply to the GH rat.
Of course there are several important differences between
the SHR and essential hypertension in humans; the SHR
(and GH rat) usually weigh less than their normotensive
control whereas the clinical hypertensive population seem
to be heavier than controls; thyroid function may be
altered in SHR but not all hypertensive patients; SHR
show inconsistent responses to commonly used
anti-hypertensive agents and in general the rat is
relatively resistant to atherosclerosis. This is in
marked contrast to the facilitative effect of an elevated
arterial pressure on the development of atherosclerosis
in hypertensive man (Hollander, 1976). Another criticism
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of the SHR is that its control strain, the Wistar Kyoto
(WKY) was not developed simultaneously. This also applies
to the GH rat and its Wistar control. The use of the rat
as an experimental animal when studying the role of PGs
in hypertension was challenged when it was discovered
that PGE2, a major renal PG and potent vasodilator,
constricted the vasculature of the isolated rat kidney,
an effect not observed in any other species examined
(Malik and McGiff, 1975). The major conclusion of this
study was that PGs of the E series could contribute to
the elevation of blood pressure in the rat i.e. PGE2 was
pro-hypertensive in the rat but anti-hypertensive in the
rabbit, and man and other species resembled the rabbit in
this respect. However, because of the importance of renal
mechanisms in the regulation of blood pressure, the
anomalous effects of PGE2 in the rat probably need only
occur in the kidney to cause elevation of blood pressure.
Indeed, there is evidence that PGE2 dilates other
vascular beds of the rat (Gerber and Nies, 1979). The
constrictor response of the renal vasculature of the rat
to PGE2 was found to be exaggerated in the GH strain and
PGs released by the action of noradrenaline (NA) were
found to augment the renal vasoconstrictor response to
NA. An important finding in relation to the use of the GH
strain in studies of hypertension was the deficiency of
the major catabolising enzyme 15-PGHD, a defect leading
to higher levels of PGE2 intrarenally (Armstrong,
Blackwell, Flower, McGiff, Mullane and Vane, 1976). Thus,
the importance of increased renal PGE2 levels in the GH
rat can be appreciated from a consideration of
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PG-adrenergic interactions, whereby increased levels of a
modulator such as PGE2 will, in the rat potentiate the
effects of the sympathetic nervous system. With these
important caveats in mind the genetically hypertensive
rat has many characteristics in common with the human
form of essential hypertension, and to date is the best
model available for this form of hypertension.
1.8 PGs in hypertension
1.8.1 Vascular actions of PGs
A large number of studies have investigated the possible
involvement of PGs in the aetiology of hypertension in
man and animal models. There is evidence that PGs are
involved in (i) the mechanisms regulating vascular
resistance; (ii) the pressor and depressor responses to
vasoactive hormones; (iii) renin secretion and renal
handling of sodium and water. A defect in the production
of certain PGs could result in a reduction in vasodilator
capacity with the consequent increase of vascular
resistance, associated with a reduction of renin
secretion (Case, Casarella, Laragh, Fowler and Canon,
1978), and increased responsiveness to noradrenaline (NA)
and angiotensin II (All) at normal endogenous levels of
these pressor hormones (Philipp, Distler and Cordes,
1978; Weidmann, 1980). The other aspect of a defect in PG
production in hypertension is seldom considered, namely
the possibility of an increased production of the
vasoconstrictor AA metabolites, PGF20C and TXA2 .
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There have been many attempts to determine the
involvement of PGs in the control of blood pressure by
the administration of cyclooxygenase inhibitors. In the
anaesthetised dog, the immediate haemodynamic effects of
indomethacin resembled those of uncomplicated essential
hypertension: elevated blood pressure, unchanged cardiac
output, a marked increase in renal vascular resistance
and a smaller increase in that of the limbs (Lonigro,
Itskovitz, Crowshaw and McGiff, 1973). Daily
administration of indomethacin was reported to elevate
mean arterial pressure in the rabbit without altering
plasma volume or increasing sodium retention
(Colina-Chourio, McGiff and Nasjletti, 1974). In
addition, in normal and in sodium-depleted subjects,
indomethacin was reported to produce modest but
significant elevations in blood pressure (Staessen,
Eagard, Lijnen and Amery, 1983). However, there are a
number of reports that indomethacin does not alter blood
pressure in normotensive animals and humans (Romero and
Strong, 1977; Muirhead, Brooks and Brosius, 1976).
Indomethacin, or similar drugs have been reported to
aggravate hypertension in humans, Goldblatt hypertensive
rats and rats with spontaneous hypertension. This is in
contrast to other reports where there was no effect of
indomethacin on rats or dogs with Goldblatt hypertension
(McQueen and Bell, 1976; Yun, Kelly and Barrter, 1979).
Seminal to the disparity in the results regarding the
effects of cycloxygenase inhibitors on blood pressure is
the effect these drugs have in reducing renin secretion
and, consequently, plasma renin activity (Romero and
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Strong, 1977). It is possible that the antihypertensive
effect of reducing plasma renin activity with
indomethacin may mask any tendency for blood pressure to
rise because of reduced synthesis of vasodilator PGs.
1.8.2 Renal PG production
Renal cortical generation of PGs contributes to the
regulation of renal blood flow, glomerular filtration
rate and renin release. Infusion of AA into the renal
artery of the rabbit is a strong stimulus for renin
release and this release is blocked by indomethacin
(Larsson, Weber and Anggard, 1974). Further experiments
with AA showed that it can cause enhanced renal blood
flow and sodium excretion in the dog, but in the rat AA
can cause renin release independently of enhanced sodium
and water excretion (Tannenbaum, Splawinski, Oates and
Nies, 1975; Weber, Holzgreve, Stephan and Herbst, 1975).
Using rabbit renal cortical slices it was found that AA,
PGG2 and PG endoperoxide analogues stimulate, while PGF20C
and indomethacin inhibit the release of renin; PGE2 was
without effect (Weber, Larsson, Anggard, Hamberg, Corey,
Nicolaou and Samuelsson, 1976). PGI2 is a potent
stimulator of renin release from rabbit cortical slices
(Whorton, Misono, Hollifield, Frolich, Inagami and Oates,
1977) or from the perfused kidney (Gerber, Branch, Nies,
Gerkens, Shand, Hollifield and Oates, 1978; Bolger,
Eisner, Ramwell, Slotkoff and Corey, 1978). In humans the
augmented renin release after the diuretic frusemide is
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inhibited by pre-treatment with indomethacin (Frolich,
Hollifield, Dormois, Seyberth, Michelakis and Oates,
1976). In a non-filtering kidney, denervated and treated
with ^-adrenergic blocking agents, the increase in renal
vein renin induced by reducing perfusion pressure is
inhibited by indomethacin, indicating that PGs may
contribute to the baroreceptor mechanism of renin release
(Data, Crumb, Hollifield, Frolich and Nies, 1976). By
involvement in these processes, renal PGs are part of the
mechanisms controlling extracellular volume and blood
pressure. The evidence to date suggests that in the
intact kidney, AA and PGI2 stimulate renin release,
probably by a direct effect on the juxtaglomerular
apparatus as well as an interaction with the
baroreceptor, the ^-adrenergic and macula densa receptor
for renin release. Furthermore, the tubuloglomerular
feed-back loop, involved in the control of sodium
excretion is dependent on an intact PG system. The
attenuation of the feed-back response to changes in loop
of Henle flow rates after inhibition of PG synthesis can
be restored by PGI2 (Schnermann and Weber, 1980). There
is also evidence that PG generation affects electrolyte
secretion and vice-versa. Intra-renal infusion of PGE2,
PGD2, PGI2 and AA increase the urinary excretion of
sodium, probably through effects on renal haemodynamics
(for review see Dunn and Hood, 1977). Chronic salt
depletion, on the other hand, increases renal PGK2
production and release into the urine, whereas chronic
high sodium intake suppresses PGE2 formation. Thus, one
of the known risk factors for hypertension, high sodium
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intake may operate through a mechanism involving a
reduction in PGE2 formation.
1.8.3 Effects of PGs on neurotransmission
The hypotensive action of the PGs of the E series has
been known for a long time, and it is now well
established that PGE2 inhibits the release of NA from
many sympathetic nerves. This latter action has been
shown in various species and in several different
preparations (for review see Hedquist, 1977). The effect
of PGI2 on transmitter release from sympathetic nerves is
contradictory. Hedquist (1979) found that PGI2 had little
or no effect on [3H] NA release in response to nerve
stimulation in rabbit kidneys, but Weitzell et al.(1978)
reported inhibition of NA release by PGI2 in rabbit
pulmonary arteries. Armstrong et al.(1979) observed a
similar effect with PGI2 in rabbit mesenteric arteries,
but not veins.
1.8.4 Correlations between PGs and pressure and flow in
blood vessels
Using an alternative model of hypertension (i.e. portal
hypertension), produced experimentally by partial
ligation of the portal vein, it was shown that after 1
week of hypertension the portal veins of these rats
released significantly greater amounts of PGI2 (Hamilton,
Rosa, Hutton, Chow, Dandona and Hobbs, 1981). In a
further study it was found that during established
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hypertension the release of PGI2 was significantly
greater than controls but as a collateral circulation
developed with a consequent fall in portal pressure, PGI2
release decreased and was significantly correlated with
portal pressure (Hamilton, Phing, Hutton, Dandona and
Hobbs, 1983). Using a different approach, Botha and Leary
(1981) constricted the aorta of genetically hypertensive
rats above the hepatic artery to produce a reduction in
blood pressure distally. There was a significant
reduction in tail pressure and segments of aorta produced
decreased amounts of PGI2 when compared to controls. The
results of these studies suggest that PGI2 release is
enhanced when there is an increase in blood pressure and
that when this influence is removed, PGI2 release
decreases again. Therefore, the increased production or
release of PGI2 from the blood vessels of genetically
hypertensive rats may be due to a mechanical effect of an
increased pulse pressure. Indeed, in the isolated,
perfused aorta the use of a pulsatile pump appears to be
a prerequisite for PGI2 release (Quadt and Voss, 1982).
Several studies have been carried out to determine the
effect of mechanical pressure on PG production by blood
vessels. Arteries have been shown to produce larger
quantities of PGI2 compared to veins (Skidgel and Printz,
1978). To test the hypothesis that PGI2 production is
related to blood pressure and flow, vein grafts were
transplanted into the arterial circulation of dogs and
rats. In the dog, although the venous grafts became
arterialised from a structural point of view, there was
no significant difference in PGI2 production by grafts
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compared with jugular veins (Eldor, Hoover, Pett, Gay,
Alonso and Weksler, 1981). In the rat, however, PGI2
production by vein grafts showed a progressive rise over
a period of 42 days until levels were close to those of
arterial controls (Petry, Burstein, Chang, Wortham, Sedor
and Hunter, 1982).
1.8.5 Differences in PG production in hypertension
It has been proposed that a deficiency of production of
vasodilator PGs in vascular beds (particularly the
kidney) may lead to the increased peripheral vascular
resistance characteristic of essential hypertension (Vane
and McGiff, 1975). However, several groups have reported
that the generation of PGI2 and PGE2-like substances from
exogenous arachidonic acid is much greater in aortic
rings and homogenates from spontaneously hypertensive
rats (SHR) than in aorta from normotensive rats (Limas
and Limas, 1977; Rioux, Quirion and Regoli, 1977;
Pace-Asciak, Carrara, Rangaraj, Nicolaou, 1978). The
release of a PGI2-like substance was greater from aortic
rings of stroke-prone and stroke-resistant SHR compared
with normotensive controls (Okuma, Yamori, Ohta and
Uchino, 1979), and was greater from aortic strips of the
New Zealand genetically hypertensive (GH) strain compared
to normotensive rats (Botha, Leary and Asmal, 1980).
Armstrong, Boura, Hamberg






action of the PG endoperoxides (PGG2 and PGH2) than
norraotensives but their sensitivity to PGE2 was similar.
Since the hypotensive action of the endoperoxides is
probably due to PGI2 this observation could be explained
either by an increased conversion of endoperoxides to
PGI2 , or by an enhancement of its vasodilator action in
these GH rats. In a subsequent study (Dusting, Davies,
Drysdale and Doyle, 1981) it was found that the
vasodepressor effects of arachidonic acid were greater
and more prolonged in SHR than in their Wistar-Kyoto
controls, but that depressor responses to PGI2 did not
differ between strains. They concluded that the SHR had
an enhanced ability to form vasodilator PGs from
exogenous arachidonic acid. In a similar study it was
concluded that rats with experimental renal hypertension
(one kidney, one clip) had a greater ability to transform
arachidonic acid into vasodilator PGs. However, SHR
showed a greater depressor response to PGI2 and a smaller
depressor response to arachidonic acid compared with
normotensive Sprague-Dawley rats, but not when compared
with their usual control strain, the Wistar-Kyoto
(Dusting, Di Nicolantonio, Drysdale and Doyle, 1981).
This finding was confirmed by Lukascko, Messina and Haley
(1980) who found a larger depressor response to
arachidonic acid in normotensive Wistar rats than in
Wistar-Kyoto or SHR, suggesting a decreased capacity to
utilise arachidonic acid for the synthesis of vasodilator
PGs in both the SHR and Wistar-Kyoto strains of rat. An
increased aortic generation of PGI2 might result in a
reduced platelet sensitivity to PGI2, but Botha and Leary
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(1981) found that platelets from SHE and normotensive
rats were equally sensitive to the anti-aggregatory
effect of PGI2. The cyclooxygenase inhibitor ibuprofen,
either given acutely or over 7 days had no significant
effect on systolic blood pressure in SHR (Levy,1982).
Using antibodies raised against 5,6-dihydro PGI2 which
cross-react with PGI2, Pace-Asciak et al. (1980) found
that although the vasodepressor effects of exogenous PGI2
were blocked, the anti-5,6-dihydro PGI2 antibodies had no
effect on resting arterial blood pressure in normotensive
rats or SHR. These latter results suggest that, contrary
to the results described previously, the production of
PGI2 is not significantly increased in the blood vessels
of genetically hypertensive rats, or that it is not
contributing to the control of blood pressure in these
animals.
Similar studies have been carried out to investigate PG
production in experimental models of hypertension. The
vasodepressor effects of PGI2, nitroprusside and AA did
not differ significantly between 2 kidney, 1 clip (2K,
1C) Goldblatt hypertensive rats compared to normotensives
when measured as a percentage of resting blood pressure,
in contrast to 1 kidney, 1 clip (IK, 1C), hypertensive
rats which showed much greater depressor responses to AA
(Dusting, Drysdale, Veroni and Doyle, 1983; Dusting,
Dickens, Nicolantonio and Doyle, 1984). The ability of
rings of arteries to produce PGs from [14C] AA was
examined in the initial (6 day) and chronic (6 week)
phase of 2K, 1C hypertension; PGI2 synthesis increased
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2.4 times in the 6 day period of development of
renovascular hypertension but there were no changes
observed in PGI2 synthesis in the 6 week period (Morera,
Santoro, Roson and De la Riva, 1983).
Although there is a vast amount of literature dealing
with PGI2 and its actions on platelet aggregation and
blood vessel tone, its proposed interaction with, and
opposing effects to TXA2, there is a paucity in the
literature on the vascular production of two other major
vascular PGs, PGF20C and PGE2 . This is particularly true
of the situation in the hypertensive state, which
requires further study since an ab eration in the
formation of any one PG relative to another may have
profound effects on blood vessel tone and hence blood
pressure. Moreover, it is generally basal PG production
which is measured and the importance of an increased
output in vasodilator PGs in response to vasoconstrictor
stimuli, particularly in the hypertensive state, has not
been established. Also, the majority of studies have
been carried out using male rats although some
differences in vascular PG production between male and
female rats have been reported.
Similarly, in the aged animal, the increase in blood
pressure observed with increasing age could involve
changes in the profile of PG production by blood vessels,
in addition to the structural changes in the blood vessel
wall found with age.
The majority of studies in
production have used tissue
vessels which may not be rep
tissue.
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vestigating human vascular PG
obtained from umbilical blood
resentative of adult vascular
Consequently, experiments described in this thesis were
undertaken to establish a more complete profile of basal
and stimulated vascular PG production in normotensive and
hypertensive, male and female rats. A study of vascular
PG production was carried out in a large sample of male
and female human subjects, undergoing coronary artery
by-pass surgery. Since the analytical methods used are
common to several sections, the next Section solely
describes these analytical methods.
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SECTION 2.0 Materials and General Methods
2.1.1 Introduction
The work presented in this thesis has involved the
measurement of PGs in aorta, vena cava and mesenteric
arterial bed of male and female rats, and in aorta and
saphenous vein of human subjects who were undergoing
coronary artery bypass surgery.
PGs were extracted from incubates of homogenised vascular
tissue or from perfusates of isolated vascular
preparations into organic solvents and were measured by
radioimmunoassay (RIA). The PGs measured by RIA in the
tissue homogenates were also identified by combined gas
chromatography and mass spectrometry (GC-MS). The
procedures described here for extracting, measuring and
identifying the PGs are common to each section.
2.1.2 Materials
Solvents




Ethyl Acetate (reagent grade)
Methanol (Analar)
Toluene (Analar)
Ethyl acetate was redistilled
B.D.H. Chemicals Ltd., U.K
J. Boroughs Ltd., U.K.
B.D.H. Chemicals Ltd., U.K
B.D.H. Chemicals Ltd., U.K














All from Amersham International Ltd., U.K.
3H PGF2k and 3H PGE2 were stored at 5 jjC i/ml in methanol,
at -20°C and 3H 6-keto-PGFla was stored at 5 /K?i/ml in
acetonitrile: water, 9:1 v/v at -20°C.
2.1.3 Other Chemicals
Authentic PGs and their metabolites were the gift of Dr.
J. Pike, Upjohn Company, Kalamazoo, USA.
- 68 -
Angiotensin II Sigma Chemical Company, UK
Arachidonic acid Sigma Chemical Company, UK
Noradrenaline Sigma Chemical Company, UK
Oestradiol benzoate Sigma Chemical Company, UK
Progesterone S igma Chemical Company, UK
2.2.1 Composition of Kreb s solution
2g glucose
2.1g sodium hydrogen carbonate
6.9g sodium chloride
1.4 ml 10% magnesium sulphate
1.6 ml 10% potassium dihydrogen orthophosphate
3.5 ml 10% potassium chloride
2.5 ml 1M calcium chloride
Kreb s solution was made up daily in 11 quantities.
All reagents were supplied by B.D.H. Chemicals Ltd., U.K.




2.1g sodium hydrogen carbonate
4.2ml 10% potassium chloride
1.4ml 10% potassium dihydrogen orthophosphate
2.4ml 1M calcium chloride
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McEwen's solution was made up daily in 11 quantities.
All reagents were supplied by B.D.H Chemicals Ltd., UK






2.3.2 Diluents for RIA
6-keto-PGF10C assay
0.05 M Tris buffer pH 6.8
0.1 g/1 Sodium azide
1.0 g/1 Gelatine
PGF2K assay
0.05 M Tris buffer pH 8.0
0.1 g/1 Sodium azide
1.0 g/1 Gelatine
PGE2 assay
0.05 M Phosphate buffer pH 7.5
0.1 g/1 Sodium azide
0.1 g/1 Gelatine
Tris (hydroxymethy1)-methylamine B.D.H. Chemicals Ltd.,
di-sodium hydrogen orthophosphate B.D.H. Chemicals Ltd.,
sodium dihydrogen orthophosphate B.D.H. Chemicals Ltd.,
sodium azide Hopkin and Williams Ltd.,
gelatine B.D.H. Chemicals Ltd.,






Donkey anti-rabbit serum (DARS) - Wellcome Reagents Ltd.
and Scottish Antibody Production Unit, UK. Normal rabbit
serum (NRS) was obtained from non-immunised male New
Zealand white rabbits by the method of Dighe, Emslie,
Henderson and Simon (1975).
2.4 Tissue homogenisation and solvent extraction of PGs
Rats were killed by stunning and incising the neck. The
aorta was removed, washed to remove trapped blood,
blotted dry and weighed. The tissue was then chopped
finely with scissors and homogenised in a Fisons glass
homogeniser with 5 ml Krebs solution. The homogeniser
was washed with 5 ml Krebs solution and the homogenate
and washings were added to a 25 ml conical flask. The
homogenate was incubated with 2 fig/ral arachidonic acid
for 60 min at 37°C, in a Grant water-bath, and was gassed
with 95% 02, 5% C02.
PGs were extracted from homogenates using the method of
Poyser (1972). The pH of the homogenate was lowered to
pH4 by the dropwise addition of IN HC1. The homogenate
was then extracted twice with two volumes of ethyl
acetate. The ethyl acetate fractions were combined and
evaporated to dryness under reduced pressure at 45°C on a
rotary evaporator. The residue was redissolved in 4ml of
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ethyl acetate and was stored at -20°C until assayed.
It is well established that extracting PGs by this method
from Krebs solution gives a high recovery for
6-keto-PGF4K, PGF2K and PGE2 . The recoveries of the
appropriate radioactive PGs at pH4 were found to be 82
+ /- 2% for 6-keto-PGFtK (Swan and Poyser, 1983), 94 +/-
3% for PGF2k and 92 + /- 5% for PGE2 (Poyser and Scott,
1980). PG concentrations measured in tissue homogenates
and perfusates have not been corrected for procedural
losses.
2.5 Measurement of PGs by radioimmunoassay
2.5.1 Assay protocol
The procedure for setting up a radioimmunoassay is
essentially the same for 6-keto-PGF lcc, PGF2a and PGE2 .
Therefore, the general procedure for the assay will be
described followed by the specific details of solutions,
antisera and crossreactivities for each prostaglandin
assay.
6-keto-PGF 1(X and PGE2 ant
after immunisation with a
conjugate (Dighe, Jones
PGE2-thyroglobulin conjugate
Whelpdale, 1978). PGF2oc an
using a PGF2a-bovine serum
Emslie, Henderson, Rutherfor
isera were raised in rabbits
6-keto-PGF 10C-thyroglobulin
and Poyser, 1978) and a
(Dighe, Smith, Ungar and
tiserum was raised in rabbits
albumin conjugate (Dighe,
d and Simon, 1975).
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The mass of [3H] prostaglandin ([3H] PG) used was chosen
to give approximately 20,000 counts in a 50 ul aliquot,
counted over a period of 4 min. The solvent containing
the [3H] PG was evaporated off under a stream of air and
the [3H] PG was redissolved in diluent.
The dilution of antiserum chosen was that which bound 60%
of the [3H] PG in the absence of any non-radioactive PG.
A stock solution of antiserum in diluent, of 1:100 was
prepared and this was used to prepare the appropriate
final dilution.
Standard solutions were made up in diluent from a stock
solution of 1 fjg/va.1 in methanol. An appropriate quantity
of the PG in methanol was taken and the methanol was
evaporated off under a stream of air. The PG was
redissolved in diluent to give a PG concentration of
10.24 ng/ml. Nine serial dilutions were made from this
highest concentration. Disposable polypropylene tubes
containing 0.5 ml of the standard PG solutions were set
up in triplicate as detailed in Table 2.5.1. Tubes were
also set up in quadruplicate for counting standards, zero
standards and non-specific binding standards.
Table 2.5.1
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The counting standards give an estimate of the average
number of radioactive counts added to each tube. The
zero standards indicate the degree of binding of the [3H]
PG to the antiserum in the absence of non-radioactive PG.
The non-specific binding standards, which contain
sufficient non-radioactive PG to completely saturate the
specific sites of the antiserum, indicate the
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non-specific binding of the [3H] PG to other 'components'
of the assay. Non specific binding was always less than
6%.
The assay protocol is detailed in Fig. 2.5.1. Extracted
samples in ethyl acetate were dispensed into disposable
tubes in two different volumes, and in duplicate, by
fixed volume Eppendorff pipette with disposable tips.
The use of different volumes was to ascertain if
parallelism existed between the volumes. Samples were
taken to dryness at 45°C under a stream of air, and were
redissolved in 500 pi of diluent. The samples and
standard PG solutions were then treated in the same way.
50 pi of antiserum and 50 pi of [3H] PG were added to
each tube, the tubes were whirlimixed and left to
incubate at room temperature, for 1 hour if the assay was
for PGF2oc and 2 hours if the assay was for 6-keto-PGFla
or PGF2. After incubation, 50 pi of normal rabbit serum
(NRS) and 50 pi donkey anti-rabbit serum (DARS) were
added to all the assay tubes which were then whirlimixed.
The tubes were left to incubate overnight at 4°C.
NRS was added after incubation to ensure that at higher
dilutions of the antiserum there was sufficient
gamma-globulin present for adequate precipitation. DARS




next morning the tubes were centrifuged at 1300 g for
min at 4°C. The supernatant fluid was poured off and
discarded. 200 pi of scintillation fluid were added
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to each tube, the tubes were whirlimixed to resuspend the
precipitate and a further 2.8 ml of scintillation fluid
were added to each tube. The tubes were put into glass
vials and were placed in a liquid scintillation counter.
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Fig. 2.5.1
Take samples in ethyl acetate to dryness at 45°C
under a stream of air
Add 500 Ml diluent
Add 50 pi [3H] PG
Add 50 jil antiserum
Whirlimix and incubate for 1 or 2 h,
depending on PG, at room temperature
Add 50 m^ NRS (1:140 dilution)
Add 50 Ml DARS (1:10 dilution)
Whirlimix and incubate overnight at 4°C
Centrifuge at 1300 g for 30 min at 4°C
Discard supernatant fluid
Add 200 Ml scintillation fluid
Whirlimix to resuspend precipitate
Add 2.8 ml scintillation fluid
Place in glass vials
Liquid scintillation counting
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The vials were counted for 4 min in a Nuclear Chicago
Liquid Scintillation counter and the results recorded on
a paper punch tape. The tape was fed into a PDP-8
computer or, latterly, a Commodore 4032 computer, both
programmed to calculate the percentage binding of the
[3H] PG. This was calculated using the formula.
bound = (sample counts - background counts) x 100
(average counting standard counts - background counts)
The computer applied a logistic curve fitting formula to
the observed values of percentage [3H] PG bound in the
standard curve and calculated the coordinates for the
curve of best fit. The two sets of values obtained,
(i.e. observed values and calculated values) were
compared, and if the variation between them was less than
5% the curve was accepted. If the gradient of the
standard curve was less than 8%, as measured over a
doubling of the concentration of PG per tube, the assay
was repeated. Values for the 'extracted PG' which did
not lie on the linear part of the curve were reassayed
using different dilutions of the sample.





standard deviation of sample duplicate
mean value of sample duplicate
total number of duplicates
xlOO
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Two tubes containing a known amount of the appropriate PG
were set up in duplicate at the end of each assay and
these results were used to calculate the interassay
coefficient of variation, using the formula:
Inter assay = standard deviation of standard
coefficient of variation mean of standard xlOO
Crossreactivities for each of the PG antisera have been
determined by Miss Isa Ramsay. A standard curve for the
PG was set up in parallel with standard curves for
different prostaglandins and their metabolites. The
concentration of PG or PG metabolite which produced a 10%
fall in binding from the zero standard was obtained and
the percentage cross-reactivity was calculated using the
following formula.
cross reactivity = concentration of the PG giving a 10%
fall in zero binding xlOO
concentration of PG or PG metabolite
giving a 10% fall in zero binding
2.5.2 6-keto-PGF 1(X Radioimmunoassay
A standard curve for 6-keto~PGF1K was set up as in Table




Tris diluent pH 6.8
3H 6-keto-PGF1K (sp. act. 150 Ci/mmol)




Incubation time at room temperature -2h.
Results
Fig. 2.5.2 shows the standard curve for the 6-keto-PGFtK
radioimmunoassay drawn from the results of 6 consecutive
assays. (Mean +/- s.e.m).
Detection limit 40 pg
Intra assay coefficient of variation 9.5%
Inter assay coefficient of variation 6.5%
Table 2.5.2 shows the cross reactivities of the
6-keto-PGF1K antiserum, rabbit 1, 6th bleed with other
prostanoids as determined by Miss I. Ramsay. Cross
reactivity was measured at 30% binding of tracer.
%binding
0-01-1 05 ng6-keto-PGF|
Fig.2.5Standardcurvefor6-keto-PGFradi immunoassay;mea±s. . .fcons cuti e assays,n. .b=non-specificbinding.
Table 2.5.2
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Prostanoid % cross reactivity at














As there was no significant cross reactivity found with
any of the prostanoids tested, this 6-keto-PGFta antibody
was considered suitable for the measurement of
6-keto-PGF j .
2.5.3 PGF20C Radioimmunoassay
A standard curve for PGF20C was set up as in Table 2.5.1.
The assay protocol described in Fig. 2.5.1 was followed.
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Reagents
Tris diluent, pH 8.0
3H PGF2K (sp. act. 160 Ci/mmol)








Fig. 2.5.3 shows the standard curve for
radioimmunoassay drawn from the results of 6
assays (mean +/- s.e.m.).
Detection limit 30 pg
Intra assay coefficient of variation 9.4%
Inter assay coefficient of variation 7.9%
Table 2.5.3 shows the cross reactivities of the PGF2oc
antiserum, rabbit 6, 4th bleed with other prostanoids, as




Fig.2.53.standardcurvefoPGF2arat^;'-o:'-minunoassay'•mean-s. .m.f6consecutive assays,n. .b.=on-specificbi ding
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Table 2.5.3
Prostanoid % cross reactivity at












The PGF2k antiserum cross reacts 100% with PGF10C.
Samples were therefore subjected to further analysis by
GC-MS to determine if significant quantities of PGF10C had
been produced.
2.5.4 PGE2 Radioimmunoassay
A standard curve for PGE2 was set up as described in
Table 2.5.1. The assay protocol in Fig. 2.5.1 was followed.
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Reagents
Phosphate diluent, pH 7.5
3H PGE2 (sp. act. 160 Ci/mmol)




Incubation time at room temperature- 2 h
Results
Fig. 2.5.4 shows the standard curve for the PGE2
radioimmunoassay drawn from the results of 6 consecutive
assays (mean + /- s.e.m).
Detection limit 40 pg
Intra-assay coefficient of variation 11.8%
Inter-assay coefficient of variation 12.2%
Table 2.5.4 shows the cross reactivities of the PGE2
antiserum, rabbit 5, 7th bleed with other prostanoids as




Fig.2.5.4.StandardcurvefoPGE2rac^o:*-mmunoassay;mea-s. .m.f6ns cutive assays.n.s.b=non-specificbi ding.
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Table 2.5.4
Prostanoid % cross reactivity at








13,14-dihydro, 15-keto PGE2 0.1
15-keto-PGF2K 1.1
13 , 14-dihydro, 15-keto PGF20C 0
6-keto-PGF10C 1.1
TXB2 0.2
The PGE2 antibody showed high cross reactivity with PGEj
and PGB2, so the samples were subjected to further
analysis by GC-MS to determine if they contained
significant quantities of PGE!, PGA2 and PGB2 which might
interfere with the measurement of PGE2 by this
radioimmunoassay.
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2.6 Column Chromatography and Gas Chromatography Mass
Spectrometry
2.6.1 Introduction
Radioimmunoassay provides a sensitive method for
measuring picogram (pg) quantities of PGs in biological
samples, routinely and on a large scale. However, this
technique does not provide an unequivocal identification
of the compounds measured. Extraction of the PGs from
the biological fluid decreases the possibility of other
compounds in the sample cross-reacting non-specifically
with the antibody, and cross-reactivity studies with
structurally related compounds give a further indication
of the specificity of the assay for a particular PG.
However, such studies are necessarily confined to
compounds identified previously and available in a pure
form.
The cross-reactivities of the different antisera have
been detailed in the previous section and it was found
that the PGF20C anti-serum cross-reacts significantly with
PGF10(, and that the PGE2 anti-serum cross-reacts
significantly with PGA2, PGB2 and PGE j . Samples from
aorta and vein which had been assayed for PGs by RIA were
therefore analysed further by combined gas chromatography
and mass spectrometry (GC-MS) to identify positively
6-keto-PGF 10( , PGF20C and PGE2 in the samples and also to
determine if these samples contained significant
quantities of PGF10<, PGA2 , PGB2 and PGE1 . There were
insufficient samples left from vena cava, femoral artery
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or mesenteric artery for analysis by GC-MS. Before GC-MS
analysis PGs were separated from tissue extracts by
column chromatography.
2.6.2 Purification of tissue extracts by column chromatography
Columns (12 cm x 1 cm) containing 4 g of silicic acid
(Unisil, Wi11iamsport, Pennsylvania, USA, 100-200 mesh)
were prepared and were washed with 100 ml of diethyl
ether.
The ethyl acetate extracts of one tissue type were
combined to give pooled samples (i.e. aorta samples from
rats, and aorta and saphenous vein from humans). Each
unit pooled sample was evaporated to dryness under
reduced pressure at 45°C was redissolved in 30 ml of 67%
ethanol, was shaken twice with petroleum ether (b.pt
40-60°C) and the ethanol fraction was evaporated to
dryness again. Each sample was then dissolved in 0.5 ml
diethyl ether and applied dropwise to the top of a
column. The columns were eluted by 100 ml diethyl ether
followed by 100 ml of 80% diethyl ether and 20% methanol.
The first solvent elutes neutral lipids, including fatty
acids, and would have therefore removed any unconverted
arachidonic acid. The second solvent mixture elutes PGs,
and this fraction from each column was evaporated to
dryness and was redissolved in 1 ml ethyl acetate.
2.6.3 Gas chromatography - Mass spectrometry (GC-MS)
GC-MS analysis was carried out on a VG-Micromass 7070 F
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double focussing gas chromatograi-raass spectrometer. The
column (3m x 4mm) was packed with 3% 0V 1 on supelcoport
100-120 mesh (Supelco Inc., Bellefonte, USA). The
conditions for operation of the mass spectrometer were:
Column temperature 260° C
Ion source temperature 250° C
Electron energy 70e V
Accelerating voltage 4k V
Signal amplification 2 x 10
Full mass spectra were recorded on photographic paper by
a light beam oscillograph (S.E. Labs (EMI) Ltd., Feltham,
UK). A mixture of straight chain saturated fatty acid
methyl esters with 16, 18, 20, 22 and 24 carbon atoms was
used to calibrate the GC column. By plotting the
retention times of each fatty acid on a logarithmic
scale, the observed retention times of the standard PGs
could be converted to carbon values. The size and shape
of the GC peak corresponding to each fatty acid also
indicates the efficiency of the GC column.
2.6.4 Derivatisation of PGs for GC-MS
The presence of carboxyl and hydroxyl groups in the free
PGs make these compounds too polar to be run directly on
a gas chromatograph. Different derivatives have
therefore been used to reduce the polarity of these
functional groups. Carboxylic acid groups on the PGs
were protected by forming methyl ester derivatives, free
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hydroxyl groups were protected by trimethyIsily1 ether
derivatives, and free ketone groups were protected by
conversion to butyl oxime derivatives.
2.6.4.1 Method
Two 0.5 ml aliquot portions of each sample were
evaporated to dryness in 1 ml eppendorff tubes at 45°C
under a stream of air. Authentic PG standards in
methanol were dispensed into 1 ml eppendorff tubes and
were also evaporated to dryness.
2.6.4.2 Methyl ester formation
To all the tubes was added 0.5 ml diazomethane solution
(diazomethane in 9 parts diethyl ether, 1 part methanol),
and the contents of the tubes were allowed to react for
10 min. The solvent was evaporated off at 45°C under a
stream of air. Drying was completed by vacuum
dessication for 15 min.
2.6.4.3 n-Butyloxime formation
Three drops of 5 mg/ml butyl hydroxylamine hydrochloride
in dry pyridine were added to one tube from each sample
and to tubes containing PGE x , PGE2, PGD2. 6-keto-PGFta
and TXB2. The tubes were stoppered and the contents
allowed to react overnight at room temperature. The next
morning the tubes were heated at 60°C under a stream of
air to complete the reaction and to evaporate off the
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pyridine.
2.6.4.4 Triinethylsi lyl ether formation
Bis(trimethyIsily1)-trifluoroacetamide (BSTFA; 30pl) was
added to each standard and 15 ul BSTFA was added to each
sample. After dosing the tubes and whirlimixing the
contents, the tubes were heated for 15 min at 60°C.
Each standard PG was injected into the gas chromatograph
in 10 ul BSTFA. Their retention times on the GC were
recorded and a full mass spectrum was taken. Each sample
was then injected into the instrument and a mass spectrum
taken at the appropriate retention time. The mass
spectra obtained from the samples were then compared with
those from the standard PGs. The limit of detection of
the mass spectrum is approximately 50 ng. However, to
obtain a full mass spectrum about 300 ng of the extracted
PG is required and in some instances there may not have
been sufficient PG present in the pooled sample to be
detected on the mass spectrum. Table 2.6.1 shows the
characteristic ions used to determine the presence of PGs
and TXB2 in biological samples.
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Table 2.6.1
Characteristic ions of methyl trimethyIsily1 ether (Me,
TMS) and methyl trimethylsily1 butoxime (Me, Buo, TMS)
derivatives of PG and TXB2 standards (m = mass of ion, e
is the ionic charge of ion = 1).
Compound Derivative Characteristic ions
(m/e value)
pga2 Me, TMS 420, 349, 190
pgb2 Me, TMS 420, 349, 173
PGF 10c Me, TMS 586, 513, 497, 425, 406
pgf2k Me, TMS 584, 513, 494, 423, 404
6-keto-PGFla Me, Buo, TMS 671, 656, 600, 598, 510,
1st isomer 508, 491
pgd2 Me, Buo, TMS 581, 510, 508, 420, 418,
2nd isomer
PGE t Me, Buo, TMS 581, 568, 510, 512, 297
1st isomer
pge2 Me, Buo, TMS 581, 566, 510, 508, 295,
2nd isomer
txb2 Me, Buo, TMS 301, 211
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SECTION 3.0
Measurement of PG production in homogenates of aorta,
vena cava mesenteric artery and femoral artery of male
rats.
3.1.1 Introduction
Since the discovery of the ability of rabbit aortic
microsomes to synthesise prostacyclin reported by Moncada
et al. (1976), prostacyclin has been assumed to be the
major product of arachidonic acid metabolism in all
vascular tissues. Other PGs identified in vascular
tissues have been suggested to have relatively
unimportant roles.
However, there is some evidence that PGI2 is not the only
PG produced by vascular tissue. PGE2, a potent
vasodilator and PGF20C, a vasoconstrictor have been shown
to be produced by bovine aorta and bovine mesenteric
arteries and veins (Terragno et al., 1975), and by
pulmonary artery and mesenteric artery of foetal and
maternal origin (Terragno et al., 1978). TXA2 synthesis
by vascular tissue has also been reported. TXA2
(measured as TXB2) is produced by the rabbit pulmonary
artery (Salzman et al., 1980), by vascular endothelial
cells in culture (Ingerman-Wojenski et al., 1981;
Goldsmith and Needleman, 1982), and by slices of human
umbilical artery, piglet aorta and vena cava (Siess et
al., 1981). The amounts of TXA2 represented by the TXB2
measured in these studies was very small, trace amounts
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in some cases, and their role in the vascular wall is not
known at present. It should also be considered that in
some instances, the production of TXA2 by tissues is due
to the presence of platelets. TXB2 has not been measured
in the experiments described here, because of the
difficulty in completely removing platelet contamination,
and because there was insufficient sample to measure 3
PGs and TXB2.
The aorta, because of its size and accessibility, is the
vessel most often used in studies of vascular PG
production. However, the aorta is not a major resistance
vessel and may not be typical of all blood vessels in its
production of PGs; therefore three other blood vessels,
the vena cava, the mesenteric artery and the femoral
artery have also been investigated in this study. The
aim of the experiments described in this section was to
characterise the overall profile of PG production by
these blood vessels.
Gender differences in PGI2 production have been reported,
with males found to release more 6-keto-PGF10c from aortic
rings than females (Pomerantz et al. 1980).
Furthermore, male lungs convert labelled or unlabelled
arachidonate into 6-keto-PGFtK more readily than female
lungs, (Maggi et al., 1980). Therefore, males and
females will be treated separately and the results from
the 2 groups compared and discussed in Section 3.4.5.
3.1.2 Methods
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Male albino Wistar rats, aged between 2 and 3 months and
weighing 200-250 g, were used. The animals were kept
under controlled lighting conditions and allowed free
access to food and water.
Six animals were killed by stunning and incising the neck
between 10.00 h and 12.00 h. The aorta and vena cava
from each rat were dissected free from surrounding
tissue, washed in Krebs solution, blotted dry and
weighed. The aorta and vena cava were homogenized
separately in 5 ml Krebs solution and the homogenates
were each added to a 50 ml conical flask. The
homogeniser was washed with 5 ml Krebs solution and the
washings were added to the flasks. The homogenates were
incubated for 60 min with 2 /ig/ml arachidonic acid.
After incubation the pH of each homogenate was taken to
pH4 with IN HC1 and the PGs were extracted with ethyl
acetate as described in Section 2.4. Samples were stored
in 4 ml ethyl acetate at -20°C until they were assayed by
RIA, for their 6—keto—PGF 1(X , PGF20C and PGE2 content as
described in Section 2.5.
Another identical group of 6 male rats was used to
investigate PG production by the femoral artery and
mesenteric artery. The animals were killed and the
femoral and mesenteric arteries were removed and weighed.
These vessels were homogenised and incubated, and the PGs
were extracted and assayed as described above.
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3.1.3 Results
Figure 3.1.1 shows the mean (+/- s.e.m, n = 6) amounts of
6-keto-PGF!K, PGF2K and PGE2 formed from exogenous
arachidonic acid in homogenates from aorta, vena cava,
femoral artery and mesenteric artery. 6—Keto—PGF 1<x was
the major PG produced by homogenates of aorta with lesser
amounts of PGF2K and PGE2. Homogenates of vena cava and
femoral artery produced similar amounts of the 3 PGs.
The mesenteric artery produced similar amounts of
6-keto-PGFla and PGF2CC with less PGE2 . Femoral artery PG
production per mg of tissue was the lowest of the 4
tissues. 6-Keto-PGF1K production by aorta was much
higher (3 to 8 fold) than the other vascular tissues,
although aortic PGF20C and PGE2 production were comparable
to the other tissues.
3.1.4 Conclusions
These experiments established that although the major PG
production by homogenates of aorta was PGI2 (measured as
6-keto-PGFjK), there were also considerable amounts of
PGF2k and PGE2 produced. Surprisingly, in the other
tissues, the vena cava, mesenteric artery and femoral
artery all 3 PGs were produced to a similar degree.
Thus, only in the aorta was this large disparity in



















Fig.3.1.1Mean(+/-sem,n=6)amou tsofprostaglandinsPGs)Synthesisedby homogenatesfaorta,CZ1v acav , artery,Hofmalerats.mesentericart ry.111111ndfe oral
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The cross reactivity studies given in Section 2.5 showed
that the PGF2K antiserum cross-reacted significantly with
PGF10( and that the PGE2 antiserum cross-reacted
significantly with PGA2, PGB2 and PGEt. A pooled sample
from the aortic homogenates was therefore analysed
further by GC-MS to identify positively the presence of
6-keto-PGF loc, PGF2oc and PGE2 and to investigate if there
was sufficient PGA2 , PGB2, PGEx or PGF1K present to
interfere with the RIA. Unfortunately, there was
insufficient sample from the other tissues for analysis
by GC-MS. The procedure for the GC-MS analysis is given
in Section 2.6.
The presence of 6-keto-PGF 10( was positively identified in
the pooled sample from aorta. The presence of PGE2 was
difficult to determine unequivocally but the detection of
small peaks at the appropriate carbon value did seem to
indicate that there was PGE2 present. Although no PGF2a
could be found this was probably because even in the
pooled sample there was insufficient PGF2oc to be detected
in a full mass spectrum. Similarly, the peaks
characteristic of PGA2 , PGB2 , PGE t and PGF10C could not be
detected, so it cannot be stated whether these compounds
were absent from or present in the samples. However,
since arachidonic acid was present in the incubations in
excess, it is unlikely that substantial quantities of
PGEj and PGF1K were formed. Furthermore, an enzyme
converting PGE2 into PGA2 (and hence to PGB2) in tissues
has not been conclusively demonstrated, so it is again
unlikely that substantial quantities of PGA2 and PGB2
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were present. Consequently, the antibodies were probably
predominantly measuring the PG to which they had been
raised.
SECTION 3.2
Measurement of aortic PG levels
3.2.1 Introduction
The PG content of extracts of aortic homogenates after a
60 min incubation period has thus far been described as
PG 'production'. Before 'production' can be equated with
'synthesis', it is necessary to determine that (i) prior
to tissue homogenisation and incubation; the levels of
PGs in the aortic tissue are low, and (ii) that
metabolism of PGs by the homogenate during incubation is
also low. As the release of free arachidonic acid is the
rate-limiting step in the biosynthesis of PGs (Flower and
Blackwell, 1976), excess arachidonic acid (2 //g/ml) was
added to each homogenate before incubation. Thus it can
be assumed that any changes in PG production observed
were not due to differences in arachidonic acid
availabi1ity.
The following experiment was performed to determine that
PG levels in rat aorta are low. PG metabolism in aortic
homogenates is described in Section 4.2.
3.2.2 Methods
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Four male rats were killed between 10.00 h and 12.00 h.
The aorta of each rat was removed, weighed and
homogenised in 5 ml absolute ethanol. The homogeniser
was washed with 5 ml ethanol and the homogenate and
washings were added to a centrifuge tube. Each
homogenate was centrifuged at 1000 x g for 15 min and the
supernatant fluid was retained. The precipitate was
washed with 5 ml absolute ethanol, centrifuged at 1000 x
g for 15 min and the resulting supernatant fluid was
combined with the previous extract.
Each extract was evaporated to dryness, under reduced
pressure at 45°C, then dissolved in 10 ml distilled
water, PGs were extracted with ethyl acetate as described
in Section 2.4, and were then stored and assayed by RIA
as described in Section 2.5.
3.2.3 Results
The mean ( + /- s.e.m., n = 4) amounts of 6-keto-PGF 4 a, PGF20C
and PGE2 in the aortic tissue of male rats are shown in
Table 3.2.1, and have been compared with the amounts
produced by homogenates during incubation.
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Table 3.2.1
Concentration (mean+/- s.e.ra.) of prostaglandins (PGs) in
ethanolic homogenates (PG levels) and in homogenates of
aorta from male rats, incubated with arachidonic acid (PG
product ion).
PG levels (n = 4) PG production (n = 6)
6-keto-PGF loc 0.83 +/- 0.08 * 4.4 +/- 0.95
PGF2k 0.25 + /- 0.11 * 1.41 +/- 0.07
PGE2 0.53 +/- 0.17 0.96 +/- 0.19
* Significantly different (P<0.05) from the amounts of PGs
produced by homogenates incubated with arachidonic acid.
3.2.4 Conclusions
Concentrations of 6-keto-PGFj«, PGF20C and PGE2 in aortae
were low when compared to the amounts of PG formed during
incubation of the homogenates with exogenous arachidonic
acid, and this was significant for 6-keto-PGF t K and PGF2(X
but not for PGE2. It can be concluded therefore, that the
increased PG production found following homogenisation
and incubation reflects fresh synthesis of PGs by the
aortic tissue. It is probable that the other blood
vessels behave similarly in this respect.
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SECTION 3.3
Measurement of PG production in homogenates of aorta,
vena cava, mesenteric artery and femoral artery of female
rats .
3.3.1 Introduction
The sex steroids may be one of the controlling factors in
arachidonate metabolism in vascular tissues. Uzonova et
al., (1977) showed that arachidonic acid-induced
thrombosis in mice is more prominent in the male than in
the female and that castration of the male abolishes this
effect. This occlusive arterial thrombosis was markedly
reduced by cyclooxygenase inhibitors suggesting a central
role for PGs. Similarly, experimentally induced arterial
thrombosis in male as well as female rats was strikingly
enhanced by testosterone treatment. Oestradiol treatment
significantly increased the obstruction time, and
decreased the thrombus weight in male rats but had no
significant effect in the females (Uzonova et al., 1976).
There is no biochemical mechanism given to explain these
results but, if vascular PGI2 were involved in these
effects of steroids on thrombosis, it could be postulated
that the male and female sex steroids were having an
opposite effect on PGI2 synthesis, with oestrogen
stimulating and testosterone inhibiting its production.
In contrast, however, Mag'gi et al. (1980) and Pomerantz
et al., (1980) found a higher spontaneous release of PGI2
from aortic rings of male as compared to female rats and
castration had no effect on this release in male rats.
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The experiments described in this section were undertaken
to characterise the overall profile of PG production by
different vascular tissues of the female rat. These
results were then compared with the results obtained from
the same vascular tissues of the male rats (detailed in
Section 3.5).
3.3.2 Methods
Female albino Wistar rats, aged between 2 and 3 months
and weighing 200-250 g were used. The animals were kept
under controlled lighting (light period 06:00 h to 20:00
h) and were allowed free access to a standard diet and
water. Vaginal smears were taken daily and examined
microscopically. Day 1 (oestrus) was determined as the
day of maximum cornification of the vaginal epithelial
cells, preceeding the day of leucocyte infiltration.
Only females showing at least 2 consecutive 4-day
oestrous cycles were used in the study.
Animals (n = 6) were killed by stunning and incising the
neck at 10:00 h on Day 4 (pro-oestrus). The females were
always killed at this time and on Day 4 to eliminate any,
as yet unknown, influences of the oestrous cycle on
vascular PG production. The aorta and vena cava from
each rat were dissected free from surrounding tissue and
washed in Krebs solution. Another 6 females were
similarly used to provide the mesenteric artery and the
femoral artery. Each tissue was weighed and then
homogenised separately in 5 ml Krebs solution. The
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homogeniser was washed with 5 ml Krebs solution and the
homogenate and washings were added to a 50 ml conical
flask. The homogenates were incubated for 60 min with 2
//g/ml arachidonic acid. After incubation the pH of the
homogenates was taken to pH 4 with IN HCL, and the PGs
were extracted with ethyl acetate as described in Section
2.4. Samples were stored in 4 ml ethyl acetate at -20°C
until they were assayed for their 6-keto-PGF loc , PGF2K and
PGE2 content by RIA as described in Section 2.5.
Results obtained from the male tissues were compared with
those obtained from the female tissues using Student's
t-test for unpaired data. Significance was tested at the
5X level.
3.3.3 Results (GC-MS)
The cross-reactivity studies given in Section 2.5 showed
that the PGF2K antiserum cross-reacted significantly with
PGFla and that the PGE2 antiserum cross-reacted
significantly with PGA2, PGB2 and PGEx. A pooled sample
of aortic homogenates was therefore analysed further by
GC-MS to identify positively the presence of
6-keto-PGF 10(, PGF20C and PGE2 and to investigate if there
was sufficient PGA2 , PGB2 , PGE y or PGF10( present to
interfere with the RIA. Unfortunately there was
insufficient sample from the other tissues for analysis
by GC-MS. The procedure for the GC-MS analysis is given
in Section 2.6.
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Similar to the results obtained from male aorta,
6-keto-PGF10C was positively identified in the pooled
sample from female aorta and there may have been some
PGE2 present. Again, it was not possible to detect the
presence of PGF20C.
Fig. 3.3.1 shows the amounts of 6-keto-PGF t a, PGF20C and
PGE2 formed from exogenous arachidonic acid in
homogenates of aorta, vena cava, mesenteric artery and
femoral artery from Day 4 female rats. The aorta
produced similar amounts of 6-keto-PGFjK and PGF2CC with
less PGE2 , the vena cava produced mainly PGF20C and PGE2
with less 6-keto-PGFjK. The major PG produced by the
mesenteric artery was 6-keto-PGFjK followed, in
descending order, by PGF20C and PGE2 . The femoral artery
produced mainly 6-keto-PGFj« with less PGF20C and PGE2 .
3.3.4 Conclusions
These experiments show that vascular tissues from female
rats, like the vascular tissues from male rats, produce
PGF2(X and PGE2 as well as PGI2 (measured as
6-keto-PGFja). Production (per mg of tissue) of
6-keto-PGFja by the aorta and mesenteric artery was much
greater than by the vena cava (3-fold) or femoral artery
(2.5 fold). Thus, in the female rat, 6-keto-PGF,K is the
major PG produced by the mesenteric and femoral arteries
with lesser quantities of PGF20( and PGE2 , whereas in
the aorta and the vena cava, PGF20C production was












Fig.3.3.1Mean(+/-sem,n=6)amou tsofprostaglandinsPGsynthesisedby homogenatesfaorta,CDv nacava,^mesentericr ry.111111ndfe or l artery,IBoffemalerats.
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SECTION 3.4
Measurement of aortic PG levels in female rats
3.4.1 Introduction
As described in Section 3.2, before the PG content of
extracts of aortic homogenates incubated for 60 min can
be termed PG 'synthesis' it is necessary to determine
that before tissue homogenisation and incubation the
levels of PGs are low, and that metabolism of the PGs is
also low. The following experiment was performed to
establish PG levels in the aorta of female rats.
3.4.2 Methods
Four female rats were killed on Day 4 of the cycle
between 10:00 and 12:00 h. The aorta of each rat was
removed, weighed and homogenised in 5 ml absolute
ethanol. The homogeniser was washed with 5 ml absolute
ethanol, and the homogenate and washings were added to a
centrifuge tube. Each homogenate was centrifuged at 1000
x g for 15 min and the supernatant fluid was retained.
The precipitate was washed with 5 ml absolute ethanol,
centrifuged at 1000 x g for 15 min and the resulting
supernatant fluid was combined with the previous extract.
Each extract was evaporated to dryness, under reduced
pressure at 45°C, and dissolved in 10 ml distilled water.
- 109 -
PGs were extracted with ethyl acetate as described in
Section 2.4, and were then stored at -20°C and assayed by
RIA as described in Section 2.5.
3.4.3 Results
The mean (+/- s.e.m., n=4) amounts of 6-keto
and PGE2 in the aortic tissue of female rats
Table 3.4.1 and have been compared with
produced by homogenates during incubation.
Table 3.4.1
Concentration (mean +/- s.e.m.) of prostaglandins (PGs)
in ethanolic homogenates (PG levels) and in homogenates
of aorta, from female rats incubated with arachidonic
acid (PG production).
PG levels (n=4) PG production (n=6)
6-keto-PGF10C 0.71 +/- 0. 14 * 3.02 +/- 0.46
PGF2(X <0.04 2.82 + /- 0.20
PGE2 0.17 +/- 0.002 * 1.52 +/- 0.44
* Significantly different (P<0.05) from the amounts of PGs
produced by homogenates of aorta incubated with arachidonic
acid.





Concentrations of 6-keto-PGF loc, PGF20C and PGE2 in aortae
were low when compared to the amounts of PG formed during
incubation of the homogenates with exogenous arachidonic
acid, and this was significant for 6-keto-PGF1C( and PGE2 .
The concentrations of PGF2a were so low as to be below
the detection limit of the assay (0.04ng), therefore the
amounts of PGF2CC produced by homogenates of aorta
incubated with arachidonic acid were much greater. Thus,
the increased PG production found following
homogenisation and incubation reflects fresh synthesis of
PGs by the aortic tissue.
3.4.5 Comparison of PG levels in and PG production by vascular
tissues from male and female rats.
PG levels in aortic tissue were measured to establish
that before homogenisation and incubation tissue levels
of PGs were low. Table 3.4.2 shows the PG levels found in
the aorta of male and female rats.
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Table 3.4.2
Mean (+/- s.e.m., n = 4) concentration of prostaglandins
(PGs) in ethanolic homogenates (PG level) of aorta from
male and female rats.
PG level (ng/mg tissue)
Male Female
6-keto-PGF10C 0.83 +/- 0.08 0.71 +/- 0.14
PGF20C 0.25 +/- 0. 11 <0.04
PGE2 0.53 +/- 0.17 0.17 + /- 0.002 *
* Significantly different (P<0.05) from corresponding male
value.
The total level of PGs present in aortic tissue before
incubation were considerably lower in the female aorta
compared to that of the male. This difference was not
significant for 6-keto-PGF loc but was significant (P<0.05)
for PGE2. PGF2a levels in the female aorta were so low
as to be below the detection limit of the assay. PGF2K
levels in male aorta were easily measurable and therefore
much higher than in the female aorta.
PG production by blood vessels from male and Day 4 female
rats is compared in Fig. 3.4.1. 6-keto-PGFtK and PGE2
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production did not differ in the homogenates of aorta
from male and female rats, but PGF2oc production was
significantly (PC0.05) greater in the aorta of female
rats. 6-keto-PGFtK production was significantly greater
(P<0.05) by the vena cava and was significantly lower
(P<0.05) by the female artery of male rats compared to
female rats. PGE2 and PGF20C production by the vena cava
and by the female artery did not differ between male and
female rats. The production of 6-keto-PGFtK, PGF2K and
PGE2 by the mesenteric artery did not differ between the
2 groups of male and female rats.
SECTION 3.5
Measurement of PG production by aorta and vena cava at
different times during the oestrous cycle.
3.5.1 Introduction
The experiments to date on the effects of sex steroids on
PG production have led to conflicting results.
Stimulation of PGI2 production by oestrogen has been
described in cultured aortic smooth muscle cells (Chang
et al., 1980). Oestrogen and a combined
oestrogen/progestagen treatment also stimulated PGI2
release from aortic rings (Karpati et al., 1980) and from
tissue segments of aorta, vena cava, heart and lung
(Roncaglioni et al., 1979). Conversely, Pomerantz et al.,
(1980) found that oestrogen suppressed and progesterone
enhanced PGI2 release from aortic rings.
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Experiments described in this section were performed to
determine if endogenous plasma levels of oestrogen and
progesterone have an effect on PG production by aorta and
vena cava. Female rats were killed at two different
times during the oestrous cycle, 02:00 h on Day 1
(oestrus) and 10:00 h on Day 4 (pro-oestrus). Plasma
oestrogen levels (oestradiol-17B) reach a peak on the
morning of pro-oestrus (Day 4), and at 02:00 h on oestrus
(Day 1) are approaching their lowest level. On the
morning of pro-oestrus plasma progesterone levels are low
but are just beginning to rise until they reach a peak
somewhere around 22:00 h on that evening (Nequin, Alvarez
and Schwartz, 1979). Thus, on the morning of pro-oestrus,
the effects of an endogenously high plasma oestrogen and
low plasma progesterone level could be studied, and on
the early morning of oestrus, the converse of a low
plasma oestrogen and high plasma progesterone level could
be investigated with regard to vascular PG production.
3.5.2 Methods
Female albino Wistar rats, aged between 2 and 3 months
and weighing 200-250 g were used. The animals were kept
under controlled lighting conditions (light period 06:00
h to 20:00 h) and allowed free access to a standard diet
and water.
Animals were killed by stunning and incising the neck at
10:00 h on Day 4 (pro-oestrus) and 02:00 on Day 1
(oestrus) 6 animals were used for each day. The aorta
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and vena cava from each rat were removed, and homogenised
and incubated as detailed in Section 3.1.1. The PGs
produced were extracted with ethyl acetate and stored
until assayed by RIA, as described in detail in Section
2.5. Results were analysed using Student's t-test for
unpaired data and significance was tested at the 5%
level.
3.5.3 Results
Figure 3.5.1 shows the amounts of 6-keto-PGF la , PGF2(X and
PGE2 formed from exogenous arachidonic acid (2 fig/ml) in
homogenates from aorta and vena cava at 10:00 h on Day 4
and at 02:00 on Day 1. 6-keto-PGF,K and PGF2a were
produced in greatest amounts by aortic homogenates from
both Day 1 and Day 4 rats, with lesser amounts of PGE2
being produced. Homogenates of vena cava produced mainly
PGF2k and PGE2 , with lesser amounts of 6-keto-PGF loc .
There were no significant differences in the production
of any one PG by homogenates of aorta and vena cava
between rats on Day 1 and Day 4 of the oestrous cycle.
3.5.4 Conclusions
At the two periods of the oestrous cycle studied here, of
high and low endogenous plasma oestrogen levels, and low
and high endogenous plasma progesterone levels, there was
no significant effect on PG production in either the
aorta or vena cava, suggesting that the stimulatory
effects of oestrogen observed in tissue culture



























Fig.3.5.1.Mean(+/-sem,n=6)amountsofprostaglandins(PGssyn hesised byhomogenatesfaortalZJandv ncav ^fr mem lr tth daysofpro-oestrus(D4;10:00h)andoestrul0.2:).
experiments or after long-term treatment in the intact
animal are pharmacological in nature. To test this
hypothesis, the effects of oestradiol and progesterone on
PG production by the blood vessels of ovariectomised rats
was investigated next.
SECTION 3.6
Measurement of PG production by aorta and vena cava of
oestrogen and progesterone treated females.
3.6.1 Introduction
Studies by other research workers have investigated the
effects of long-term treatment with oestrogen or an
oestrogen/progestagen combination on vascular PG
production. Karpati et al. (1980) and Roncaglioni et al.
(1979) designed their experiments specifically to
investigate the effects of long-term treatment with a
synthetic oestrogen/progestagen combination. These
studies were all performed in intact rats, and since no
atttempt has been made to mimic or consider the animals'
natural production of steroids by the ovary, the
following experiment was undertaken using a more
physiological model of oestrogen and progesterone
treatment, which was designed to simulate the plasma
steroid hormone concentrations occurring around
ovulation. (Karla, Fawcett, Krulich and McCann, 1973).
3.6.2 Methods
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Female albino Wistar rats weighing between 200 and 250 g
were kept under controlled lighting conditions and
allowed free access to food and water. Twelve rats were
ovariectomised between 09:00 h and 10:00 h on di-oestrus
(Day 3), under Althesin anaesthesia (0.5 ml / 100 g body
weight, i.p). Six of these animals received 10 /?g
oestradiol benzoate in 0.5 ml of arachis oil as a
subcutaneous injection (s.c.). The other six animals
were injected with 0.5 ml of the arachis oil vehicle. On
the following day, the expected pro-oestrus, the animals
were injected at 10:00 h with 2 mg progesterone s.c. in
0.5 ml arachis oil. At 17:00 h, five hours after the
progesterone injection, the rats were killed and their
aorta and vena cava dissected out, weighed, homogenised
and incubated as described previously in Section 2.4.
The PGs produced were extracted and assayed by RIA as
described in Section 2.5. Results were compared by means
of Student's t-test for unpaired data and significance
was tested at the 5% level.
3.6.3 Results
Fig. 3.6.1 compares PG production by homogenates of aorta
and vena cava from acute ovariectomised, oestrogen and
progesterone treated rats and control, ovariectomised
rats. 6-keto-PGFjK was the major PG produced by the
aorta of both treated and control animals, followed in
descending order by PGF2K and PGE2 . In both groups PGF20C
and PGE2a were the major PGs produced by homogenates of
vena cava with lesser amounts of 6-keto-PGF loc. There
















Fig.3.6.1.Mean(+/-sem,n=6)amountsofprostagl ndi(PGssynthesi edby homogenatesfa rta(Z3andvecavafciJfromcut lyovariectomised ratswithout(C)andithToestradiolprogesteronetreatment.
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were no significant differences in the production of any
one PG by either the aorta or vena cava of oestrogen and
progesterone-treated rats compared to control,
ovariectomised rats.
However, the procedure of ovariectomy in itself appears
to have had a significant effect on vascular PG
production. Comparing intact Day 1 or Day 4 rats to
ovariectomised control or treated rats there was a
significant (P<0.05) increase in 6-keto-PGF 1(X production
by aorta from ovariectomised rats, and a significant
increase in PGE2 production by vena cava from
ovariectomised compared to intact rats.
3.6.4 Conclusions
A model of oestrogen and progesterone treatment,
involving short-term ovariectomy and 2 days of steroid
treatment, designed to simulate the steroid changes found
at ovulation did not influence PG production by the aorta
or vena cava. These results agree with the findings of
the previous sub-section that changes in plasma levels of
oestrogen and progesterone in the female rats do not
stimulate PG production by these vascular tissues. One
observation of interest is that the profile of PG
production in rats ovariectomised for 33 h is different
to that of the intact animal. Deprivation of steroid
hormones may therefore have affected PG production by the
blood vessels, suggesting that these hormones do have a
long-term, as opposed to a short-term effect on vascular
PG production. Short-term treatment with steroids did not
reverse the effects of ovariectomy.
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3.7 Discussion
The experiments described in this section have
established that several vascular tissues from male and
female rats have the capacity to produce PGF2a and PGE2
as well as PGI2 (measured as 6-keto-PGF t) . With the
exception of the aorta in the male rat and the mesenteric
artery in the female rat the synthetic capacity of the
blood vessels for producing these two vasoactive PGs was
as great as for PGI2 . Recent studies have verified that
vascular cells have the ability to release PGs other than
PGI2, with 6-keto-PGF!a, PGF2K and PGE2 shown to be
produced by porcine endothelial cells in culture (Ody et
al., 1983) and by rabbit blood vessels (Foerstermann et
al., 1984; Boeynams and Galand, 1983).
In rabbit, rat and dog, arteries have been shown to
produce, and also release more PGI2 than veins (Buchanan
et al., 1979; Skidgel and Printz, 1978; Eldor et al.,
1981) but no difference in PG production by bovine
arteries and veins was detected (Terragno et al., 1975).
In the present study, aortic 6-keto-PGFta production was
certainly greater than that of the vena cava. However,
in the male rat, 6-keto-PGFja production by the
mesenteric and femoral arteries was not significantly
greater than by the vena cava, although it was greater in
the female.
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In dogs, a segment of jugular vein implanted into the
carotid artery for up to 6 weeks, although becoming
'arterialised' from a structural point of view,
maintained a lower production of PGI2 than the carotid
artery (Eldor et al., 1981). However, a similar study in
rats, implanting a segment of epigastric vein into the
femoral artery showed a progressive rise of PGI2
production by the graft from venous levels to values
close to the arterial controls (Petry et al, 1982). This
suggests that in the rat at least, PGI2 production may be
related to blood pressure and flow.
Contrary to the findings of Pomerantz et al. (1980) and
Wey et al. (1983), the aorta from male rats did not
produce more 6-keto-PGFt« than the aorta from females,
but their studies were looking at 6-keto-PGFta release
from aortic rings rather than synthetic capacity as
measured here. However, 6-keto-PGFt« production was
greater by male vena cava than by female vena cava.
No difference in PG production was observed at 10:00/l on
pro-oestrus and 02:00 h on oestrus. Ali and Williams
(1983), found that PGI2 production was lowest at oestrus
and significantly greater at pro-oestrus, met-oestrus and
di-oestrus, showing a similar fluctuation to the PGI2
production of the myometrium. These results were
obtained in the presence and in the absence of
arachidonic acid but the authors do not record at what
time of the day their experiments were carried out. The
inability of the present study to detect any change in PG
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production during the cycle may have been because the
times chosen did not coincide with any increase in PG
production. Further experiments are required to clarify
this point.
There are conflicting results regarding the influence of
sex steroids on PGI2 production. In the present
investigation short-term treatment with oestrogen and
progesterone after acute ovariectomy had no effect on the
production of 6—keto—PGF tK by aorta or vena cava. This
agrees with the observation that PG production does not
vary during the periods of high and low plasma oestrogen
levels during the oestrous cycle. However, oestrogen
treatment significantly inhibits the thrombus formation
induced by electric shock with the concomitant
stimulation of PGI2 synthesis in the aorta (Ohtsu et al.,
1983). Thus, providing a biochemical mechanism for the
findings of Uzonova et al. (1976) who found that
oestrogen treatment increased the obstruction time and
reduced the thrombus weight of male mice injected with
arachidonic acid.
Oestrogen also stimulated PGI2 production in cultured rat
aortic smooth muscle cells (Chang et al., 1980) and from
cultured porcine endothelial cells from female animals
(Seillan et al., 1983). Stilboestrol treatment of
ovariectomised rats stimulated aortic PGI2 production
(Ali and Williams, 1983) and neonatal oestrogen
administration to female rats resulted in an increased
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capacity for 6-keto-PGF1K synthesis in adult aortae (Wey
et al., 1983). Conversely, oestrogen inhibited
(Needleman and Parks, 1982) or had no effect (Corvazier,
Dupuy, Dosne and Maclouf, 1984) on PGI2 production by
human umbilical vein endothelial cells in culture.
In the present study acute ovariectomy produced a
significant increase in 6-keto-PGFtK production by the
aorta in agreement with Wey et al., (1983) who found that
neonatal ovariectomy increased the capacity of the aorta
for 6-keto-PGF!K synthesis, and Pomerantz et al., (1980)
who found that ovariectomy at 3 weeks of age increased
the aortic synthesis of 6-keto-PGF10c in the adult rat.
Therefore, in this situation, the absence of oestrogen
appears to stimulate PGI production. Testosterone has
been reported to inhibit PGI2 production by rat aortic
smooth muscle cells (Nakao et al., 1981) or to have no
effect (Pomerantz et al., 1980; Wey et al., 1983; Seillan
et al., 1983).
The relationship of sex hormones and PGI2 production and
their relation to thrombosis is complex and the work of
Uzonova et al. (1976) showing that male rats have twice
the thrombus size and death rate compared with females
and that oestrogen reduced the thrombus weight in male
rats can not be explained simply by the conflicting
results of the effects of steroid hormones on PGI2
production. Other factors to be taken into consideration
appear to be the hormonal background of the experimental
model chosen, whether the animal has or has not been
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ovariectomised, or, in the case of the umbilical vein
endothelial cells, whether the hormonal milieu of




Measurement of the PG synthetic capacity of homogenates
of aorta, the basal release of PGs from the perfused
aorta and the stimulated release of PGs from the perfused
mesenteric arterial bed of male and female normotensive
and New Zealand genetically hypertensive rats.
Introduction
The level of arterial blood pressure is set by complex
interactions of several mechanisms which influence blood
flow and resistance of the vascular system. In
hypertension the final common pathway that leads to a
raised arterial pressure is an increased total peripheral
resistance. This is regardless of the underlying cause
such as increased activity of the sympathetic nervous
system, of the renin-angiotensin system, or excessive
secretion of mineralocorticoids. One of the earliest
known properties of PGs was their effect on blood
pressure, and many of the current studies on hypertension
are aimed at determining the association of PGs with
blood pressure regulation. The hypothesis that PGs could
be involved in these mechanisms has gained strength with
the demonstration that the kidney and blood vessels are
major sites of PG synthesis, that pressor hormones
induce the release of PGs and that PGs are probably
involved in the renal mechanisms affecting blood pressure
control.
The hypotensive action of PGs of the E series has been
known for a long time, and it is now well established
that PGE-, inhibits the release of NA from many
sympathetic nerves. This latter action has been shown in
various species and in several different preparations
(for review see Hedquist, 1977). The effect of PGI2 on
transmitter release from sympathetic nerves is
contradictory. Hedquist (1979) found that PGI2 had
little or no effect on [3H]-noradrenaline release
in response to nerve stimulation in rabbit kidneys, but
Weitzell et al. (1978) reported inhibition of NA release
by PGI2 in rabbit pulmonary arteries. Armstrong et al.
(1979) observed a similar effect with PGI2 in rabbit
mesenteric arteries, but not veins.
It has been proposed that a deficiency of production of
vasodilator PGs in vascular beds, (particularly the
kidney) may lead to the increased peripheral vascular
resistance characteristic of essential hypertension (Vane
and McGiff, 1975). However, several groups have reported
that the generation of PGI2 and PGE2-like substances from
exogenous arachidonic acid is much greater in aortic
rings and homogenates from spontaneously hypertensive
rats (SHR) than in aorta from normotensive rats (Limas
and Limas, 1977; Rioux et al., 1977; Pace-Asciak et al.,
1978). The release of a PGI2-like substance was also
greater from aortic rings of stroke-prone and
stroke-resistant SHR compared with normotensive controls
(Okuma et al., 1980) and was greater from aortic strips
of the New Zealand genetically hypertensive (GH) strain
compared to normotensive rats (Botha et al., 1980).
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Because of the equivocal nature of the results obtained
to date on the role of vascular PGs in the control of
blood pressure, it seemed necessary to investigate PG
production by blood vessels in the hypertensive rat in
greater detail. PGI2 is the PG most often measured,
while PGE2 and PGF2K are often completely overlooked.
The results described in the previous section indicate a
considerable capacity of rat blood vessels for producing
PGE2 and PGF2(X, therefore, experiments described in this
section aimed to characterise more complete profiles of
PGI2 , PGE2 and PGF20C production in separated layers of
aorta, of the release of these 3 PGs from perfused aorta,
and of the stimulated release of these 3 PGs from the
mesenteric arterial bed of male and female normotensive
and hypertensive (GH) rats.
SECTION 4.1
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Measurement of the PG synthetic capacity of homogenates
of aorta and vena cava from normotensive and genetically
hypertensive male rats.
4.1.1 Introduction
The experiments described in this section were undertaken
to establish the blood pressure of the control
normotensive Wistar rats and of the New Zealand
genetically hypertensive rats (GH) which had been kept as
a colony for a number of years in the departmental animal
house. The ability of homogenates of aorta and vena cava
from GH rats to synthesise PGs was compared with that of
normotensive Wistar control male rats.
4.1.1 Methods
Male albino Wistar rats aged 2-3 months and weighing
200-250 g and male New Zealand genetically hypertensive
rats (GH) of the same age, weighing 180-200 g were used.
The animals were housed under controlled conditions and
were allowed a standard diet and water.
4.1.3 Blood pressure measurement.
Measurements were made in the same cage order and the
same time of day (11:00 h to 13:00 h), every day for 2
weeks. Systolic blood pressure was measured indirectly
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using the tail cuff method. Pulsations of the tail
artery in pre-warmed rats were monitored by a
photo-electric detector (Huntingdon Instruments Rat Blood
Pressure Monitor) and recorded on a Servoscribe
Two-channel Recorder, together with cuff pressure.
Rats were pre-warmed using heating lamps. The animals
were then placed in a heated (37 °C) holder and lightly
restrained. The tail cuff was applied firmly to the tail
but without constricting the artery, and 5 consecutive
readings of systolic pressure were obtained. Blood
pressure was determined by rapidly increasing the
pressure in the cuff until the tail artery pulse
disappeared, then gradually releasing the pressure over
10-15 sec and noting the pressure at which the pulsations
first reappeared. This value was taken as the systolic
blood pressure. After about a week, the rats were
trained in this routine and consistent readings were
obtained.
After consistent blood pressure measurements had been
made, the animals were killed (6 in each group) and the
aorta and vena cava were removed. Each vessel was
weighed, was homogenised separately and was incubated for
60 min with arachidonic acid (2 //g /ml). The PGs
produced were then extracted into ethyl acetate (as
described in Section 2.4) and stored until assayed for




The systolic blood pressure of the normotensive rats was
104.8 +/- 4.3 mmHg (mean +/- s.e.m.; n = 6) and that of
the GH rats was 150.5 +/- 3.1 mmHg (mean +/- s.e.m.;
n = 6) .
Figure 4.1.1 compares PG production by homogenates of
aorta and vena cava from male normotensive and GH rats.
6-Keto-PGF twas the major PG produced by aorta of
normotensive and GH rats followed by lesser amounts of
PGF20C and PGE2 . The vena cava from normotensives
produced similar amounts of the 3 PGs whereas the vena
cava from GH rats tended to produce more PGF20C.
There was no difference in the amounts of either
6-keto-PGF 10( or PGE2 produced between the 2 groups.
However, the amount of PGF20C produced was significantly
greater (P < 0.05) by homogenates of aorta from GH rats
compared to normotensive rats. PGF2a production by the
vena cava tended also to be higher between the two groups
but the difference was not statistically significant (P >
0.05).
4.1.5 Conclusions
Although the systolic blood pressure of the GH rats was
not as high as reported by others (Simpson, Phelan,
Jones, Butt, Young and Ledingham, 1979) it was











Figure 4.1.1. Mean (+/- s.e.m., n=6) amounts of prostaglandins (PGs)
synthesised by homogenates of aorta and vena cava from
normotensive and New Zealand genetically hypertensive
male rats.
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normotensive rats. The lower blood pressure found in
these GH rats was probably as a result of the colony not
being as stringently maintained as possible i.e. with
continual brother to sister mating of the animals with
the highest blood pressure. However, all of the GH
animals measured did have a markedly higher blood
pressure than that of their normotensive controls.
PGI2 production, measured as 6-keto-PGFtK, was not
significantly greater in either homogenates of aorta or
vena cava of normotensive compared to GH rats which does
not agree with the findings of Limas and Limas, (1977);
Rioux et al. (1977); or Pace-Asciak et al., (1978) but
their studies were carried out in the spontaneously
hypertensive rat (SHR) not in the New Zealand GH rat as
in this study. The most striking difference between the
2 groups was the increased production of PGF20C by
homogenates of aorta and vena cava of hypertensive
compared to normotensive rats. This observation has not
been reported previously.
SECTION 4.2
Measurement of the ability of aortic homogenates to
metabolise PGF20C.
4.2.1 Introduction
Augmented production and release of PGs from a
indicate either enhanced synthesis and/or





PGs in tissues. The enzyme 15-prostaglandin
hydroxydehydrogenase (15-PGHD) is responsible for the
catabolism of PGE2 and PGF20C and this enzyme has been
shown to be present in both arteries and veins (Wong and
McGiff, 1977). It can also inactivate PGI2 by converting
it to 6, 15 di-keto PGF1CC (Sun et al., 1979).
A deficiency of 15-PGHD activity has been found in the
renal vessels of New Zealand GH rats (Armstrong et al.,
1976) and also in SHR (Pace-Asciak, 1976). An endogenous
inhibitor of 15-PGHD has been recovered from the kidney
of GH rats (Wong, Baer, McGiff, 1979). If the kidney of
GH rats shows an aberration in 15-PGHD activity it is
possible that this defect is also present in the 15-PGHD
from other blood vessels, so the metabolism of [3H] PGF20c
was investigated in homogenates of aorta from
normotensive and GH male rats.
4.2.2 Methods
Four normotensive and four GH male rats (2-3 months old)
were used. The animals were killed, the aortae were
removed, and each aorta was cut in half and weighed.
Each half aorta was then homogenised in 5 ml of Krebs
solution. Nicotinamide-adenine dinucleotide (NAD+) at a
final concentration of 2 mM and 10 jug of PGF20C were added
to one of the aortic halves. Each homogenate was then
incubated in the presence of 0.5 //Ci of [3h3 PGF2k
(sp.act.160 Ci/mmol) for 60 min. The PGs were extracted
as described in Section 2.4. The extracts were taken to
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dryness at 45°C under reduced pressure and the residues
were redissolved in 0.2 ml of methanol and subjected to
thin layer chromatography (TLC).
Non-radioactive marker standards (10 //g) of PGF20C,
15-keto-PGF2K and 13,14-dihydro-15-keto-PGF2K were
spotted onto a pre-coated silica gel TLC plate (Merck,
U.K.). Sample extracts were also streaked onto separate
TLC plates. The plates were developed in the solvent
system, chloroform: methanol:glacial acetic acid: water,
90:9:1:0.65, to give a solvent front 15 cm from the
origin. Standard spots on the control plates were
developed in iodine vapour for 30 min and the Rf values
were calculated. Experimental plates were scanned using
a Panax radio TLC plate scanner to localize the
radioactivity. The plates were marked at 0.5 cm
intervals and the silica gel was scraped off the plates
into scintillation vials. Methanol (1 ml) was added to
each vial followed by 10 ml scintillation fluid (10.5 g
PPO, 1.5 1 toluene). Radioactivity was monitored in a
Philips scintillation counter using sample channels ratio
counting. The Rf values of radioactive peaks on the
plate were compared to Rf values of standard PGF20C and
metabolites. Due to the close proximity of the two PGF20C
metabolites on the TLC plate, they were not separated for
counting purposes and the percentage metabolism of PGF20C
into these two products was expressed as a single
percentage of the total radioactivity on the plate.
4.2.3 Results
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The Rf values for the non-radioactive marker standards
are shown in Table 4.2.1.
Table 4.2.1









Table 4.2.2 shows the percentage metabolism of PGF20C in
aortic homogenates of male normotensive and GH rats.
Table 4.2.2
Percentage metabolism of PGF20( in aortic homogenates of
normotensive and GH male rats, incubated in the absence
and presence of NAD + (mean +/- s.e.m.).
Normotensive Hypertensive
Without NAD+ With NAD+ Without NAD+ With NAD+
Total
metabolism 17.1+/-2.5 17.8+/-1.9 15.2+/-2.4 17.1+/-2.3
Metabolism per 3.5+/-0.7 4.0+/-0.7 3.5+/-0.6 5.0+/-1.2
10 mg tissue
Incubation of homogenates of aorta resulted in the
formation of metabolites with Rf values corresponding to
the 15-keto and 13, 14-dihydro-15-keto metabolites of
PGF20C. The percentage metabolism of PGF20C in the absence
of NAD+ was low and did not increase significantly with
the addition of NAD+, in either group. The percentage
metabolism of PGF20C did not differ significantly between






PGF20C in aortic homogenates in the absence
of NAD+ is low. As blood vessel PG levels
it can be concluded that the amounts of PG
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produced by incubating these homogenates with arachidonic
acid reflect the PG-synthesising capacity of the vascular
tissue.
Metabolism of PGF20C in homogenates of aorta from GH rats
was not significantly lower than that in homogenates from
normotensive, suggesting that the increased amounts of
PGF2k measured in aorta and vena cava from hypertensive
animals are due to increased production of PGF2K and not
due to a decrease in its metabolism.
As the same enzyme, 15-PGHD is responsible for the
catabolism of PGE2 and PGI2 it is probable that, in the
absence of NAD+, metabolism of these PGs by homogenates
is also low. Another enzyme, 9-prostaglandin E
ketoreductase (9-PGEKR) catalyses the stereospecific
reduction of PGE2 to PGF20C (Leslie and Levine, 1973).
The activity of 9-PGEKR was not investigated in this
study but it is probable that the increased amounts of
PGF20C found in homogenates of aorta from GH rats is not
due to increased conversion of PGE2 to PGF20C, as PGE2
production was not significantly reduced in aortic
homogenates of GH compared to normotensive rats.
SECTION 4.3
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Measurement of PG production in the separate layers of
aorta from normotensive and GH male rats.
4.3.1 Introduction
The lack of reactivity between platelets and vascular
endothelium has been known for many years. However, when
sub-endothelial layers are exposed, platelet aggregation
is strongly stimulated. The reasons for the absence of
platelet aggregation in the presence of an intact
endothelial layer were unknown until the discovery of an
enzyme for the synthesis of the potent vasodilatory and
anti-aggregatory PG, PGI2, in rabbit blood vessel.
(Moncada et al., 1976). These authors postulated that
PGI2 might be formed from endoperoxides released by the
platelets, thus formulating an hypothesis of endothelial
cell and platelet interaction (discussed in detail in
Introduction section).
Subsequently, PGI2-like activity, measured by platelet
bioassay, was found to be produced by all layers of the
rabbit thoracic aorta. The amount of PGI2 formed was
found to decrease progressively from the endothelial
layer to the adventitia (Moncada et al., 1977).
The technique of cell culture has since been used to
identify and quantitate the PGs produced by vascular
endothelial and smooth muscle cells. However, changes in
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the pattern of PG production during culture have been
observed in pig aortic endothelial and smooth muscle
cells (Ager et al., 1979 & 1982) and in endothelial cells
from human artery (Siess et al., 1981). Differences have
also been observed in the absolute amounts of PGE2 and
PGI2 produced from fresh tissue compared to cultured
cells (Ager et al., 1982; Goldsmith, et al., 1982).
In this set of experiments therefore, the previous
technique of separation of the vessel layers, followed by
homogenisation and incubation of the layers with AA has
been employed to investigate the profile of PG production
by the aorta of normotensive and GH male rats.
4.3.2 Methods
Male albino Wistar rats weighing 250g-300g (2-3 months
old) and male GH rats of the same age, weighing 200-250 g
were used.
Preparation of the different layers of the vessel wall
The method of Moncada et al. (1976), using rabbit aorta
was followed with some modifications. Six animals from
each group were killed and the aorta carefully dissected
from surrounding tissue. The aorta was rinsed in Krebs
solution to remove any blood, was opened longitudinally
and, with its endothelial surface uppermost, was pinned
out on a plastic petri-dish. The endothelial cells were
carefully scraped off with a scalpel blade and were
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suspended in 5 ml Krebs solution. The adventitia and the
smooth muscle layer were also separated with a scalpel
blade and then weighed.
The adventitia and smooth muscle layers were homogenised
separately in 2.5 ml Krebs solution. The homogeniser was
washed with 2.5 ml Krebs solution and the homogenate and
washings were added to a 25 ml conical flask. The
endothelial cell layer was left as a cell suspension. An
aliquot portion (100 pi) from each of the three layers
was kept for determination of protein content according
to the method of Lowry et al. (1951). After 2 pg/ml of
arachidonic acid had been added to each flask, the flasks
were incubated for 60 min and the PGs produced were
extracted with ethyl acetate as described in Section 2.4.
Samples in ethyl acetate were stored at -20°C until
assayed for PG content by RIA as detailed in Section 2.5.
4.3.3 Results
Figure 4.3.1 details PG production by homogenates of
adventitia and smooth muscle from the aorta of
normotensive and GH male rats. The results are expressed
as ng of PG per mg of tissue rather than ng of PG per mg
of protein because the smooth muscle layer from the aorta
of GH rats was found to contain a significantly higher (P
< 0.001) amount of protein per mg of wet weight than that
of normotensives, this difference distorted the results
when expressed per mg of protein. Also, there was
insufficient protein present in the 100 fil aliquot














portion from the 5ml endothelial cell suspension to
determine accurately enough the protein concentration.
Thus, a direct comparison of the PG synthetic capacity
(per mg protein or per unit weight) of the three
different layers was not possible. However, a comparison
of the synthetic capacity of the different layers for PG
production, expressed as total PG production by a 2.5 cm
length of aorta is shown in Table 4.3.1.
The results per mg wet weight of tissue will be discussed
first. Adventitia from normotensive and GH rats produced
similar amounts of the 3 PGs and there was no significant
difference in PG production between the two groups. The
smooth muscle layer had a much greater capacity for PG
production than the adventitia. 6-keto-PGF loc was the
major PG produced by normotensives followed by lesser
amounts of PGF20C and PGE2 . 6-keto-PGFsK and PGF20C were
produced in similar amounts by the smooth muscle layer of
GH rats with less PGE2 formed. This difference in the
profile of PG production between normotensive and GH rats
was a significant (P < 0.001) decrease (Figure 4.3.1) in
the quantity of 6-keto-PGFtK produced and a significant
(P < 0.01) increase in the production of PGF2<X by the
smooth muscle layer of GH rats. There was no difference
in PGE2 production.
Figure 4.3.2 shows endothelial PG production expressed as
ng of PG per 2.5 cm length of aorta. 6-keto-PGF1K was
the PG produced in greatest amounts by the endothelium of
normotensives with lesser amounts of PGF2K and PGE2. In
Figure4.3.2.







endothelial cells from the aorta of GH rats, the
descending order of production was 6—keto—PGF lcc > PGF20C >
PGE2 . There was no difference in 6-keto-PGF loc production
between the two groups but there was an increased
production of PGF2K (P < 0.01) and a decreased production
of PGE2 (P < 0.05) by the endothelium from GH rats.
When the results were expressed as total PG production
per 2.5 cm length of aorta, 6-keto-PGF1K was the major PG
produced by smooth muscle homogenates and by endothelial
cell suspensions, whereas PGF20C was the major PG produced
by homogenates of adventitia. The total amounts of
6-keto-PGFj« synthesised by the separate layers were in
the order of smooth muscle > adventitia > endothelial
cell layer for normotensive rats, and smooth muscle >
adventitia = endothelial cell layer for GH male rats. The
total amounts of PGF2K and PGE2 synthesised were higher
by smooth muscle and adventitia than by endothelial cells
of both groups of rats. However, as the endothelial cells
constitute about 2% of the total tissue of the aorta, the
capacity for synthesising 6-keto-PGF 4K, PGE2 and PGF26C is
3 to 30-fold higher in the endothelial cells than in
smooth muscle or adventitia.
The amounts of 6-keto-PGF,K produced by homogenates of
smooth muscle and adventitia were significantly lower (P
< 0.05) in hypertensive compared to normotensive rats but
the amounts of 6—keto—PGF loc synthesised by the
endothelial cells were similar between the two groups.
PGF2k synthesis was significantly higher (P < 0.05) by
Table4.3.1.












Male:I Normotensive9.5±1 752.830 6.12.20 37.71 544±3.40 51 8.926.3 Hypertensive8.5±0 731.8.1+.11.26.00.42 23 817 6±4.2+20. +1 861 0-1+̂ Female Normotensive8.3±2 074.119 92.05.1*5.97405.7*36 6±.723 01.9*1 Hypertensive2.4±0.6*+7.92.8+6.801 60. +*17.4±2.817.0±2.2+3 90 524 4.9*5.21
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the smooth muscle and endothelial cell layers, and was
significantly lower (P < 0.05) by adventitia of
hypertensive compared to normotensive male rats. PGE2
synthesis was significantly lower (P < 0.05) by the
endothelial cell layer and adventitia, but was similar in
smooth muscle of GH compared to normotensive male rats.
Significant differences in the production of
6-keto-PGFtK, PGF2K and PGE2 by smooth muscle were
present whether the results were expressed on a unit
weight or a unit length basis. However, significant
differences in the amounts of 6-keto-PGF jK, PGF20C and
PGE2 produced by adventitia of normotensive and GH male
rats disappear when the results are expressed on a unit
weight as opposed to a unit length basis. Obviously,the
amount of adventitia in the aorta is greater in
normotensive compared to GH rats. Also, although both
groups of rats were the same age, the body weight of the
normotensive rats was slightly greater than that of the
hypertensive rats. However, correcting the results for
differences in body weight had no effect on the
significant differences observed.
4.3.4 Conclusions
Arterial wall thickening in hypertension has been
observed previously in rabbits and is the result of both
hyperplasia and hypertrophy of the vascular smooth muscle
(Bevan, 1976; Bevan, Eggena, Hume, Van Martheus and
Bevan, 1980). Mulvany, Aalkjaer and Christensen, (1980)
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have found a correlated increase in blood pressure and
smooth muscle layer thickness in 12- and 24-week old SHR
compared to normotensives of the same age, and Hume
(1980) has demonstrated in the rabbit that protein
synthesis and cell division can be induced in the vessel
wall solely by an increase in wall tension. The
increased protein content of blood vessels from
hypertensive rats has been well documented. Folkow,
(1978) has reviewed the evidence that the increased
peripheral resistance of hypertension can be accounted
for by an increased wall thickness; an altered vessel
lumen to wall ratio producing the increased microvascular
resistance response.
The finding that homogenates of smooth muscle have a
considerable capacity to synthesise PGs is of interest
since it is generally assumed that the endothelial cell
layer is the only part of the blood vessel which
synthesises PGs to any significant extent. Although this
study was measuring PG synthesis in homogenates of smooth
muscle incubated with exogenous AA, there is some
evidence which suggests that PGI2 synthesis by the smooth
muscle layer may be important in vivo. Cultured smooth
muscle cells from pig aorta have been shown to produce
mainly PGE2 and PGF20C (Ager et al., 1982; Siess, et al.,
1981; Ody et al., 1982 and 1983) but the possible
importance of the ability of smooth muscle to produce
PGI2 can be appreciated from studies where the aortic
endothelial cell layer was removed by balloon
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catheterisation. Immediately after de-endothelisation
the aorta was covered with adherent platelets, but, after
several days only a few adherent platelets remained on
the luminal surface. This decrease in the number of
adherent platelets correlated with an increase in the
production of PGI2, from non-detectable levels to levels
found in normal endothelium (Eldor et al. 1981; Tschopp
and Baumgartner, 1981).
Interestingly, the smooth muscle and endothelial cell
layers of hypertensive males produced significantly more
PGF20C than the same layers from normotensive male rats.
However, the endothelial cell layer from GH rats also
produced significantly lower amounts of PGE2 than
normotensives therefore, it is not possible to discount
that the increased amount of PGF20C measured was due to
increased activity of 9-PGE-KR in GH rats, thus
increasing conversion of PGE2 to PGF2K. There was a
concomitant decrease in the production of 6—keto—PGF lcc in
the smooth muscle, but not the endothelial cell layer
from GH rats. This increase in blood vessel PGF20C, but
not the decrease in 6-keto-PGFjK has already been
observed in homogenates of whole aorta from hypertensive
rats (see section 4.1).
SECTION 4.4
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Measurement of unstimulated PG release from the isolated
perfused aorta.
4.4.1 Introduction
Measurement of PG production from exogenous arachidonic
acid in homogenates gives an indication of the PG
synthetase enzymes present in the tissue and of the
synthetic capacity for the different PGs, but it does not
necessarily reflect PG output in the whole animal. The
perfusion of an intact vessel and collection of the
perfusion fluid, with subsequent measurement of the PGs
present, probably gives a more accurate profile of PG
release in vivo.
The experiments described in this sub-section, therefore,
were carried out to determine the profile of PGs released
from the isolated perfused aorta of normotensive and GH
male rats.
4.4.2 Methods
Male albino Wistar rats aged between 2 and 3 months and
weighing 250-300g and GH rats of the same age, weighing
200-250g were used. The animals were housed as before.
Six animals
aorta was
from each group were killed and the




removed, was placed in a heated (37°C) chamber and
perfused with oxygenated (95% 02 , 5% C02) Krebs solution
at a rate of 4 ml/min. After 30 min perfusion to allow
for equilibration of the tissue after the trauma of
dissection, the perfusate was collected over a period of
30 min. The pH of the perfusate was taken to pH4 with
HC1 and was extracted twice with two volumes of ethyl
acetate, which is the same extraction procedure as was
described for homogenates in Section 2.4. The samples
were stored in ethyl acetate until assayed by RIA for
6-keto-PGF jw, PGF2C( and PGE2 content as detailed in
Section 2.5.
Results for normotensive and GH male rats were compared
using Student's t-test and significance was tested at the
5* level.
4.4.3 Results
Figure 4.4.1 shows the basal release of PGs during a 30
min period from the aortae of normotensive and GH male
rats. 6-keto-PGF10C was the major PG released by
normotensives, followed by PGE2 and a very small amount
of PGF20C. In the aorta from GH rats 6—keto—PGF loc was the
main PG released with similar amounts of PGF20C- and PGE2
measured. This was a significant increase (P < 0.01) in
the amount of PGF20C released from the perfused aorta of
GH rats. There was no difference in the amounts of
6-keto-PGF lcc or PGE2 released between the 2 groups.
Figure4.4.1.










A recent study by Elliot and Adolfs, (1984) has shown
that PGI2 release by the isolated, perfused aorta is
initially high but gradually declines to a stable level
which is maintained for at least 180 min. Levels of
6-keto—PGF,K, measured by RIA, reflected the changes in
biological activity monitored on the superfused rat
stomach strip. Thus, the isolated perfused aorta appears
to be a good model for investigating the profile of
endogenous PG release.
In this study, a different profile of PG release from
intact aorta compared to PG synthetic capacity of
homogenates was observed. The amount of 6—keto—PGF loc
released was much greater than that of PGE2, and the
amount of PGF20C released was much lower than the other 2
PGs. The ratio of 6—keto—PGF1K:PGF2 K:PGE2 was 1:0.3:0.2
for aortic homogenates compared with 1:0.1:0.6 for
release from intact aorta in normotensive rats, and was
1:0.6:0.2 for aortic homogenates compared with 1:0.4:0.4
for release from intact aorta of GH rats. The release of
PGF20C from the aorta of GH rats was markedly increased
(3-fold) compared to normotensives and this was possibly
a reflection of the increased synthetic capacity of the




observations made using homogenates of
1<x release from the intact aorta was not
normotensive and GH rats. This is not
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in agreement with the findings of Okuma et al., 1980 and
Pace-Asciak et al. (1978) using aortic rings from SHR, or
of Botha et al., 1980 using aortic strips from the GH
strain of hypertensive rats. However, the spontaneous
release of PGI2 from aortic rings or strips is probably
due to the metabolism of arachidonic acid released by
PLA2 from the damaged cells, and therefore may reflect
the ability of the damaged tissue to synthesise PGI2
rather than the true basal rate of synthesis.
SECTION 4.5
Measurement of stimulated PG release from the isolated,
perfused mesenteric arterial bed of normotensive and
genetically hypertensive male rats.
4.5.1 Introduction
Although the aorta is generally the blood vessel most
often studied with regard to vascular PG synthesis it is
not necessarily typical of the vascular system, and in
particular of the small resistance vessels such as the
arterioles. The isolated, pefused mesenteric arterial
bed preparation, if dissected carefully, retains the
majority of its small resistance vessels and can be used
to investigate the actions of natural or pharmacological
compounds on a resistance bed. This preparation then,
can be used to study the PG-releasing abilities of some
of these compounds.
- 154 -
Angiotensin II-(All)-stimulated PG release
The potent vasoactive hormone, All has also been studied
in relation to its ability to cause the release of PGs.
AI and All caused the release of a PGI2-like substance
(measured on a platelet bioassay) from the rabbit
mesenteric artery (Grodzinska et al., 1980) and the
release of a PGE2-like substance from the same rabbit
preparation (Blumberg et al., 1977). Saralasin, an All
analogue and a competitive inhibitor, prevented the
All-induced release of PGE2, but did not block PGE2
release by bradykinin. Similarly, Grodzinska et al.
(1980) found that saralasin inhibited the All-stimulated,
but not the bradykinin-stimulated release of PGI2.
Captopril, a converting enzyme inhibitor abolished the
release of PGE2 and PGI2 induced by AI, but had no effect
on All-induced PG release. These results suggest that
the release of PGs stimulated by All is mediated via a
specific AII-receptor. Exogenous PGE2 and PGI2 reduce
the vasoconstrictor response to All in rabbit mesenteric
artery (Malik et al., 1976) and in rabbit hindquarters
vascular bed (Gottlieb et al., 1980).
Although the synthetic capacity of blood vessel
homogenates for PG synthesis and the basal release of PGs
from blood vessel pieces in the hypertensive state have
been studied quite extensively, there has been very
little information published on the stimulated release of
PGs from the vessels of hypertensive animals. Basal PGI2
release from the mesenteric vascular bed of hypertensive
rats was found to be higher than in normotensives but
nerve stimulation failed to increase PGI2 and PGE2
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release from the mesenteric bed of hypertensive compared
to normotensive rats (Pipili and Poyser, 1982). In the
present study, the effects of NA and All on PG output
from the mesenteric vascular beds of GH and normotensive
male rats has been investigated.
Noradrenaline-(NA)-stimulated PG release
An infusion of NA into the mesenteric vascular
preparation of the rabbit produced a rise in perfusion
pressure and the release of a PGE-like material.
Indomethacin prevented, but AA augmented this
NA-stimulated release of a PGE-like material (Grodzinska
et al., 1976). Simmet et al. (1980) however, using the
same preparation in the rabbit found that NA did not
produce any detectable PG release. A high K+
concentration was the stimulus which induced contractions
of the vascular bed and PGE release. Using the rat
mesenteric vascular bed Coupar et al. (1980) found that
indomethacin inhibited the vasoconstrictor effect of NA,
and in contrast to the findings in the rabbit, observed
that the pressor responses were actually restored by
exogenous PGE2, or even more potently by its analogue
12,S-15 methyl PGE2 methyl ester. Exogenous PGI2 and
PGE2 reduced vasoconstrictor responses to NA and nerve
stimulation in rabbit mesenteric arteries (Malik et al.,
1976) and in the rabbit hindquarters vascular bed
(Gottlieb et al., 1980). PGE2 and PGI2 are also released
from the mesenteric artery of rats and rabbits following
nerve stimulation, (Horton et al., 1980; Pipili and
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Poyser, 1981) but it is PGE2 and not PGI2 which reduces
the output of NA from the rabbit mesenteric artery during
nerve stimulation (Armstrong and Thirsk, 1979).
4.5.2 Methods
Normotensive albino Wistar male rats and male GH rats of
2-3 months of age and weighing 250-300g and 200-250g
respectively were used. The mesenteric arterial bed was
prepared according to McGregor (1965) with some
modifications. Briefly, the superior mesenteric artery
was cannulated about 2 cm distal to the abdominal aorta.
The entire mesentery was carefully dissected away from
the gut and the vascular bed was removed to a heated
(37°C) chamber where it was perfused at 4 ml/min with
oxygenated (95% 02, 5% C02) McEwen's solution. The
vascular bed was perfused for 30 min to allow for
recovery of the tissue after the trauma of surgery.
NA and All (0.1 pg and 1.0 pg) were given as a bolus
injection in a random order. Samples were collected at 1
min intervals for the 2 min before stimulation, for the 4
min immediately after stimulation and for a further two
periods, 8 min and 12 min after stimulation. Pressor
responses were recorded on a Polygraph recorder via a
Statham pressure transducer. 6-keto-PGFtK, PGF20C and
PGE2 content in the perfusion fluid were measured by RIA,
without extraction. It has been shown previously that
the PG content of perfusates does not differ
significantly between extracted and non-extracted samples
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(Pipili and Poyser, 1981). The effects of NA and All on
PG release were tested for significance by comparing the
1 min period prior to stimulation with the two 1 min
periods post-stimulation using Student's t-test for
paired data. Significance was tested at the 5% level.
4.5.3 Results
6-Keto-PGF1K was the major PG released by the mesenteric
vascular bed of normotensive rats, with considerably less
PGE2 and PGF2K being released. The amounts of PGF20C
released into the perfusate during the 1 min collection
period were below the detection limit of the assay (< 30
ng/min). In the mesenteric vascular bed of hypertensive
rats, 6-keto-PGFtK was also the major PG released
followed by lower amounts of PGE2 and PGF2K.
The release of all 3 PGs declined over the duration of




The release of prostaglandins (PGs) from the isolated,
perfused mesenteric arterial bed of normotensive and
hypertensive male rats mean+/-s.e.m., n=4; ND- < 30
ng/min).
Normotensive Hypertensive
PG ng/min START END START END
6-Keto-PGF,„ 1.30+/-0.22 0.98+/-0.22 1.94+/-0.22 1.09+/-0.19
PGE2 0.54+/-0.10 0.36+/-0.03 0.80+/-0.27 0.48 (2 ND)
PGF2cc ND ND 0.44+/-0.06 ND
4.5.3.1 All-stimulated PG release
Both the low (0.1 jig) and high (1.0 jag) dose of All
caused a significant (P <0.05) increase in the release
of 6-keto-PGFja from the mesenteric bed of male
normotensives (Figure 4.5.1). Neither dose of All
produced any stimulation of PGF20C release above
non-detectable levels. Although there was some
stimulation of PGE2 release above base-line levels at the
0.1 fig dose of All, this was not significant. However,
the higher dose of 1.0 jag All produced a significant (P <
0.01) increase in the release of PGE2 from the mesenteric
vascular bed of male normotensives (Tables 4.5.2 and
4.5.3). The bolus injections of All had a pressor effect
Figure4.5.1.




















AngiotensinII(All)-stimulatedreleaofprostaglandin(PG)F^frthiso ated,perfusm sen eric arterialbedofno motensivenN wZe landg n tic lyhyp rte sivemaler ts(ND-<20pg/ n) -1PGF2areleasengmm 0.1ygAII1.0ll
TIME:MIN-12123404-121 ND-*■"> ND-»■D ND ->•D" ND-*■NORMOTENSIVE MALES HYPERTENSIVE MALESND-*■ ND-> ND-*■ 0.61423ND->0.48554. 3327ND ND ND0.569374 0.26806575.37ND
Table4.5.3.









































































































































































on the vascular bed producing a 28.8 +/- 9.8 % increase
in the basal perfusion pressure (42.5 +/- 3.7 mmHg) at
0.1 fig All and an increase of 57.2 +/- 7.7 % at the 1.0
fig dose of All. This was a significant (P < 0.01)
increase in perfusion pressure at the higher dose of All.
In the mesenteric vascular bed from male hypertensives
both the 0.1 fig and 1.0 fig doses of All failed to elicit
a significant increase in the basal release of
6—keto—PGF loc. Similarly, there was no significant change
in the release of PGF2« and PGE2 at either dose of All
from the mesenteric bed of male hypertensives. All also
had a pressor effect on the vascular bed of hypertensives
with the 0.1 fig dose causing a 58.0 +/- 20.2% increase
and the 1.0 fig dose giving a 136 +/- 30.3% increase in
basal perfusion pressure (37.5 +/- 2.5 mmHg). The
increase in perfusion pressure was significant (P < 0.05)
at the higher dose of All. There was a significantly
greater (P < 0.05) pressor response to the 1.0 fig dose of
All in the mesenteric vascular bed of hypertensives
compared to normotensives.
4.5.3.2 NA-stimulated PG release
Both doses of NA produced a significant increase (0.1 fig
NA; P < 0.05, 1.0 fig NA; P < 0.01) in the release of
6-keto-PGFjK from the mesenteric bed of male
normotensives (Figure 4.5.2). NA did not appear to
affect the release of PGF20C as the amounts of this PG
remained below the detection limit of the assay.
Figure4.5.2.Noradrenaline( A)-stimulat drele seofprostaglandin(POI^,measured6-k to-PGF^fromh isolated,perfusemesent ricarterialbof4normotensive-BandN wZ al ndg eticallyhypertensivemalats-A.*comparedtv uei mediatelyprec dingstimul tion. A. ng/min 40 30 20 10 1234560 t NA 0-1qg**PcO-01B. ng/min 60- 50- 40- 30- 20 10H 1234560min i NA 10ug1234560 i NA 0-1ug
*P<0-05
1423 560 t NA 10ug
CO
Table4.5.4.




























































































































































































































































Similarly, NA at either dose, had no effect on the
release of PGE2 from the mesenteric bed of male
normotensives (Tables 4.5.4 and 4.5.5). NA also had a
pressor effect on the mesenteric vascular bed. 0.1 fig
produced a 63.2 +/- 34.7% increase, and 1.0 fig a 174.0
+/- 4.4% increase in perfusion pressure. The higher dose
of NA produced a significant (P < 0.01) increase in
perfusion pressure.
In the mesenteric vascular bed of male hypertensives, NA
at both the 0.1 fig and 1.0 jug doses produced a
significant (P < 0.05) increase in the basal release of
6-keto-PGF t K . There was no stimulation of PGF20C release
after the low dose of NA and although there was some
stimulation at the higher dose, this was not significant.
Both doses of NA failed to elicit any increase in PGE2
release from the mesenteric bed of male GH rats. NA at
the 0.1 jug dose caused a 153.0 + /- 43.5% increase in
perfusion pressure. The higher dose of NA gave a 261 +/-
33.5% increase in perfusion pressure. This was a
significant increase in perfusion pressure at both the
low (P < 0.05) and high (P < 0.01) doses of NA.
4.5.4 Conclusions
To summarise briefly by comparing the responses of the
mesenteric beds from normotensives and hypertensives, All
(1.0 fig) elicited an increase in the release of
6-keto-PGFjK and PGE2 from the mesenteric bed of
normotensive but not from GH male rats. The release of
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PGF2o; was not affected by All in either the normotensive
or hypertensive group. All (1.0 pg) produced a
significantly (P < 0.05) greater increase in perfusion
pressure in the mesenteric bed from hypertensive compared
to normotensive male rats.
Both doses of NA gave an increase in the release of
6—keto—PGF loc, without affecting the release of PGF20C and
PGE2 in normotensive and hypertensive males. NA (1.0 pg)
also produced a significantly greater increase in




Measurement of PG production in the separate layers of
aorta from normotensive and GH female rats.
4.6.1 Introduction
The conflicting effects of the sex steroids on thrombosis
and vascular PGI2 production have been discussed in
Section 3.6. Testosterone enhanced thrombus formation in
male and female rats whereas oestradiol reduced thrombus
size in male rats, but not in female rats (Uzonova et
al.t 1976). However, a greater release of PGI2 from
aortic rings of male compared to females was found (Maggi
et al., 1980, Pomerantz et al., 1980). Oestrogen was
found by various authors to conversely either inhibit or
stimulate PGI2 release from cultured rat aortic smooth
muscle cells or rat aortic rings.
The experiments described in Section 2, established that
there are significant differences in the PG synthetic
capacity of homogenates of different blood vessels from
male compared to female rats. However, PG production by
homogenates of aorta did not differ between day 1 and day
4 of the oestrous cycle and PG production was not
affected by short-term OVX and oestrogen and progesterone
treatment.
As there is such a paucity of information in the
literature on the production or endogenous release of PGs
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in the female, further experiments were carried out in
the female rat to characterise the profiles of vascular
PG production and release and to contrast these findings
with those observed in the male rat.
4.6.2 Methods
Female albino Wistar rats aged 2-3 months and weighing
200-250g and female GH rats of the same age weighing
180-200 g were used. Animals were housed and fed as
before. Vaginal smears were taken daily and after two
consecutive 4-day oestrous cycles had been established,
the animals were killed at 10:00h on pro-oestrus (day 4).
The aortae were removed and the three different layers
were separated, homogenised and incubated as described in
Section 2.4. Samples in ethyl acetate were stored at
-20°C until assayed by RIA for PG content as detailed in
Section 2.5. The results from normotensive and GH female
rats were compared using Student's t-test and
significance was tested at the 5% level.
4.6.3 Results and Conclusions
Figure 4.6.1 compares PG production by homogenates of the
adventitia and smooth muscle layers of aorta from
normotensive GH, day 4 female rats expressed as ng per mg
wet weight. The adventitia from normotensives produced
similar amounts of the 3 PGs. PGE2 was the PG produced



















lower amounts of 6-keto-PGF,K and PGF2K. PGE2 production
by the adventitia was significantly greater (P < 0.01) in
GH than in normotensive female rats. In the smooth
muscle layer 6-keto-PGF!K was the major PG produced by
normotensives followed by PGF20C and PGE2 . In GH rats
6-keto-PGF!K was also the main PG produced but PGE2
production was greater than that of PGF2CC. The
differences between the 2 groups were a decreased
production of both 6-keto-PGFtK and PGF20C (P < 0.05) and
an increased production of PGE2 (P < 0.01) by the smooth
muscle layer of GH rats compared to normotensive female
rats.
Figure 4.6.2 shows endothelial PG production expressed as
ng of PG per 2.5 cm length of aorta. The endothelial
cell layer from normotensives produced mainly
6-keto-PGF j K and PGF20C with less PGE2 . However, in GH
rats PGE2 was the main PG produced with similar amounts
of 6-keto-PGF, K and PGF2C(. There were significant
decreases (P < 0.05) in the production of 6-keto-PGFtK
and PGF20C by GH females compared with normotensive female
rats.
Table 4.3.1 shows a comparison of the mean PG production
by homogenates of adventitia and smooth muscle and by an
endothelial cell suspension, expressed per unit length,
from the aorta of day 4 female normotensive and GH rats.
6—Keto—PGF,K was the major PG produced by smooth muscle
homogenates of normotensive and GH female rats.














6-Keto-PGFja was also the major PG produced by the
endothelial cell suspension of normotensives, but PGF2CC
was the major PG produced by this layer of GH female
rats. PGF20C was the major PG produced by the adventitia
of both groups of female rats, followed by PGE2 and
6-keto-PGF1K. The total amounts of 6-keto-PGF,K
synthesised by the separate layers were in the order of
smooth muscle > adventitia > endothelial cell layer for
normotensive and hypertensive female rats. However, as
discussed previously in relation to male rats, as the
endothelial cells constitute a very small percentage
(approx. 2%) of the total aortic tissue, the capacity for
synthesising the 3 PGs is 3- to 30-fold higher in the
endothelial cells than in the smooth muscle or
adventitia.
The amounts of 6-keto-PGF t K, and PGF2CC synthesised by
adventitia, smooth muscle and endothelial cells were
significantly lower (P < 0.05) in hypertensive compared
to normotensive female rats. There was no difference in
PGE2 production by the three layers in normotensive
compared to GH rats.
4.6.4. Comparison of the amounts of PGs produced by
separate layers of aorta of male and female, normotensive
and hypertensive rats.
PG production per mg wet weight
There was no significant difference in the production of
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any of the 3 PGs by homogenates of adventitia of male
normotensives compared to female normotensives. PGF2K
production by smooth muscle homogenates of females was
significantly (P < 0.001) greater than that by
homogenates of males, whereas 6-keto-PGF 10c and PGE2
production did not differ between the 2 groups.
6-keto-PGFjK and PGE2 production by the endothelial cell
suspension did not show any sex difference and, although
PGF2k production was greater by the endothelium of
females than males, this difference was not significant
(Student's t-test).
There was no significant sex difference in the production
of the 3 PGs by the adventitia of aortae from
hypertensive rats. The production of 6-keto-PGF4K and
PGF20C were not significantly different by homogenates of
aortic smooth muscle layer of male compared to female
hypertensive rats. Smooth muscle layer PGE2 production,
however, was significantly (P < 0.05) greater in
hypertensive females compared to hypertensive males.
6-keto-PGF jK and PGF2CC productions were greater (P <
0.001) by the endothelial cell suspension from GH males
than from GH females. PGE2 production by the endothelial
cells was not significantly different between the two
groups.
PG production per unit length
Table 4.6.1 shows a comparison of the mean production of
PGs by the separate layers of aorta of normotensive and
GH male rats compared to normotensive and GH female rats.
6-Keto-PGF10C synthesis was significantly lower (P < 0.05)
by the adventitia of female compared to male normotensive
rats, but there was no difference in 6-keto-PGF,K
synthesis by the smooth muscle or endothelial cell
layers. The amounts of PGF2K and PGE2 produced by
homogenates of smooth muscle, but not by adventitia or
endothelial cells, were significantly higher (P < 0.05)
in female than in male normotensive rats.
6-Keto-PGF i« and PGF20C synthesis were significantly lower
(P < 0.05) by the endothelial cells of female
hypertensive compared to male hypertensive rats, but
there was no difference in 6-keto-PGF, K or PGF20C
synthesis by the smooth muscle or adventitial layers.
PGE2 synthesis was significantly (P < 0.05) greater by
the smooth muscle and adventitia, but not by the
endothelial cells of female hypertensives compared to
male hypertensives.
SECTION 4.7
Measurement of basal PG release from the isolated
perfused aorta of normotensive and GH female rats.
4.7.1 Introduction
Tissue homogenates give an indication of the PG
synthesising enzymes present in a particular tissue and
of their capacity for generating PGs but they probably do
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not provide an accurate representation of the amounts of
PGs released in vivo. In this context, the reasons for
using the isolated intact aorta for the measurement of
basal release of PGs have been discussed previously with





of PG release from the
of female normotensive and GH
4.7.2 Methods
Female albino Wistar rats and female GH rats aged 2-3
months and weighing 200-250 g and 180-200 g respectively
were used. Consecutive 4-day oestrous cycles were
established by taking vaginal smears daily and six
animals from each group were killed on day 4 at 10:00h.
The thoracic aorta was cannulated and a 2.5 cm portion
was carefully removed and placed in a heated (37°C)
chamber. The isolated aorta was perfused at 4 ml/min
with oxygenated (95% 02, 5% C02) Krebs solution. After
an equilibration period of 30 min, the perfusate was
collected during the next 30 min period. The pH of the
perfusate was taken to 4 with IN HC1 and the PGs were
extracted twice with 2 volumes of ethyl acetate as
described in section 2.4. The samples were stored in
ethyl acetate until assayed by RIA for PG content as
detailed in Section 2.5.
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Results for noraotensive and GH rats were compared using
Student's t-test and significance was tested at the 5%
level.
4.7.3 Results
As shown in Figure 4.7.1, 6-keto-PGFtand PGE2 were the
major PGs released from the aorta with considerably less
PGF20C measured. The perfused aorta of hypertensive
females released similar amounts of 6-keto-PGFjK and PGE2
with less PGF2o:. There was an increased release of
6-keto-PGF t K (P < 0.05), PGE2 (P < 0.05) and PGF20C (P <
0.01) from the aorta of GH compared to normotensive
female rats.
4.7.4 Conclusions
Unlike the homogenates of the separated layers of aorta
and the endothelial cell layer, where 6-keto-PGFtK and
PGF2a production were greater by normotensives than by
hypertensives, the perfused aorta from hypertensives
released greater amounts of all 3 PGs. This finding
emphasises that the production of PGs measured in
homogenates in vitro does not necessarily reflect PG
output from the intact tissue in vitro . The latter
parameter may be a better reflection of the in vivo
situation.














4.7.5. Comparison of basal
male and female normotensive
179 -
PG release from the aorta
and hypertensive rats.
of
The basal release of 6-keto-
0.05) greater from the iso
compared to female normotens
difference in the release
sexes (Table 4.7.1).
PGF10C was significantly (P <
lated, perfused aorta of male
ive rats, but there was no
of PGF2CC and PGE2 between the
6—keto—PGF 10c and PGF20C release from the aorta of GH rats
was not significantly different when comparing male and
female rats. The release of PGE2 was significantly (P <
0.05) greater from the perfused aorta of female
hypertensive compared to male hypertensive rats.
SECTION 4.8
Measurement of stimulated PG release from the isolated,
perfused mesenteric arterial bed of normotensive and
genetically hypertensive female rats.
4.8.1 Introduction
The isolated, perfused mesent
vascular preparation which c
actions of pressor compounds
possible PG-releasing prope
This preparation was used to
NA and All on PG release in n
female rats.
eric arterial bed provides a
an be used to study the
on a resistance bed, and the
rties of these compounds,
investigate the effects of
ormotensive and hypertensive
Table4.7.1.Comparisonfthb saloutputpro taglandins(PGs),e+/-s e.m., =6)frt isolated,perfusedaortafmalndfe lenormotensivehy tensir . PGoutput(ng/30min/2.5cmlengthfaorta) NormotensiveHyper sive MaleFemale 6-Keto-PGF4.4+/0 82 6*7/5 21 PGF0.6+/-.07551 /34 PGE22.5+/-0 2/-3/4 69* *Significantlydifferent(P^0.05)fromcor espondingmalevalu .
4.8.2 Methods
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Normotensive female albino Wistar rats and female GH
rats, aged 2-3 months and weighing 200-250g and 180-200g
respectively were used. The mesenteric arterial bed was
prepared according to McGregor (1965) with some
modifications. The superior mesenteric artery was
cannulated about 2 cm distal to the aorta. The entire
mesentery was carefully dissected away from the gut and
the vascular bed was placed in a heated chamber at 37°C,
where it was perfused at 4 ml/min with oxygenated (95%
02, 5% C02) McEwen's solution. The vascular bed was
perfused for 30 min to allow for equilibration of the
tissue after the trauma of dissection.
NA and All (0.1 jjg and 1.0 fig) were given as a bolus
injection in a random order. Samples were collected at 1
min intervals for the 2 min before stimulation; for the 4
min immediately after stimulation and for a further two
periods, 8 min and 12 min after stimulation. Pressor
responses were recorded on a Polygraph recorder via a
Statham pressure transducer. 6-Keto-PGF loc, PGF2CC and
PGE2 were measured by RIA, without extraction. It has
been shown previously that the PG content of perfusates
does not differ significantly between extracted and
non-extracted samples (Pipili and Poyser, 1981). The
effects of NA and All on PG release were tested for
significance by comparing the 1 min period prior to
stimulation to the two 1 min periods post-stimulation
using Student's t-test for paired data. Significance was
tested at the 5% level.
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4.8.3 Results and Conclusions
6-Keto-PGF 10c was the major PG released by the mesenteric
vascular bed of normotensive and GH female rats, with
lower amounts of PGE2 and PGF20C. The release of all 3
PGs declined over the duration of the experiment (60 min)
in both groups of rats, as shown in Table 4.8.1.
Table 4.8.1
The release of prostaglandins (PGs) from the isolated,
perfused mesenteric arterial bed of normotensive and
hypertensive female rats (mean+/-s.e.m., n=4; ND- < 30
ng/min).
Normotensive Hypertensive
PG ng/min START END START END
6-keto-PGF loc 2.75 + /-0.51 0.58+/-0.14 2.15 + /-0.38 0.78+/-0.80
PGE2 0.71+/-0.24 0.44 (2-ND) 0.58+/-0.29 0.48+/-0.13
PGF20( 0.61 + /-0.24 ND 0.63+/-0.23 0.31 + /-0.08
The decline in the release of 6-keto-PGF 1<x was
significant (P < 0.01) in both normotensive and GH female
rats. The amount of PGE2 released by normotensives
declined considerably, since PGE2 reached non-detectable
levels in the perfusate of 2 out of 4 animals. The
amount of PGE2 released by GH rats was not significantly
lower at the end of the experiment. The amount of PGF20C
- 183 -
released by the mesenteric bed of normotensive females
declined rapidly and reached non-detectable levels. The
mesenteric bed of hypertensive females, however, showed a
consistent release of PGF20C over the duration of the
experiment.
The initial amounts of PGs released per min from the
mesenteric vascular bed did not differ significantly
between normotensive and GH female rats (Student's
t-test).
4.8.3.1 All-stimulated PG release
All had variable effects on the release of 6-keto-PGF,a
from the mesenteric vascular bed of female normotensives
(Figure 4.8.1) with both doses producing some stimulation
if not in the first minute then in the next 3 min,
although this was significant only for the 1.0 jig dose of
All. All, at both doses, had no significant effect on
the release of PGF2a or PGE2 (Tables 4.8.2 and 4.8.3).
All had a pressor action on the mesenteric bed of female
normotensives; the 0.1 fig dose gave a 15.5 +/- 6.0%
increase and the 1.0 jug dose gave a 38.0 +/- 9.73.
increase in the perfusion pressure (58.3 +/- 2.2 mmHg) of
the vascular bed. This was a significant increase in
perfusion pressure at the higher dose of All (P < 0.05).
In the mesenteric preparation from GH female rats All
again had variable effects on 6-keto-PGF trelease and
although there was some stimulation at the lower dose of
Figure4.8.1.
AngiotensinII(All)-stimulatedreleaseofprostaglandin(POI^,m asureds6-keto-PGF^romtheisolated,perfusedmesentericart rialb dof4normotensive-B,d4N wZ alandgeneticallyhypertensivef malr ts-A.*comparedtvalueim ediatelyprecedingstimulation.
Table4.82
AngiotensinII(All)-stimulatedreleaofpro agl ndin(PG)F2afrthiso a e ,perfusem s nteric arterialbedofnormotensivendN wZe lang n ticallyhypert sivefemalr s( D-<20pg/m n) PGF2areleasengmin^ 0.1ygAll1 0 4̂-
TIME:MIN-12123404 ND->D-*■ NORMOTENSIVE0.75. 0324D1 08875930 FEMALESND-* ND->0.326644550 0.30895456961 172 HYPERTENSIVE0.538127344561 162 00998 FEMALES0.49514058232ND 0.5027943621.6
Table4.83
AngiotensinII(All)-stimulatedrel afpr s aglandi(PG)Êfrothis late ,perfusedm t ric arterialbedofno motensivendN wZeala dg n ticallyhyp rte sivefemalr t( D-<20pg/m n) PGE2releasengmin* 0.1ygAll1 0 4'
TIME:MIN-12123404- ND"»■ NORMOTENSIVE0.701 016D0.3546.521 18872 FEMALES0.304251. 820 1604 ND0.2140343.520 85672 1.10460 358. 21 16.4365240 99350 HYPERTENSIVE1.000.8064.342ND0.366 FEMALESND0.4422. 3637 ND0.267403582->
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All, this was not significant. The 1.0 pg dose of All
produced a significant stimulation in the amount of
6-keto-PGF,K released (Figure 4.8.1). The mesenteric bed
of hypertensive females showed a similar response to
normotensives with regard to PGE2 and PGF20C release, with
neither dose of All producing a significant stimulation
in the release of these 2 PGs (Tables 4.8.2 and 4.8.3).
The 0.1 pg dose of All gave a 31.6 +/- 16.1% rise, and
the 1.0 pg dose of All gave a 61.8 +/- 25.8% rise in
basal perfusion pressure (49.1 + /- 4.2 mmHg) of the
mesenteric bed. Neither dose of All produced a
significant increase in perfusion pressure.
4.8.3.2 NA-stimulated PG release
Both the 0.1 pg and the 1.0 fig dose of NA produced a
significant stimulation (P < 0.05) in the release of
6-keto-PGFjK from the perfused mesenteric bed (Figure
4.8.2). The release of PGF20( and PGE2 did not change
significantly after either dose of NA (Tables 4.8.4 and
4.8.5). The 0.1 pg dose of NA produced a 40.8 +/- 4.7%
increase, and the 1.0 pg dose of NA a 150.4 +/- 33.2%
increase in basal perfusion pressure of the mesenteric
vascular bed. The increases in perfusion pressure were
significant (P < 0.05) at both doses of NA.
A bolus injection of 0.1 pg or 1.0 pg NA produced a
significant (P < 0.05) increase in the release of
6-keto-PGFlcc from the mesenteric bed of female
hypertensive rats (Figure 4.8.2). The release of PGF20(
Figure4.8.2.Noradrenaline(NA)-stimulatedrele seofprostaglandin(PG)^,measureda6-ket -PGF^froth isolated,perfusedmesentericarte i lbedof4normoten ive-B,andNewZe langenet cally hypertensivefemalerat-A.*co par dtvalueimmedi t lypr edings i ulati n.
Table4.8.4.
Noradrenaline(NA)-stimulatedrele sfprostagla din(PG)F2(xfrothis late ,erfusm sent ric arterialbedofno motensivendNewZeala dg ticallyhyp rt s vefem ler t( D-<20pg/min) PGF2areleasengmin* 0.1ygNA1.0
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Table4.85
Noradrenaline(NA)-stimulatedreleaseofprostaglandin(PG)E^romtheisolated,perfusedmesentericarterialb dofnormotensivea dNewZ alandge eticallyhyp rtensivefemaler ts(ND-<20pg/min) PGE2releasengmin* o.lygNA 1.0ygNA
TIME:IN-1-2341014-1-2341014ND-*■ ND-*■ I
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and PGE2 did not change significantly after either dose
of NA in the mesenteric bed of female hypertensives. NA
produced a rise in basal perfusion pressure (49.1 +/- 4.2
mmHg) in the mesenteric bed of hypertensives; a 52.2 +/-
26.2% increase at 0.1 jug NA and a 136.6 +/- 42.6%
increase at 1.0 jug NA. This was a significant (P < 0.05)
increase in perfusion pressure at the higher dose of NA.
In summary, All had similar effects in both normotensive
and hypertensive females with only the higher, 1.0 jug
dose of All producing a significant stimulation in the
release of 6—keto—PGF loc from the mesenteric bed. The
pressor effect of All tended to be greater in the
mesenteric bed of GH compared to normotensive rats, but
this was not significant.
NA at both doses produced a significant increase in the
output of 6—keto—PGF1K from the perfused mesenteric bed
of normotensive female rats, but only the higher (1.0 jug)
dose of NA produced an increase in 6-keto-PGFj« output in
hypertensive female rats. PGE2 and PGF20C release were
not changed markedly by the administration of NA in
either group. Similarly, the vasoconstrictor response to
NA did not differ between GH and normotensive females.
SECTION 4.9
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A comparison of the effects of noradrenaline (NA) and
angiotensin II (All) on PG release from the perfused
mesenteric arterial bed of male and female normotensive
and hypertensive rats.
Table 4.9.1 compares the 6-keto-PGFja - releasing
abilities of NA and All in male compared to female
normotensive rats.
Table 4.9.1
Comparison of the ability of noradrenaline (NA) and
angiotensin II (All) to cause a significant (P < 0.05) or
non-significant (NS) release of 6-keto-PGF t from the
isolated, perfused mesenteric bed of male and female
normotensive rats.
NA All
0 . 1 jjg 1. 0 pg 0 . 1 pg 1. 0 //g
Male P < 0.05 P < 0.05 P < 0.05 P < 0.05
Female P < 0.05 P < 0.05 NS P < 0.05
Male and female normotensive rats were similar in their
response to NA, with both doses producing a significant
stimulation in the output of 6-keto-PGF tK, but not PGF2CC
and PGE2, from the mesenteric bed. There is a difference
in the ability of All to stimulate the release of
6-keto-PGF!K from the mesenteric bed, with no significant
stimulation observed at the low dose of All in females,
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in contrast to the stimulation observed in male rats.
Also, in contrast to females, males showed a significant
stimulation in the release of PGE2 from the mesenteric
bed in response to the higher dose of All. Neither group
showed any stimulation in PGF20C release.
Table 4.9.2 compares the 6-keto-PGF1K-releasing abilities
of NA and All in male compared to female hypertensive
rats.
Table 4.9.2
Comparison of the ability of noradrenaline (NA) and
angiotensin II (All) to cause a significant (P < 0.05) or
non-significant (NS) release of 6-keto-prostaglandin Floc
from the isolated, perfused mesenteric bed of male and
female hypertensive rats.
NA All
0. 1 //g 1.0 pg 0.1 pg 1. 0 fig
Male P < 0.05 P < 0.01 NS NS
Female NS P < 0.05 NS P < 0.05
Male and female GH rats showed a similar significant
increase in the release of 6-keto-PGFtK in response to
both doses of NA. Male and female hypertensive rats
differed slightly in their response to All in the
mesenteric bed; no stimulation of 6-keto-PGFxK release
was observed in males at either dose of All, but females
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showed a significant stimulation in the release of
6-keto-PGF loc at the 1.0 pg dose of All. Male and female
hypertensive rats were similar in their response to NA
and All regarding PGF20t and PGE2 release, with neither
group of rats showing any stimulation in the release of




The experiments described in this section were undertaken
to determine whether there was a fundamental difference
in the production of PGI2 , PGF20C or PGE2 in the blood
vessels from normotensive compared to New Zealand
genetically hypertensive rats and, within these groups,
whether the production of these 3 PGs differed between
male and female rats. Three parameters of PG production
were investigated; total synthetic capacity in
homogenates of the separated layers of aorta, basal
release of PGs from the perfused aorta, and stimulated
release of PGs from a resistance bed.
Unlike the majority of work on blood vessels from
hypertensive rats, an increase in either the production
or basal release of PGI2 (measured as 6—keto—PGF 1(X) was
not observed from the vessels of GH rats. However, the
most marked difference between the two groups of male
rats was the increased production of PGF2K by whole
aorta, smooth muscle and endothelial cell layers; and the
greater basal output of PGF20C from the perfused aorta and
mesenteric arterial bed of hypertensives compared to
normotensives. The difference in the amounts of PGF20C
synthesised by aorta was not due to differences in
metabolism, and is possibly related to a greater
synthetic capacity of aortic endothelial and smooth
muscle cells for PGF20C production in hypertensive male
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rats. Female hypertensive rats however, showed a
decreased production of both 6—keto—PGF 10c and PGF2K by
the smooth muscle and endothelial cell layers but an
increased production of PGE2 compared to normotensives.
In contrast to the synthetic capacity of homogenates, the
basal output of 6-keto-PGF loc, PGF20C and PGE2 were greater
by the perfused aorta of hypertensive than normotensive
females. Interestingly, the higher output of PGI2 from
the aorta of GH female rats is in agreement with previous
studies.
Since the discovery of PGI2 and its being 'labelled' as
the major and most important product of AA metabolism in
blood vessels, PGF20C and PGE2 have either been ignored or
deemed unimportant. Yet, both of these PGs have potent
effects on blood pressure. In the rat and dog PGF2o: is
pressor; intra-arterial administration of PGF2K increases
vascular resistance, reportedly through a selective
venoconstrictor action (DuCharme and Weeks, 1967;
DuCharme et al., 1968). In the micro-circulation of the
cat (pial vessels), topical administration of PGF20C
produces significant arterial constriction (Welch et al.,
1974), and in the rat, arteriolar constrictor responses
to PGF20C have been observed in the mesocaecum (Vignera et
al., 1969) and cremaster muscle (Ellis and Hutchins,
1974).
The potent vasodepressor actions of PGE2, in all species
studied, are well documented but the effects of PGE2 are
not universally vasodepressor in different vascular beds
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of the rat. In the splenic vasculature and cremaster
muscle, PGE2 produces vasodilation (Malik, 1979; Messina
et al., 1974) but the situation in the kidney is less
clear. Inhibition of PG synthesis produced
vasoconstriction, suggesting that an influence of
vasodilator PGs had been reduced (Dusing et al., 1977),
but direct administration of PGE2 into the rat kidney
increased vascular tone (Malik and McGiff, 1975; Gerber
and Neiss, 1979).
The output of PGF20C from the kidney is higher than normal
in humans with essential hypertension (Weber et al.,
1979), and in the SHR an increased renal PGF20C formation
was found even before overt hypertension had developed
(Ahnfelt-Ronne and Arrigoni-Martelli, 1978). PGE2 output
however, did not change. These observations made using
the kidney from hypertensive rats and the findings made
using the aorta in the present study, support the idea
that an alteration in the pathway of PG formation from
PGE2 to PGF20C may lead to an increase in blood pressure,
and that it is the ratio of these PGs that is critical
for blood pressure control rather than the absolute
amounts of vasodilator PGs.
As discussed in the introduction to this section the
release of PGs may be important in the attenuation of the
vasoconstrictor responses to certain hormones. PGE2 is
believed to act by reducing the amount of transmitter
released, whereas PGI2 does not act in this way and
probably has a direct action on myogenic tone. The
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response of PG output to NA was similar in normotensive
and hypertensive male rats i.e. an increase in the
release of 6-keto-PGF1K, and a tendency for increased
PGE2 release, but the pressor response to NA was greater
in GH than normotensive male rats implying that PGI2 can
not be the only factor involved in the control of the
vasoconstrictor response to NA.
PGI2 (measured as 6-keto-PGF 1<x) and PGE2 are released
from the mesenteric bed of normotensive males in response
to All, in agreement with other authors
(Desjardins-Giasson, Gutkowa, Garcia and Genest, 1982;
Dusting, Mullins and Nolan, 1981), but are not released
from the same preparation of hypertensive males.
Interestingly, hypertensives showed a greater pressor
response to All than normotensives suggesting that there
may be a deficiency in these proposed aspects of the
control of vascular tone by PGE2 and/or PGI2 in the GH
male rat.
However, the results from female rats do not agree with
this hypothesis since All (1.0 fig) stimulated
6-keto-PGFia output in female normotensive and
hypertensive rats, unless there is a fundamental sex
difference in the control of vascular tone. Certainly,
the pressor response to All (1.0 jug) did not differ
significantly between normotensive and hypertensive,
female rats. Comparing males to females, the pressor
effects of NA and All were always smaller in females
(normotensive or hypertensive) but this was not
signifies nt.
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It has been known for a long time that vascular
hyperresponsiveness to vasoconstrictor agents is a
characteristic of human essential hypertension, and of
other forms of experimental hypertension in rats (Somlyo
& Somlyo, 1970), However, despite extensive
investigation, the relationship between elevated blood
pressure and hyperresponsiveness has not been defined. A
recent study has shown that young GH rats show
hyperresponsiveness before the blood pressure is
significantly elevated. Delaying the development of
hypertension by bilateral renal denervation does not
lessen the hyperresponsiveness, but 1 kidney, 1 clip
renal hypertensive rats show a much smaller increase in
vascular hyperresponsiveness than age-matched controls
(Baer, 1984). These results indicate that vascular
hyperresponsiveness of GH rats is a primary
characteristic and is not due solely to an elevated blood
pressure.
The observation that basal PGF2« release was greater from
the mesenteric bed of hypertensive male and female rats
compared to their normotensive controls is of
considerable interest in relation to the potent
vasoconstrictor actions of PGF2K. In the dog, PGF20C is a
potent mesenteric vasoconstrictor (Chapnick et al.,
1978). It also enhances the vasoconstrictor response
following nerve stimulation (Hedquist, 1976) and there
are reports that All induces the release of PGF2K from
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the canine kidney (Dunn et al., 1978). Thus, although
there was no actual stimulation of PGF20C release in the
mesenteric bed of hypertensive rats after NA and All, the
observation that PGF20C was always present in higher
amounts in these animals may be of relevance to the
greater pressor response found in these animals. Whether
the increased capacity for PGF20C synthesis and the
increased basal output of PGF2K from perfused vessels is
connected with the increased blood pressure found in
these animals requires further investigation.
Blood pressure increases with increasing age in rats and
humans. The experiments described in the next section
were designed to investigate the profile of PG production
and basal output from blood vessels of male and female
aged rats, established to have significantly higher blood
pressures than young male and female rats.
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SECTION 5.0
Measurement of the PG synthetic capacity of homogenates
of aorta, the basal release of PGs from the perfused
aorta and the stimulated release of PGs from the perfused
mesenteric arterial bed of male and female, young and old
rats .
5.1.1 Introduction
A complex interrelationship exists between blood pressure
and arterial disease, hypertension increasing the
susceptibility of blood vessels to arteriosclerosis. It
is generally recognised that blood pressure increases
with age and that the incidence of coronary heart disease
and thrombosis also increases with age in both men and
women. The mortality and morbidity from cardiovascular
diseases is much greater in males than in pre-menopausal
females (Kuller, 1976). Studies to date do not show
unequivocally that these increases in blood pressure and
thrombotic tendency with increasing age are related to PG
mediated effects. It has been shown that
15-hydroperoxyarachidonic acid (15-HPAA), a lipid
peroxide, is a potent and selective inhibitor of PGI2
generation by porcine vessel wall microsomes or by fresh
vascular tissue (Moncada et al., 1976). Other fatty acid
peroxides and their methyl esters show similar effects
(Salmon, Smith, Flower, Moncada and Vane, 1978). Lipid
peroxidation induced by free radical formation is known
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to occur in the ageing process (Slater, 1972) and it is
reasonable to suggest that PGI2 generation could be
reduced in aged blood vessels because of the effects of
greater concentrations of lipid peroxides.
Pace-Asciak and Carrara (1979) and Panganamala et al.,
(1981) have shown that PGI2 formation by aortic
homogenates or intact aorta increases with age in the
rat. However, these authors were studying a very limited
age range using rats of up to 20 weeks of age and were
not looking at the situation in the old animal. Aortic
smooth muscle cells from old rats produced less PGI2 in
culture than those obtained from young rats and this was
due to a specific decrease in PGI2 synthetase activity.
These cells from old rats were found to produce more PGE2
than PGI2 (Chang et al., 1980). Using bovine smooth
muscle and endothelial cells in vitro (Ager et al., 1982)
it was observed that during sub-culture the ability to
generate PGI2 decreased while PGE2 formation increased.
It is not known if these changes are due to specific
effects of lipid peroxides on PGI2 synthetase. The
experiments described in this section were carried out to
determine the profile of PG production and release in
aorta and mesenteric bed of old (12-14 months) male and
female rats.
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5.1.2 Measurement of the PG synthetic capacity of separated
layers of the aorta from young and old male rats.
Introduction
In this and in following sub-sections, the appropriate
data for young rats is taken from Section 4.
5.1.3 Methods
Male albino Wistar rats aged 2-3 months weighing
200-250g, and male albino Wistar rats aged 12-14 months
and weighing 680-730g were used. The animals were housed
under controlled conditions and were allowed a standard
diet and water. The aged rats (12-14 months old) were
bought from the supplier at the age of 2 months and were
kept in the departmental animal house until they reached
the age of 12-14 months.
5.1.4 Blood Pressure measurement
Measurements were made in the same cage order and at the
same time of day (ll:00h to 1300:h), every day for 2
weeks. Systolic blood pressure was measured indirectly
using the tail cuff method as described in detail in
Section 4.1.3. The restraining holder for the aged rats
was adapted to accomodate their rather large size. After
consistent blood pressure measurements had been obtained,
the animals were killed (6 in each group) and a 2.5 cm
length of the thoracic aorta was removed. The aorta was
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rinsed in Krebs solution to remove any blood, was opened
longitudinally and with its endothelial surface
uppermost, was pinned out on a plastic petri-dish. The
endothelial cells were carefully scraped off with a
scalpel blade and were suspended in 5ml Krebs solution.
The adventitia and smooth muscle layers were also
separated with a scalpel blade and then weighed. The
adventitia and smooth muscle layers were homogenised
separately in 2.5ml Krebs solution. The homogeniser was
washed with 2.5ml Krebs solution and the homogenate and
washings were added to a 25 ml conical flask. The
endothelial cell layer was left as a cell suspension in
5ml Krebs solution. Arachidonic acid (2 //g/ml) was added
to each flask and the flasks were incubated for 60 min.
PGs were extracted with ethyl acetate as described in
Section 2.4. Samples in ethyl acetate were stored at -20°
C until assayed for PG content by RIA as detailed in
Section 2.5. The results from young and old rats were
compared using Student's t-test and significance was
tested at the 5% level.
5.1.5 Results
The mean (+ s.e.m., n=6) systolic blood pressure of the
young male rats was 104.8 + 4.3 mmHg and that of the old
male rats was 179.7 + 9.2 mmHg. This was a significant
increase (P < 0.001) in the blood pressure of the old
male compared to the young male rats. As can be seen
from Figure 5.1.1, homogenates of adventitia from old and
young males produced similar amounts of the 3 PGs. There
Figure5.1.1.
Mean(+/-s. .m., =6)amou tsofprostaglandins(PG )synthesi edbyho og ates ofadventitia(ADV)dsmoothmuscle(SMfromy ung(2-3onths)a dl (12-14months)alerats.


















was no significant difference in PG production by
adventitia of old compared to young male rats. The
capacity of the smooth muscle layer for PG synthesis was
much greater than for the adventitia in both young and
old rats. 6-Keto-PGF10C was the major PG produced by the
smooth muscle layer of young male rats with lesser
amounts of PGE2 and PGF2(X. 6-Keto-PGF!a was also the
major PG produced by the smooth muscle layer of old rats
with considerably lesser amounts of PGE2 and PGF20C. There
was a marked increase in the production of 6-keto-PGF4«
(P < 0.001), PGF20C (P < 0.001) and PGE2 (P < 0.01) by
homogenates of smooth muscle layer of old compared to
young male rats. The endothelial cell layer from young
rats produced mainly 6—keto—PGF loc with lower amounts of
PGE2 and PGF20C (Fig. 5.1.2). The endothelium from old
rats however, produced similar amounts of the 3 PGs.
There was a significant (P < 0.05) decrease in the
production of 6-keto-PGF1K and a significant increase (P
< 0.01) in the production of PGF20C by the endothelium of
old compared to young male rats. PGE2 production did not
differ significantly between the 2 groups.
5.1.6 Conclusions
Consistent measurements of systolic blood pressure were
obtained from old male rats and it was established that
the blood pressures of these old rats were significantly
greater than that of young male rats. The old rats
therefore provided an additional means of studying the
effects of a naturally elevated blood pressure on
vascular PG production.








The most striking difference in PG production by the
aorta of old compared to young male rats was the marked
increase in the production of all 3 PGs by horaogenates of
smooth muscle from old male rats. The increase in
6-keto-PGFla was 6-fold, the increase in PGE2 was 3-fold;
but the greatest increase was in PGF2C( production which
was 8-fold. The profile of PG production by the
endothelium of old rats was also considerably different
to that of young male rats. There was a change in the
6-keto-PGF10C : PGF2(X ratio from 3.9 : 1.0 in the
endothelium of young rats to 1.3 : 1.0 in the endothelium
of old male rats. PGE2 production was not different
between the two groups. Thus, the profile of PG
production by smooth muscle and endothelium from old rats
was changed in favour of PGF20C. These findings are not in
agreement with Chang et al., 1980, using cultured smooth
muscle cells, who found that smooth muscle cells from 24
month old rats produced less PGI2 in culture than those
from 12 month old rats. However, a later study by the
same authors, Chang et al., 1983, showed that PGI2
release from aortic rings of mature (12 month) rats is
increased compared to young (2 month) rats, but is
significantly decreased in senescent (24 month) rats
compared to young rats. So the rats used in the present
study are comparable to the mature rats used in the study
of Chang et al., 1983 and show a similar trend in
producing greater amounts of 6-keto-PGFta from the aorta
than young male rats. It is not possible to comment on
the increased production of PGF20C by the aorta of old
male rats in the present study as this PG was not
measured by the previous authors.
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SECTION 5.2
Measurement of unstimulated PG release from the isolated
perfused aorta of young and old male rats.
5.2.1 Introduction
As discussed in Section 4.4.4, the perfusion of an intact
vessel with collection of the perfusate and subsequent
measurement of the PGs present probably gives a good
indication of PG release in vivo. The experiments
described in this sub-section were carried out to
determine the profile of PG release from the aorta of
young and old male rats.
5.2.2 Methods
Male albino Wistar rats aged 2-3 and 12-14 months, and
weighing 250-300g and 680-730g respectively, were used.
The animals were housed as previously. Six animals from
each group were killed and the thoracic aorta was
cannulated. A 2.5 cm length of aorta was carefully
dissected free of surrounding tissue and was removed to a
heated (37°C) chamber and was perfused with oxygenated
Krebs solution at a rate of 5ml/min. After the
preparation had equilibrated for 30 min the perfusate was
collected for 30 min and was extracted in the same way as
described for homogenates in Section 2.4. Samples were
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stored in ethyl acetate until assayed for 6-keto-PGFtK,
PGF2K and PGE2 content as detailed in Section 2.5. The
results were compared using Student's t-test for unpaired
data and significance was tested at the 5% level.
5.2.3 Results
Figure 5.2.1 compares the basal release of PGs during a
30 min period from the aortae of young and old male rats.
6—Keto—PGF loc was the major PG released by the isolated,
perfused aorta of young rats followed by lower amounts of
PGE2 and considerably lower amounts of PGF20C. The
perfused aorta from old rats also released mainly
6-keto-PGF lo: and lesser, but almost equal amounts of
PGF20C and PGE2 . There was a significantly greater (P <
0.01) quantity of PGF2(X released from the aorta of old
compared to young male rats. 6-Keto- PGF10C release tended
to be greater from the aorta of old rats but this was not
significant. PGE2 release was not significantly different
between the two groups.
5.2.4 Conclusions
The perfused aorta of old male rats showed a different
profile of PG release compared to young rats with a
considerable increase in the release of PGF20C being
observed in the old male rats. This resulted in a change
in the 6-keto-PGFla : PGF2a ratio. In young rats this
ratio was 8.5 : 1.0 and in old rats it was 2.6 : 1.0.
This change in the 6-keto-PGF t K : PGF20C ratio was













possibly a reflection of the increased synthetic capacity
of the smooth muscle homogenates and the endothelial cell
layers from old males to produce PGF20C.
SECTION 5.3.
Measurement of stimulated PG release from the
perfused mesenteric arterial bed of young and
rats.
5.3.1 Introduction
There does not appear to be any information in the
literature on the effects of pressor hormones on the
release of PGs from any vascular bed from aged rats. As
genetically hypertensive male rats show an increased
pressor response to both NA and All and appear to have a
deficiency in the release of 6-keto-PGF4K in response to
All compared to normotensive males (see Section 4.5.3.1),
it seemed of interest to establish the PG-releasing
abilities of NA and All in old male rats which were found
to have systolic blood pressures in excess of those of
young normotensive and also young hypertensive male rats.
5.3.2 Methods
Young albino Wistar male rats aged 2-3 months, weighing
200-250g and similar old male rats aged 12-14 months,
weighing 680-730g were used. The mesenteric arterial bed




modifications and this is described in detail in Section
4.5.2. The vascular bed was perfused at 5ml/min with
oxygenated (95% O2 , 5% CO2) McEwen's solution. After an
equilibration period of 30 min, NA and All (0.1 jig and
1.0 jjg) were given as a bolus injection in a random
order. Samples were collected at 1 min intervals for the
2 min before stimulation, for the 4 min immediately after
stimulation and for a further two periods, 8 min and 12
min after stimulation. Pressor responses were recorded on
a Polygraph recorder via a Statham pressure transducer.
6-Keto-PGF la, PGF2a and PGE2 content of the perfusion
fluid was measured by RIA, without extraction (Section
2.5). The effects of NA and All on PG release were
tested for significance by comparing the 1 min period
prior to stimulation with the two 1 min periods
post-stimulation using Student's t-test for paired data.
Significance was tested at the 5% level.
5.3.3 Results
6—Keto—PGF loc was the major PG released by the mesenteric
bed of young male rats with considerably less PGF20C and
PGE2 being released. The amounts of PGF20C released into
the perfusate during the 1 min collection period were
below the detection limit of the assay (< 0.30 ng/ml).
6-Keto-PGF 1(X was also the major PG released from the
mesenteric bed of old male rats followed by lower amounts
of PGF2k and PGE2. In contrast to the situation in young
rats, there was sufficient PGF2K in the perfusate from
old rats to be measured. The amounts of 6-keto-PGFsK and
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PGE2 were greater (P < 0.05) at the start of the
experiment in the perfusates from old male compared to
young male rats. The amounts of all 3 PGs released
declined over the duration of the experiment
(60 min) in both groups of rats and this was
significant (P < 0.05) for 6—keto—PGF l(X , PGE2 and PGF20C
in old, but not young male rats.
5.3.3.1 All-stimulated PG release
Both the low (0.1 fig) and high (1.0 fig) doses of All
caused an increase in the release of 6-keto-PGFta from
the mesenteric bed of young male rats and this was
significant (P < 0.05) at 1.0 fig All (Fig. 5.3.1).
Neither dose of All produced any stimulation of PGF20C
release above non-detectable levels (Table 5.3.2). There
was some stimulation of PGE2 release at the 0.1 fig dose
of All but this was not significant (Table 5.3.3). The
higher dose of 1.0 fig All, however, produced a
significant increase (P < 0.01) in the release of PGE2
from the mesenteric bed of young male rats. All had a
pressor effect on the vascular bed producing a
28.8+/-9.8% increase in the basal perfusion pressure
(42.5 + /-3.7 mmHg) at 0.1 fig All and an increase of
57.2 + /-7.7% at the 1.0 fig dose of All. This was a
significant increase (P < 0.01) in perfusion pressure at
the 1.0 jug but not the 0.1 fig dose of All.
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doses of All produced a significant increase (P< 0.05) in
the basal release of 6—keto—PGF lcc. There was no
significant change in the release of PGF20C and PGE2 at
either dose of All from the mesenteric bed of old males
(Tables 5.3.2 and 5.3.3). All had a pressor effect on the
vascular bed of old rats with the 0.1 fig dose causing a
24.1+/-16.8& increase and the 1.0 fig dose giving a
83.0+/-21.3& increase in basal perfusion pressure. The
increase in perfusion pressure was significant (P < 0.05)
at the 1.0 fig dose of All. There was no significant
difference in the magnitude of the pressor responses to
All in young male compared to old male rats at either
dose.
5.3.3.2 NA-stimulated PG release
Both doses of NA produced a significant increase (0.1 jug
NA; P < 0.05, 1.0 fig NA; P < 0.01) in the release of
6-keto-PGFtK from the mesenteric bed of young male rats
(Figure 5.3.2). NA did not produce any increase in the
amount of PGF2K released to detectable levels (Table
5.3.4). Similarly, NA at either dose, had no effect on
the release of PGE2 from the mesenteric bed of young male
rats (Table 5.3.5). Noradrenaline, at 0.1 fig produced a
63.2 + /-34.7% increase, and 1.0 fig a 174+/-4.4% increase
in perfusion pressure. The increase in perfusion pressure
was significant (P < 0.001) at the 1.0 fig dose of NA.
In the mesenteric vascular bed of old male rats, both
doses of NA produced a significant (P < 0.05) stimulation
 






of 6-keto-PGF loc release . There was no significant
stimulation of PGF2K or PGE2 release after either dose of
NA (Tables 5.3.4 and 5.3.5). The 0.1 pg dose of NA
produced a 211.7+/-41.0% increase, and the 1.0 pg dose a
367.7+/-64.6% increase in basal perfusion pressure. These
increases in perfusion pressure were significant at the
0.1 pg (P < 0.05) and at the 1.0 pg (P < 0.01) dose of
NA. The increases in perfusion pressure induced by both
doses of NA were significantly greater (P < 0.05) in old
compared to young male rats.
5.3.4 Conclusions
All and NA caused a similar response in the mesenteric
vascular bed of both old and young male rats, producing a
significant increase in the release of 6-keto-PGF loc .
However, All (1.0 pg) produced a significant increase in
the release of PGE2 from the mesenteric bed of young, but
not old male rats. The pressor response to All was
similar in young and old male rats, but both doses of NA
produced a considerably greater pressor response in the
mesenteric bed of old compared to young male rats. The
increased pressor response to NA in old rats does not
appear to be due to a deficiency in the release of PGI2.
Table5.3.4.
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SECTION 5.4
Measurement of PG production in the separate layers of
aorta from young (2-3 months) and old (12-14 months)
female rats.
5.4.1 Introduction
The experiments described in Sections 2 and 3 have shown
that there are appreciable differences in the production
of PGs by the vascular tissues of male and female rats.
The production of 6-keto~PGF1K is greater by homogenates
of aorta from males compared to females. In the separated
layers of aorta, the smooth muscle layer from female rats
produced more PGE2 than this tissue from males, but
6-keto-PGF1<x and PGF20( production were greater by the
endothelial cell layer of male compared to female rats.
Therefore, in studying the production of PGs by blood
vessels from aged rats it seemed important to study the
aged female as well as the aged male rat. The experiments
described in this sub-section were undertaken to
determine the profile of PG production by separate layers
of aorta from old female rats, and to compare this




Female albino Wistar rats aged 2-3 months and weighing
200-250g and aged 12-14 months and weighing 330-380g were
used. The old rats had been purchased from the supplier
at the age of 2 months and were kept in the departmental
animal house for 10-12 months. Animals were housed under
controlled conditions and allowed free access to food and
water. Vaginal smears were taken daily for the 2 weeks
prior to the experiment and were found to show a
persistent oestrous smear (i.e. persistent cornification of
the vagina). Young rats exhibited regular 4 day cycles
and were used on day 4. Blood pressure measurements were
made daily for 2 weeks in the old rats as detailed in
Section 4.1.3.
The animals were killed between lO.OOh and 12.00h (n=6 in
each group) and a 2.5 cm length of the thoracic aorta was
removed. The three different layers of each aorta were
separated, homogenised and incubated as described in
Section 4.3.2. Samples in ethyl acetate were stored at
-20°C until assayed by RIA for PG content as detailed
in Section 2.5. The results from young and old female
rats were compared using Student's t-test and
significance was tested at the 5% level.
5.4.3 Results and Conclusions
Similar to the findings in male rats, the




than that of young female rats. Figure 5.4.1 compares PG
production by homogenates of adventitia and smooth muscle
from the aorta of young and old female rats. Homogenates
of adventitia from young rats produced slightly more
PGF20c and PGE2 than 6-keto-PGF 4K . Homogenates of
adventitia from old female rats produced mainly PGF2K
with lower amounts of PGE2 and 6-keto-PGFtK. The smooth
muscle layer had a much greater capacity for PG synthesis
than the adventitia. 6-Keto-PGF loc was the major PG
produced by young rats followed by PGF2a and PGE2.
6-Keto-PGFjK was produced in greatest amounts by the
smooth muscle layer of old rats with similar amounts of
PGF20c and PGE2 formed. The amounts of 6-keto-PGF ta , PGF2a
and PGE2 synthesised by the adventitia were significantly
higher (P < 0.01) in old compared to young female rats.
In the homogenates of smooth muscle however, 6-keto-PGFta
and PGE2 were both significantly (P < 0.001) greater by
the smooth muscle layer of old compared to young female
rats. PGF2k production did not differ between the 2
groups.
Figure 5.4.2 shows endothelial PG production expressed as
ng of PG per 2.5 cm length of aorta. 6-Keto-PGFxK and
PGF2k were produced in similar amounts by the endothelium
of young rats with less PGE2. Endothelial cells from the
aorta of old rats produced mainly 6-keto-PGFla with lower
amounts of PGE2 and PGF2K. There was no difference in the
production of 6-keto-PGFt« or PGF2a between the two
groups but there was an increased production of PGE2 by
the endothelium from old female (P < 0.02) compared to
young female rats.





















Table 5.4.1 compares the mean production of PGs by
homogenates of adventitia, smooth muscle and endothelial
cell layer from the aorta of old (12-14 months) male and
female rats.
There was no significant difference in the production of
6-keto-PGF loc and PGF2o: by homogenates of adventitia from
old male rats compared to old female rats. PGE2
production however, was significantly (P < 0.05) greater
by the adventitia of old female than old male rats.
6—Keto—PGF loc production was significantly greater (P <
0.05) by homogenates of smooth muscle from old male
compared to old female rats, whereas PGF20C and PGE2
production did not differ significantly between the two
groups. The endothelial cell suspension from old female
rats produced significantly greater amounts of
6-keto-PGF1K and PGE2 than the endothelium from old male
rats, but there was no difference in PGF20C production
between the sexes.
Table5.4.1. Comparisonfean(+/-)s. .m.,n=6)productionrostaglandins(PGsbyhom genatefve titia, smoothmuscleandendotheliumfroma r afl(12-14n s)aM)dfe le(Fr t 6-Keto-PGFlaPGF2aE2 MF Adventitia0.34+0341. 5818920 70 * (ng/mgtissue) S.muscle17.6+2.459 890.86*4 1403 25778. 3 (ng/mgtissue) Endothelium4.50+0 47.2.40*3 634 8 (ng/2.5cmof aorta)
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SECTION 5.5
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Measurement of unstimulated PG release from the isolated,
perfused aorta of young and old female rats.
5.5.1 Introduction
It has been shown in experim
that 6-keto-PGFla release fr
than in females. The exp
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5.5.2 Methods
Female albino Wistar rats aged 2-3 months and 12-14
months and weighing 200-250g and 350-470g respectively
were used. The animals were housed as before. Vaginal
smears were taken daily to establish the stage of the
oestrous cycle in the young rats, and to establish the
presence of a persistent oestrous smear in the old rats.
Six animals from each group were killed (the young rats
on Day 4 of the cycle) and the thoracic aorta was
cannulated. A 2.5 cm length of aorta was removed and
placed in a heated (37°C) chamber and was perfused at
5ml/min with oxygenated Krebs solution. After an
equilibration period of 30 min, the perfusate was
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collected for 30 min and was extracted in the same way as
for homogenates as described in Section 2.4. The samples
were stored in ethyl acetate until assayed for PG content
as detailed in Section 2.5.
5.5.3 Results and Conclusions
Figure 5.5.1 compares the basal release of PGs from the
isolated perfused aorta of young (2-3 months) and old
(12-14 months) female rats. 6—Keto—PGF loc and PGE2 were
the major PGs released by the aorta of young female rats
with considerably less PGF2K measured. The aorta from old
rats released mainly 6-keto-PGFjK followed in descending
order by PGE2 and PGF20C. The release of 6-keto-PGF t a and
PGE2 was not significantly different between the two
groups but PGF2K release was significantly greater (P <
0.01) from the aortae of old compared to young female
rats.
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Table 5.5.1 compares the release of PGs from the
isolated, perfused aorta of old (12-14 months) male and
female rats.
Table 5.5.1
Comparison of mean ( + /~ s.e.m., n=6) release of
prostaglandins from the isolated, perfused aorta of old
(12-14 months) male (M) and female (F) rats.
M F
6-Keto-PGF10C 7.00 +/- 0.90 4.20 +/- 0.70*
PGF20C 2.80 +/- 0.70 0.90 +/- 0.07
PGEo 2.70 +/- 0.40 2.10 +/- 0.30
* Significantly different from corresponding male value using
Student's t-test for unpaired data, P < 0.05.
The amounts of 6-keto-PGF t« and PGF20C released from the
perfused aorta of old male rats were significantly
greater (P < 0.05) than those from the perfused aorta of
old female rats. The release of PGE2 was not
significantly different from the aorta of old males
compared to females. Thus, similar to the situation
observed in young animals, old males released greater




Measurement of stimulated PG release from the isolated,
perfused mesenteric arterial bed of young and old female
rats.
5.6.1 Introduction
In contrast to young male rats, young females failed to
show a significant stimulation of 6-keto-PGF 1K release
after the 0.1 pg dose of NA and All (see Section 4.8).
Thus, it is possible that old female rats show a
different response to their young counterparts with
respect to NA- or All- stimulated release of PGs in the
mesenteric arterial bed.
5.6.2 Methods
Female albino Wistar rats aged 2-3 months and 12-14
months and weighing 200-250g and 350-470g" respectively
were used. Consecutive 4-day oestrous cycles were
established in young rats and the presence of a
persistent oestrous smear was confirmed in old female
rats. The mesenteric arterial bed was prepared according
to McGregor, (1965). This procedure is described in
detail in Section 4.5.2. The vascular bed was perfused at
5 ml/min with oxygenated (95% O2, 5% CO2) McEwen's
solution for 30 min to allow for equilibration of the
tissue. NA and All (0.1 pg and 1.0 pg) were given as a
bolus injection in a random order. Samples were collected
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at 1 min intervals for the 2 min before stimulation, for
the 4 min immediately after stimulation and for two
periods, 8 min and 12 min after stimulation. Pressor
responses were recorded on a Polygraph recorder via a
Statham pressure transducer. 6-Keto-PGF 1K, PGF20c and PGE2
content of the perfusate was measured by RIA without
extraction (Section 2.5). The effects of NA and All on PG
release were tested for significance by comparing the 1
min period prior to stimulation with the two 1 min
periods after stimulation using Student's t-test for
paired data. Significance was tested at the 5% level.
5.6.3 Results and Conclusions
6-Keto-PGFta was the PG released in greatest amounts by
the mesenteric bed of young female rats, with lower
amounts of PGE2 and PGF20C. 6-Keto-PGF t a was also the
major PG released by the mesenteric bed of old female
rats with less PGE2 and PGF20C. The release of all 3 PGs
declined over the duration of the experiment (60 min) in
both groups of rats.
The decline in the release of 6-keto-PGFta was
significant (P < 0.01) in both young and old female rats.
The amount of PGE2 released by young rats declined
considerably, since PGE2 reached non-detectable levels in
the perfusate of 2 out of 4 animals. The decline in the
release of PGE2 from the mesenteric bed of old rats was
not significant. The amount of PGF20C released by young
females declined rapidly and reached non-detectable
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levels. The release of PGF20C from the mesenteric bed of
old females also declined rapidly and reached
non-detectable levels in 2 out of 4 animals. Although the
initial amounts of all 3 PGs released were greater by the
mesenteric vascular bed of old compared to young female
rats this was not significant.
5.6.3.1 All-stimulated PG release
All, at both doses, produced some stimulation of
6-keto-PGF loc release from the mesenteric vascular bed of
young females but this was significant (P < 0.05) only
for the 1.0 pg dose (Figure 5.6.1). All had no effect on
the release of PGF20C or PGE2 . All had a pressor effect
on the mesenteric bed with the 0.1 pg dose giving a
14.7+/-6.3& increase and the 1.0 pg dose giving a
33.9+/-8.0& increase in perfusion pressure (58.3+/-2.2
mmHg) of the vascular bed. The increase in perfusion
pressure was significant (P < 0.05) at the 1.0 pg, but
not the 0.1 pg dose of All.
In the mesenteric preparation of old rats, 0.1 pg All
failed to produce an increase, whereas 1.0 pg All
produced a significant increase (P < 0.05) in the release
of 6-keto-PGFtK. Old female rats showed a similar
response to young rats with regard to PGF20C and PGE2
release, with neither dose of All producing a significant
stimulation in the release of these two PGs (Tables 5.6.2
and 5.6.3). The 0.1 pg dose of All gave a 36.1+/-8.3&
rise, and the 1.0 pg dose of All gave a 46.9+/-7.9S, rise
Figure5.6.1.AngiotensinII(All)-stimulatedrel sefprostaglandin(PG)1^,e ured-ke o-PGFf m theisolated,perfusemes nt rica terialb df4young(2-3months)-A,a dl(12-1^months) femalerats-B.*comparedwithv lueimmediatelyprec ingstim l tion. A. ng/min 60 50 40 30- 20 10 1234560 \ All 0-lug1234560 t All 1-0ugmmB. ng/min 60- 50- 40- 30- 20 10 123456W t AD 0'ljjg
*p<005
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in basal perfusion pressure of the mesenteric bed. Both
doses of All produced a significant (P < 0.01) increase
in perfusion pressure. There was no significant
difference in the pressor response to All in the
mesenteric bed of young compared to old female rats.
5.6.3.2 NA-stimulated PG release
NA at the 1.0 jjg, but not the 0.1 //g dose, produced a
significant increase in the release of 6-keto-PGFxK from
the mesenteric bed of young female rats (Figure 5.6.2).
Similarly, there was no significant effect of NA on the
release of either PGF2K or PGE2. NA produced a rise in
basal perfusion pressure of 40.8+/-4.7% at the 0.1 //g
dose and a 150.4+/-3.2& increase at the 1.0 //g dose of
NA. The rise in perfusion pressure was significant (P <
0.05) at both doses of NA.
In the mesenteric vascular bed of old female rats, NA at
the 0.1 //g dose failed to have any significant effect on
the release of 6-keto-PGF t . The 1.0 //g dose however,
produced a significant increase (P < 0.05) in the amount
of 6-keto-PGF1K released. There was no significant effect
of NA on the release of PGF20C at either dose tested
(Table 5.6.4). The 0.1 pg dose of NA had no effect on
the release of PGE2 and although there was some
stimulation of PGE2 release at the higher dose, this was
not significant (Table 5.6.5). Noradrenaline (0.1 //g) ,
caused a 86.5+/-10.1% increase in basal perfusion
Figure5.6.2.
Noradrenaline(NA)-stimul tedreleasfp ostaglandi(PG)I,measured6-ket -PGFfr theisolated,perfus dm sentericart rialbedf4yo ng(2-3m nth )-A,' (12-14months)fe alerats-B.*comparedwithv luimmedi telyp cedingsti ul tion.
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Noradrenaline( A)-stimulatedrele sofprostaglan in(PG)Ff mthi l t d,perfusemes nt ric arterialbedofyoung(2-3months)a dol12 14nths)femalera(ND-<30pg/min) PGF^^releaseng/min 0.1UgNA1.0li 14-
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Table5.6.5.
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pressure and the 1.0 pg dose produced a 259.4+/- 11.8%
increase in the perfusion pressure of the mesenteric bed.
The increase in perfusion pressure was significant at the
0.1 pg (P < 0.05) and at the 1.0 pg (P < 0.01) dose of
NA. There was a significantly greater (P < 0.05) pressor




A comparison of the effects of angiotensin II (All) and
noradrenaline (NA) on PG release from the perfused
mesenteric arterial bed of old (12-14 months) male and
female rats.
Table 5.7.1 compares the 6-keto-PGFtK releasing abilities
of NA and All in old male compared to old female rats.
Tab 1e 5.7.1
Comparison of the ability of noradrenaline (NA) and
angiotensin II All) to cause a significant (P < 0.05) or
non-significant (NS) release of 6-keto-PGF1K from the
isolated perfused mesenteric bed of old male and female
rats.
NA All
0 . 1 jug 1. 0 jug 0 . 1 pg 1. 0 pg
MALE P< 0.05 P < 0.05 P < 0.05 P < 0.05
FEMALE NS P < 0.05 NS P < 0.05
Old male and female rats were similar in their responses
to the higher (1.0 pg) dose of NA and All, but old female
rats failed to show a significant increase in
6-keto-PGF! a release at the low (0.1 pg) dose of either
NA or All. There was no effect of either NA or All on
PGF2a and PGE2 release in both male and female rats.
5 . 8 Discussion
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In conclusion, a number of differences in PG production
and output were observed in the blood vessels of old male
and female rats compared to young male and female rats.
Specifically, an increase in age produced a marked
stimulation of 6-keto-PGF,^ production by homogenates of
aortic smooth muscle in both male and female rats, with
the greater stimulation being found in male rats.
Conversely, there was a significant depression in
6-keto-PGFxK production by aortic endothelial cells of
old male, but not old female rats. However, these
differences in PG production were not reflected in a
significant change in 6-keto-PGFla output from the
isolated perfused aorta with age, although 6-keto-PGFiK
output did tend to be higher in the older rats of both
sexes. There was a sex difference in PG output from the
aorta, 6-keto-PGF j K output being significantly lower in
young and old female rats, than in young and old male
rats, respectively. In the mesenteric arterial bed, the
basal release of 6-keto-PGF4a was higher in old male and
female rats than in young male and female rats, and
6-keto-PGF ia release was higher in old male rats than in
old female rats. The increases in 6-keto-PGF1K output
stimulated by NA and All were not attenuated with an
increase in age in either male or female rats.
Considering the other 2 PGs, homogenates of aortic smooth
muscle again showed the greatest changes, with PGF2a and
PGE2 production increasing with age in male rats and PGE2
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production increasing with age in female rats. PGE2
production by aortic endothelial cells increased with age
in old female, but not old male rats. The output of PGE2
from the perfused aorta did not change significantly with
age, but PGF2k output was significantly increased from
the aorta of old male and female rats. Moreover, PGF2K
was readily detectable in perfusates of the mesenteric
arterial bed of old male and female rats, whereas the
amounts of PGF2K were below the detection limit of the
assay in young male and female rats. Thus, there was an
overall increase in the output of PGF2a from the
vasculature of the rat (both sexes) with an increase in
age. This finding is of interest in view of the action of
PGF2cc as a vasoconstrictor, but also as a potentiator of
the responses to sympathetic nerve stimulation in blood
vessels (Brody and Kadowitz, 1974). Indeed, this study
has shown that the pressor response to NA but not to All,
was significantly greater in old than in young, male and
female rats. Whether this increase in vascular PGF2k
production is involved in the increase in blood pressure
of these rats with age requires further investigation.
Obviously, this study is using an animal model to look at
the effects of increasing age on vascular PG production
and the situation in humans may be different.
Consequently, the experiments described in the next
section aimed to investigate the profile of PG production
by aorta and saphenous vein of human subjects and to




Measurement of the PG synthetic capacity of homogenates
of aorta and saphenous vein and the release of PGs from
rings of saphenous vein from male and female human
subjects : effects of age, sex and drug treatment.
Introduction
Following the discovery of PGI2 production by rabbit
blood vessels it was established that human mesenteric
artery and vein also produce this PG (Moncada et al.,
1977). Rings of human umbilical artery (Ritter, Ongari,
Barrow, Orchard, Blair and Lewis, 1982) and rings of
forearm vein obtained by biopsy have also been shown to
release PGI2 (Preston, Greaves, Jackson and Stoddard,
1982). For obvious reasons it is difficult to obtain
human vascular tissue for studies investigating PG
production and release, so umbilical artery or umbilical
vein endothelial cells in culture are commonly used in
studies of human vascular PG production. Gimbrone and
Alexander (1975) showed that cultured umbilical vein
endothelial cells release PGE into the medium and that
this release is stimulated by All. In 1977 Weksler,
Marcus and Jaffe demonstrated inhibition of platelet
aggregation by intact cultured umbilical vein endothelial
cells and these cells converted [3H] AA to PGI2 and PGE2.
Baenzinger, Dillinger and Majerus (1977) demonstrated
that human aortic smooth muscle cells in culture produce
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PGI2. Later studies have shown that a number of agents
will stimulate PGI2 production by cultured umbilical vein
endothelial cells e.g. AA, histamine, thrombin and A23187
but that unstimulated umbilical vein endothelial cells do
not produce detectable amounts of PGI2 (Baenzinger, Force
and Becherer, 1980; Baenzinger, Fogerty, Mertz and
Chernuta, 1981; Weksler, Ley and Jaffe, 1978). Another
study by Alhenc-Gelas, Tsai, Callaghan, Campbell and
Johnson, (1982) has shown that arterial and venous
umbilical endothelial cells in culture synthesise PGF20C
and PGE2 as well as PGI2 and that histamine stimulates
not only PGI2 release but also PGF2K and PGE2 release
from venous cells. In addition, bradykinin enhanced the
release of PGE2 (as well as PGI2) in arterial cells.
However, the use of umbilical vascular tissue to
demonstrate PG production has been criticised since the
stimulation of PGI2 formation in such tissues by various
agents may not neccessarily represent the situation in
other parts of the vasculature.
As PGI2 is not extensively metabolised by the lung and
experiments using bio-assay suggested that PGI2 produced
by the lung (and possibly by other tissues) acted as a
circulating platelet inhibitory factor and a
vasodepressor agent in rabbits and cats (Moncada et al.,
1978; Gryglewski et al., 1978). Studies in humans in
which trans-pulmonary measurements of plasma 6-keto-PGFta
concentrations were made by GC-MS in patients undergoing
cardiac catheterisation (Hensby et al., 1979) suggested
that PGI2 was released from the lung at a rate
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(5ng/kg/min) which is sufficient to inhibit platelet
aggregation in vitro, as established when synthetic PGI2
was infused into human volunteers (Fitzgerald, Friedman,
Miyamori, O'Grady and Lewis, 1979). However, evidence now
suggests that the rate of secretion of PGI2 into the
circulation of human volunteers is very much lower,
approximately 0.09 ng/kg/min (Fitzgerald et al., 1981).
Other studies have substantiated this finding using RIA
(Forder and Carey, 1982) where venous plasma levels of
approximately 7 pg/ml were reported, and capillary column
gas chromatography with negative ion mass spectrometry
where plasma levels of 6-keto-PGFla were found to be less
than 3 pg/ml (Blair et al., 1982).
Studies yielding interesting findings on 6-keto-PGF,K
levels under different conditions and pathological states
have been carried out, but the above findings must be
considered when discussing these results, and in a number
of cases the validity of the absolute concentrations of
6-keto-PGFja quoted, must be questioned. Hensby et al.
(1981) measured venous plasma 6-keto-PGFxa by GC-MS and
found no significant difference between normal males and
females. Another study by Ylikorkala, Osterman, Linden
and Viinika (1982) found that plasma 6-keto-PGF,K (as
measured by RIA) was higher in subjects of 10-20 years
than subjects of 21-30 or 51-70 years. The levels of
6-keto-PGFla in subjects of 71-90 years did not differ
significantly from those under 20 years and the levels in
women over 70 years were significantly higher than those
in men of the same age. Plasma 6-keto-PGFja was found to
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be significantly lower in women on combined oestrogen and
progestagen oral contraceptives than in controls but
women on a progestagen only pill had levels of
6-keto-PGF la in the normal range (Ylikorkala, Puolakka
and Viinika, 1982). Using an alternative approach Nordoy,
Svensson, Haycraft, Hoak and Wiebe (1978) observed that
spontaneous platelet aggregation was commonly found in
women (21-31 years) using combined oral contraceptives,
post-menopausal women (45-66 years) and men in the 48-71
age group. The inhibitory effect of human endothelial
cells on ADP-induced aggregation was significantly
reduced in young women taking oral contraceptives and in
post-menopausal women. Also, the inhibitory effect of
PGI2 on ADP-induced aggregation was less in all groups of
females compared to males. Thus, a number of differences
in plasma levels of 6-keto-PGF loc have been observed
depending on age, sex and whether the women have been
taking oral contraceptives or not.
A number of studies have been carried out to determine if
levels of 6-keto-PGFjK differ in normotensive compared to
essentially hypertensive subjects. Grose, Lebel and
Gbeassor (1980), observed a diminished excretion of
6-keto-PGFla in the urine of patients with essential
hypertension compared to controls. In agreement with
these findings plasma 6-keto-PGFjK levels (as measured by
RIA) were found to be significantly reduced in
hypertensive compared to normotensive subjects but,
during an infusion of NA, there was a greater increase in
6-keto-PGF 1<x in the plasma of hypertensive than
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normotensive subjects (Ishii, Uehara, Hirata, Atarashi,
Ikeda, Sugimoto, Takeda and Murao, 1982). However,
Friedman, Webster, Hensby and Lewis (1981) found that,
although plasma 6-keto-PGFtK was slightly elevated in
patients with essential hypertension, it was not
significantly elevated compared to age-matched controls.
The hypertensive patients in the former study were older
than their normotensive controls and this may have
affected the results.
The present study aimed to characterise the profile of PG
production by homogenates of aorta and saphenous vein,
and the release of PGs from rings of saphenous vein from
a large number of male and female subjects. These
subjects were patients undergoing surgery for coronary
heart disease and despite the limitations imposed by such
a population group the effects of a number of parameters
(i.e. age, sex, smoking habits and drug regime) on
vascular PG production has been investigated.
6.1.1 Patient Characteristics
A total of 127 patients were studied, 88 males and 39
females. The age range for the males was 36-79 years
(mean +/- s.e.m.; 54.4 +/-0.9) and for the females was
30-76 years (mean +/- s.e.m.; 54.7 +/- 2.5). Of the 88
males; 24 were smokers, 31 had stopped smoking for some
time prior to the operation and 33 were non-smokers. Of
the 39 females; 10 were smokers, 19 had stopped smoking
Table6.1.1.
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some time prior to the operation and 10 were non-smokers.
All of the patients were receiving a range of medications
and the major drugs being taken, age groupings and
smoking habits are detailed in Table 6.1.1.
A large percentage of men (61.435) and women (66.735) were
taking a ^-adrenoreceptor blocking drug, and a large
percentage (men 73.835, women 76. 935) were also taking a
nitrate drug. A greater proportion of women were taking a
loop diuretic compared to men, 23.1 % and 15.9 X
respectively. A greater percentage of men (8335) were
2+
taking a Ca antagonist compared to women (46.235) and a
greater percentage of women (33.3%) were taking a
thiazide diuretic compared to men (12.5%).
6.1.2 Effects of age and sex on PG production by aorta and
saphenous vein of male and female subjects.
6.1.2.1 Introduction
The 127 patients were divided into groups according to
age and sex. Thus males and females were divided into 5
age groups; 31-40, 41-50, 51-60, 61-70 and 71-80 years.
The majority of male patients (73%) were aged 41 to 60
years whereas the majority of female patients (74%) were
aged 51-70 years. Due to the nature of the operation
there are no patients under the age of 30 years and very
few in the 31-40 age group, therefore the discussion of
the effects of age on vascular PG production will be
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limited to subjects of middle age and older. Also, the
well-documented difference in the incidence of
cardiovascular disease between men and women is reflected
in this sample group, since only 31% of the total number
of patients were female.
6.1.2.2 Methods
Vascular tissue was obtained from patients undergoing
coronary artery by-pass surgery. From each patient an
excess segment of saphenous vein and the small piece of
aorta punched out during the joining of the section of
saphenous vein to the aorta were placed in Krebs solution
by the operating theatre nurse. The tissue was then
collected as soon as possible from the operating theatre.
The aorta and segment of saphenous vein were blotted
dry, weighed, and then homogenised separately in 5ml
Krebs solution. The homogeniser was washed with 5ml Krebs
solution and the homogenate and washings were added to
25ml conical flasks. The homogenates were incubated with
2 ^/g/ml AA, for 60 min at 37°C, in an atmosphere of 95%
O2, 5% CO2. The incubates were then extracted with ethyl
acetate as described in Section 2.4. The dried extracts
were redissolved in 4 ml ethyl acetate and stored at
-20°C until assayed for PG content by RIA as detailed in
Section 2.5. If sufficient saphenous vein tissue was
obtained, the piece of tissue remaining after using a
segment for homogenisation was cut into 2mm rings and was
incubated in 5ml Krebs solution. The PGs present in the
incubation fluid from the rings were extracted with ethyl
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acetate and assayed for PG content as described in
Sections 2.4 and 2.5 respectively. The tissue samples
were collected from the operating theatre by Mr. Ian
Ansell of the department of Clinical Surgery, Royal
Infirmary and coded by him before being passed on to the
Department of Pharmacology. All of the patient details
were collated by Mr.Ansell and were not consulted until
after the RIAs had been completed. The results obtained
were analysed with respect to age and sex, the effects of
cigarette smoking, and the effects of various drug
treatments, as follows:-
6.1.2.3 Results
Table 6.1.2 shows the mean (+/- s.e.m.) amounts of PGs
produced by homogenates of aorta and saphenous vein of
male and female subjects respectively, according to age.
6.1.2.4 Conclusions
It can be seen from Table 6.1.2 that homogenates of aorta
from male subjects produced similar amounts of the three
PGs. Homogenates of saphenous vein however, produced
mainly 6-keto-PGF 4 K with lesser amounts of PGF20C and
PGE2. This profile of PG production was similar in all
of the age groups studied. Homogenates of aorta and
saphenous vein produced similar amounts of 6-keto-PGF loc,
but aortic PGF2oc and PGE2 production were considerably
greater than that of the saphenous vein. Again this was
true for all age groups studied. There were no
significant differences in PG production by homogenates
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of aorta and vein when comparing the age groups although
there did appear to be a trend towards increased
production of 6-keto-PGF10c by aorta and vein with
increased age. There was also a trend towards decreased
production of both PGF20( and PGE2 by the aorta, but not
by the vein with increasing age. The profile of PG
production by blood vessels of female subjects was
slightly different to that of the males (Table 6.1.2).
As was observed for males, the aorta from females
produced similar amounts of the three PGs. The profile
of PG production by the saphenous vein of females was
more complex with differences being found in different
age groups. In the 41-50 age group, PGF2a was the major
PG produced with lesser amounts of 6-keto-PGF,a and PGE2 ;
in the 51-60 age group, 6-keto-PGFta was the major PG
produced with lesser amounts of PGF20C and PGE2 ; and in
the 61-70 age group, PGF20C was the major PG produced with
lesser amounts of 6—keto—PGF loc and PGE2 . These
differences in the profile of PG production were
reflected by significant differences in PG production
with age; the veins of women aged 51-60 produced
significantly greater (P<0.01) amounts of 6-keto-PGF!a
compared to the veins of women aged 41-50 or 61-70 years
of age. The veins of women in the 51-60 age group also
produced significantly less (PC0.01) PGF2oc than the veins
of women in the 41-50 and 61-70 age groups. There was a
change in the 6-keto-PGF,a to PGF2K ratio from 2.07 : 1.0
in the 51-60 age group to 0.34 : 1.0 and 0.45 : 1.0 in
the 41-50 and 61-70 age groups respectively. PGE2
- 258 -
production did not vary significantly with age. There
were no significant differences in the production of the
3 PGs by homogenates of aorta with age.
Comparing males and females in the same age group there
was no significant sex difference in the aortic
production of 6-keto-PGFtK, PGF2K or PGE2. There were
significant sex differences however, in the venous
production of 6-keto-PGFta, with females in the 41-50 and
61-70 age groups producing smaller (P<0.01) amounts of
6-keto-PGF1K from homogenates of saphenous vein than
males in the same age group. But, females in the 41-50
and 61-70 age groups produced significantly (P<0.01) more
PGF20C from venous homogenates than males in the same age
groups. There was no significant difference in the
production of PGE2 by veins of males compared to females.
6.1.3 Measurement of the basal release of PGs from rings of
saphenous vein from male and female patients.
6.1.3.1 Introduction
The experiments described in the previous sub-section
give details of PG production by homogenates of aorta and
vein incubated with exogenous AA. Experiments described
here aimed to characterise the basal release of PGs from
rings of saphenous vein in the absence of stimulation
with AA and to determine if there were any age or sex
differences in PG release. A total of 48 males and 16
females were studied in this way.
- 259 -
6.1.3.2 Results
Tables 6.1.4 and 6.1.5 show the mean (+/-s.e.m.) amounts
of PGs released from rings of saphenous vein from male
and female subjects divided according to age.
Table 6.1.4
Mean (+/-s.e.m.) release of prostaglandins (PGs) from
rings of saphenous vein from male subjects aged 35-79
years.
Prostaglandin output (ng/mg wet wt/30 min)
AGE GROUP 31-40 41-50 51-60 61-70 71-80
n (2) (11) (20) (16) (0)
6-keto-PGFlcc 1.9 4.5+/-1.2 4.9+/-1.0 3.8+/-0.5
PGF2a 1.6 2.5+/-0.4 2.8+/-0.5 1.9+/-0.3
PGE2 1.3 2.7+/-0.6* 2.2+/-0.3 1.5+/-0.2*
* Significantly (P<0.05) lower than males in the 41-50
age group using Student's t-test.
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Table 6.1.5
Mean ( + /-s. e.in. ) release of prostaglandins (PGs) from
rings of saphenous vein from female subjects aged 30-76
years.
Prostaglandin output (ng/mg wet wt/30 min)
AGE GROUP 31-40 41-50 51-60 61-70 71-80
n (1) (2) (6) (6) (1)
6-keto-PGFjK 3.8 5.5 4.6+/-0.8 5.2+/-1.3 4.7
PGF2o( 0.7 3.3 1.7+/-0.2 4.0+/-1.3# 2.9
PGE2 1.9 1.8 1.6+/-0.2 2.0+/-0.2 2.0
# Significantly (P<0.05) different fromi corresponding
male value using Student's t-test.
6.1.3.3 Conclusions
6-Keto-PGF10C was the major PG released in all age groups
of male subjects followed by lesser and approximately
equal amounts of PGF2a and PGE2. (Table 6.1.4). There was
a decline in the release of all 3 PGs in the 61-70
compared to the 41-50 years age group; this was not
significant for 6-keto-PGF 1K or PGF20C but was significant
(P<0.05) for PGE2. 6-Keto-PGFjK was also the major PG
released by saphenous vein of females with lesser and
similar amounts of PGF2K and PGE2 (Table 6.1.5). Because
of the small number of female subjects it was not
possible to determine if there were any age differences
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in PG production. The only sex difference apparent in the
release of PGs was in the 61-70 years age group where the
vein from females released significantly (P<0.05) greater
amounts of PGF2K than the males.
Section 6.2.1
The effects of cigarette smoking on PG production by
aorta and saphenous vein of male and female subjects.
6.2.1.1 Introduction
Smoking is considered to be one of the major risk factors
for coronary heart disease (US Report to the Surgeon
General on Smoking and Health, 1963; Kannel and Thorn,
1979). Several studies have been carried out to
investigate the effects of cigarette smoke on the blood
vessel wall and also on vascular PG production. Pittilo
et al., (1982) exposed rats to graded doses of fresh
cigarette smoke (5 days per week for 25 days) and
examined the aortic endothelium by scanning electron
microscopy. Alterations in the endothelium, blebbing and
microvilli-like projections from the luminal surface were
consistently seen. In addition, the majority of cases had
micro-thrombi in the low shear areas near the intercostal
branches. In vitro, aortic strips from these rats showed
a reduction in PGI2 release and the platelets from these
rats aggregated more readily than controls. Similarly,
Lubawy, (1983) found that aortic rings from rats exposed
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to cigarette smoke daily 5 times a week for 10 weeks
synthesised less PGI2 from [14C] AA than sham-smoked rats.
Also, the platelets from the smoke exposed rats
synthesised more TXB2 from [14C] AA than room control rats
but not sham-smoke rats.
The responses to exogenously administered PGI2, i.e. a
fall in systolic and diastolic blood pressure and
tachycardia, were significantly reduced in rats exposed
to smoke 1 and 24 hours (but not 48 hours) previously.
The responses to PGF2K, PGE2 and AA were not
significantly affected by prior exposure to smoke (Boura
et al.,1981). There is also some evidence from human
studies that smoking may affect vascular PGI2 production.
Diminished PGI2 formation was demonstrated in umbilical
arteries of babies born to mothers who smoke (Dadak et
al., 1981). Busacca et al., (1982) measured PGI2 release
from rings of umbilical artery and found that, although
PGI2 release was lower by rings of smokers than
non-smokers, this difference was not significant; but,
cultured umbilical artery endothelial cells from smokers
stimulated with AA produced significantly less PGI2 than
non-smokers. Interestingly, the success rate in
establishing cultures of endothelial cells from smokers
(particularly those who smoked more than 15/day) was much
lower than that of non-smokers. Urinary PGI2 (measured as
6-keto-PGF loc) was measured in 12 chronic smokers and 12
non-smokers after inhalation of smoke from nicotine and
nicotine-free cigarettes (Nadler et al., 1983).
Nicotine-free cigarettes had no effect on urinary PGI2
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levels in smokers or non-smokers but the inhalation of
nicotine-smoke in chronic smokers produced a highly
significant reduction in urinary PGI2 levels. In
contrast, nicotine-smoke had no effect on urinary PGI2 in
non-smokers. In the present study, the effect of
cigarette smoking on PGI2 , PGF20C and PGE2 production by
homogenates of aorta and saphenous vein has been
examined.
6.2.1.2 Results
The results for male and female patients were treated
separately because of the differences observed in PG
production between the two groups, but were not divided
according to age. Although there were some differences in
PG production between the female age groups it was felt
that because of the small number of female subjects it
might be more informative to divide the whole group into
smokers and non-smokers. The patients were subdivided
further into non-smokers i.e. those who had never smoked,
ex-smokers; those who used to smoke but had stopped some
time prior to the operation and smokers; those who were
currently smoking. Tables 6.2.1 and 6.2.2 show the mean
(+/-s.e.m.) production of PGs by homogenates of aorta and
saphenous vein of male patients.
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Table 6.2.1
Mean (+/-s.e.m.) production of prostaglandins (PGs) by
homogenates of aorta (A) and saphenous vein (V) from male
non-smokers, ex-smokers, smokers and ex-smokers and
smokers combined.
Prostaglandin production (ng/mg wet wt.)
Non-Smokers Ex-smokers Smokers Ex-smokers +
smokers
n (33) (31) (24) (55)
6-Keto-PGF1(
A 14.7+/-1.7 10.6+/-1.4 12.3+/-1.6 11.3+/-1.0
V 17.4+/-1.3 13.7+/-1.2* 13.8+/-1.8 13.8+/-1.0*
PGF2 OC
A 14.4+/-1.6 12.4+/-1.6 17.2+/-2.4 14.1+/-1.4
V 8.6+/-1.0 5.7+/-0.6* 7.1+/-1.1 6.4+/-0.6*
PGE.
A 14.2+/-1.8 12.0+/-1.7 11.7+/-1.9 12.1+/-1.2
V 5.0+/-0.5 4.0+/-0.4 3.5+/-0.5* 3.7+/-0.3*
* Significantly (PC0.05) different from value for
non-smokers using analysis of variance.
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Table 6.2.2
Mean (+/-s.e.m.) production of prostaglandins (PGs) by
homogenates of aorta (A) and saphenous vein (V) from
female non-smokers, ex-smokers, smokers and ex-smokers
and smokers combined.
PG production (ng/mg wet wt.)
Non-smokers Ex-smokers Smokers Ex-smokers +
smokers
n (10) (19) (10) (29)
6-Keto-PGF10C
PGF,
A 9.3+/-0.9 12.0+/-1.7 10.7+/-2.5 11.5+/-1.4
V 16.6+/-2.9 15.4+/-2.1 12.4+/-2.6 14.3+/-1.6
A 20.3+/-4.2 16.5+/-3.0 13.5+/-3.7 15.5+/-2.3
V 8.4+/-0.8 11.0+/-1.7 8.9+/-1.5 10.3+/-1.2
PGE.
A 13.7+/-2.5 12.0+/-2.1 10.9+/-1.5 11.6+/-1.4
V 4.2+/-0.6 4.2+/-0.5 6.4+/-2.0 5.0+/-0.8
6.2.1.3 Conclusions
It can be seen from Table 6.2.1 that the production of
6-keto-PGFjK is significantly greater (P<0.05) by
homogenates of saphenous vein from male non-smokers
compared to ex-smokers. Although 6-keto-PGF loc production
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was lower in veins from male smokers than non-smokers
this was not significant. But, 6-keto-PGFjK production
by veins was greater by non-smokers when smokers and
ex-smokers were combined (P<0.05). PGF20C production was
significantly lower (P<0.05) by homogenates of vein from
male ex-smokers, or ex-smokers and smokers combined than
non-smokers. PGE2 production was significantly lower
(P<0.05) by homogenates of vein from male smokers and
ex-smokers and smokers combined compared to non-smokers.
The production of all 3 PGs tended to be lower by
homogenates of aorta from male smokers or ex-smokers than
non-smokers but this was not significant. There were no
significant diferences in the production of the 3 PGs by
homgenates of aorta and vein from female non-smokers
compared to smokers, ex-smokers, or smokers and
ex-smokers combined (Table 6.2.2).
Section 6.2.2
The effects of cigarette smoking on PG release from
saphenous vein of male and female subjects.
6.2.2.1 Introduction
The experiments described in Section 6.2.1 measured PG
production by homogenates of vascular tissue. The
experiments described in this section have measured PG




Male and female subjects were divided into non-smokers,
ex-smokers, smokers and ex-smokers and smokers combined
as in the previous sub-section. Tables 6.2.3 and 6.2.4
show the mean (+/-s.e.m.) release of PGs from rings of
saphenous vein from male and female subjects
respectively.
Table 6.2.3
Mean (+/-s.e.m.) release of prostaglandins (PGs) from
rings of saphenous vein from male subjects.
Prostaglandin output (ng/mg wet wt.)
Non-smokers Ex-smokers Smokers























Mean (+/-s.e.m.) release of prostaglandins (PGs) from
rings of saphenous vein from female subjects.


























The release of 6-keto-PGFtK from saphenous vein rings of
males tended to be less in smokers and ex-smokers than
non-smokers but this was not significant (Table 6.2.3).
PGE2 release was not significantly different in smokers
or ex-smokers compared to non-smokers but the release of
PGF2cc was significantly (P<0.05) less from the vein of
ex-smokers, but not smokers, compared to non-smokers.
The saphenous vein from female smokers or ex-smokers
tended to release lower amounts of all 3 PGs compared to
non-smokers but because of the small number of subjects




The effects of JB-blockers on PG production by aorta and
saphenous vein of male and female subjects.
6.3.1 Introduction
Several early studies showed that JB-adrenergic blocking
agents depressed platelet function and inhibited platelet
aggregation (Bygdeman and Johnson, 1969; Bucher and
Stucki, 1969; and Frishman et al., 1974). More recent in
vivo studies using inhibitors of PG synthesis have
suggested that ^-blockers may also stimulate the release
of vasodilator PGs from the vasculature in rabbits (Durao
and Rico, 1977) and in humans (Durao, Prata and
Goncalves, 1977 and Watkins, Abbott, Hensby, Webster and
Dollery, 1980). Consequently, the effect of treatment
with ^-blockers on PG production by homogenates of aorta
and saphenous vein was investigated.
It was not possible to draw any valid conclusions on the
effects of ^-blockers on PG release from rings of
saphenous vein as very few of this group of patients were
not taking a ^-adrenergic blocking agent. Similarly, with
regard to subsequent sections, there were insufficient
numbers of patients not taking nitrates and Ca2+
antagonists, and too few people taking a thiazide or loop
diuretic to draw significant conclusions about the




The results for males and females were considered
separately because of the differences observed in PG
production between the two groups. Patients were divided
into those who were taking a B-blocker and those who were
not receiving this form of treatment. Tables 6.3.1 and
6.3.2 show the mean (+/-s.e.m.) production of PGs by




Mean (+/-s.e.m.) production of prostaglandins (PGs) by
homogenates of aorta (A) and saphenous vein (V) of male
subjects taking a ^-blocker.
n






A 12.3 +/- 1.1 12.5 +/- 1.4
V 14.5 +/- 1.3 17.9 +/- 1.4
A 14.2 +/- 1.3 15.2 +/- 1.9
V 7.1 +/- 0.7 7.6 +/- 0.9
A 12.6 +/- 1.2 13.2 +/- 1.8
V 4.8 +/- 0.8 4.6 +/- 0.5
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Table 6.3.2
Mean (+/-s.e.m.) production of prostaglandins (PGs) by
homogenates of aorta (A) and saphenous vein (V) of female
subjects taking a ^-blocker.





A 13.0 +/- 1.4 *
V 15.2 +/- 1.8
A 17.4 +/- 2.7
V 10.4 +/- 1.4 #





A 11.9 +/- 1.6
V 5.3 +/- 1.9
12.8 +/- 1.9
3.7 +/- 0.5
♦ Significantly different (P<0.01) from value for females not
taking a B-blocker using Student's t-test.
# Significantly (P<0.05) different from corresponding male
value using Student's t-test.
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6.3.3 Conclusions
It can be seen from Table 6.3.1 that the use of a
^-blocking agent by male patients does not affect the in
vitro production of PGs by homogenates of aorta and
saphenous vein. There was no significant difference in
the production of 6—keto—PGF1K, PGF2CC or PGE2 by aorta or
vein of males taking a ^-blocker compared to those who
were not taking these agents. In female patients however,
the production of 6-keto-PGFla was significantly greater
(P<0.05) by homogenates of aorta from patients who were
taking a ^-blocker compared to those who were not (Table
6.3.2). The production of 6-keto-PGFt^ was not
significantly different by the saphenous vein of the two
groups. PGF20C and PGE2 production were not significantly
different by either aorta or vein of females taking a
^-blocker than females who were not taking these agents.
Comparing male and female patients, homogenates of aorta
from females not taking a ^B-blocker produced
significantly less (P<0.05) 6-keto-PGF loc than aorta from
males not taking a ^-blocker. In addition, homogenates of
vein from females taking a ^-blocker produced
significantly greater (P<0.05) amounts of PGF2K than the
vein from males taking a ^-blocker.
Section 6.4
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The effects of nitrates on PG production by aorta and
saphenous vein of male and female subjects.
6.4.1 Introduction
Nitrates, including isosorbide mononitrate, isosorbide
dinitrate and glyceryl trinitrate (GTN) are agents used
in angina pectoris and their efficacy and rapidity of
action are well-established (Hillis and Braunwald,
1977).However, the mechanism of action of nitrates is
poorly understood. Evidence is accumulating that at least
part of the vasodilatory action of GTN is mediated
through the release of PGI,. Levin et al. (1981), showed
that GTN stimulates PGI2 release by isolated human
umbilical endothelial cells in culture and Shroer et al.
(1981) showed that GTN significantly increased the basal
and AA-stimulated release of PGI2 from rings of bovine
coronary artery. This increase in vessel PGI2 release
inhibited TXAz formation in human platelets as seen when
aliquot portions of the vessel incubates were added to
platelets prior to thrombin. In vivo, however, although
NTG decreased peripheral vascular resistance in
anaesthetised dogs, blood flow did not change
significantly and no significant changes in plasma
6-keto-PGF la, PGEj and PGF20( were found (Kai et al.,
1982). Sakai et al. (1984), using open-chest dogs, found
that intra-coronary or intra-venous NTG increased
coronary blood flow but this effect was not significantly
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modified by indomethacin. Although actual PG levels were
not measured in the latter study it does seem that in the
dog the effects of NTG are not mediated through the PG
system. Nevertheless, in the present study it was thought
relevant to examine the effect of treatment with nitrates
on PG production by homogenates of human aorta and
saphenous vein.
6.4.2 Results
The results for males and females were considered
separately because of the differences observed in PG
production between the two groups. The patients were
separated further into those who were taking a nitrate
(either GTN, isosorbide mononitrate or isosorbide
dinitrate) and those who were not taking these agents.
Tables 6.4.1 and 6.4.2 show the mean (+/-s.e.m.)
production of PGs by homogenates of aorta and saphenous
vein of male and female patients.
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Table 6.4.1
Mean (+/-s.e.m.) production of
homogenates of aorta (A) and
subjects taking a nitrate.
prostaglandins (PGs) by
saphenous vein (V) of male






A 12.4 +/- 1.0 13.8 +/- 1.7
V 15.5 +/- 1.1 15.9 +/- 1.8
A 14.4 +/- 1.1 14.4 +/- 2.8
V 7.2 +/- 0.6 7.4 +/- 1.2
A 13.7 +/- 1.2 11.0 +/- 2.2
V 4.4 +/- 0.3 3.9 +/- 0.4
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Table 6.4.2
Mean (+/-s.e.m.) production of prostaglandins (PGs) by
homogenates of aorta (A) and saphenous vein (V) of female
subjects taking a nitrate.






A 10.8 +/- 1.1 12.4 +/- 3.1
V 16.8 +/- 1.5 * 9.0 +/- 2.6
A 15.6 +/- 1.9 22.3 +/- 6.4
V 9.4 +/- 1.1 10.6 +/- 2.0
A 13.5 +/- 1.4 8.2 +/- 2.0
V 5.3 +/- 0.7 3.0 +/- 0.6
* Significantly (P<0.05) different from value for females
not taking a nitrate using Student's t-test.
6.4.3 Conclusions
It can be seen from Table 6.4.1 that taking a nitrate for
the relief of angina does not affect the in vitro
production of PGs by homogenates of aorta and saphenous
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vein from male patients. The saphenous vein from female
patients taking nitrates however, produced significantly
(P<0.05) greater amounts of 6-keto-PGF10C than the vein
from females not taking these drugs (Table 6.4.2). There
was no significant difference in the production of
6-keto-PGFtk by the aorta of females taking nitrates
compared to females who were not taking them. There was
no significant difference in the production of PGF2a and
PGE2 by either aorta or vein of females taking nitrates.
PG production did not differ significantly by aorta or
vein of males compared to females.
Section 6.5
The effects of thiazide diuretics on PG production by
aorta and saphenous vein of male and female subjects.
6.5.1 Introduction
The thiazide diuretics, commonly used in
anti-hypertensive therapy, may have effects on PG
formation. Indomethacin blunted the fall in blood
pressure after administration of thiazide diuretics in
humans (Watkins et al., 1980) and in a complimentary
study, increased levels of 6-keto-PGFtK were found in the
plasma of hypertensive patients given bendrofluazide
(Webster, Dollery and Hensby, 1980). The effect of
thiazide diuretic treatment on PG production by




The results for male and female patients were treated
separately because of the differences observed in PG
production between these two groups. Patients were
divided into those who were taking a thiazide diuretic
and those who were not receiving this form of treatment.
Tables 6.5.1 and 6.5.2 show the mean (+/-s.e.m.)
production of PGs by homogenates of aorta and saphenous
vein of male and female patients.
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Table 6.5.1
Mean (+/-s.e.m.) production of prostaglandins (PGs) by
homogenates of aorta (A) and saphenous vein (V) of male
subjects taking a thiazide diuretic.






A 10.3 +/- 2.0
V 15.5 +/- 2.1
A 13.0 +/- 3.4
V 9.6 +/- 2.4
A 12.2 +/- 3.2









Mean (+/-s.e.m.) production of prostaglandins (PGs) by
homogenates of aorta (A) and saphenous vein (V) of female






A 12.5 +/- 2.2 10.4 +/- 1.3
V 19.4 +/- 2.3 * 13.3 +/- 1.7
A 13.7 +/- 3.2 18.4 +/- 2.6
V 9.6 +/- 1.1 9.6 +/- 1.3
A 8.8 +/- 1.0 13.9 +/- 1.6
V 6.4 +/- 1.8 4.2 +/- 0.5
♦ Significantly (P<0.05) different from value for females
not taking a thiazide diuretic.
6.5.3 Conclusions
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There was no significant difference in the production of
any of the 3 PGs by aorta or saphenous vein of male
patients taking a thiazide diuretic compared to males not
taking these drugs. Similarly, thiazide diuretics did not
appear to have a significant effect on the in vitro
production of PGF20( and PGE2 by aorta and vein of female
patients. Although 6-keto-PGF10C production by aorta did
not differ between the two groups, 6—keto—PGF loc
production was significantly greater by saphenous vein of
females taking a thiazide diuretic.
Section 6.6
The effects of loop diuretics on PG production by aorta
and saphenous vein of male and female subjects.
6.6.1 Introduction
Frusemide is a well-known loop diuretic which has a
pronounced anti-hypertensive action. Its mode of action
appears to be related to the PG system as cyclooxygenase
inhibitors partially block the natriuretic response and
the effects on renal blood flow (Bailie, Crosslan and
Hook, 1976; Williamson, Bourland and Marchand, 1974). It
has been suggested that frusemide may also have
extra-renal effects on PG formation. Weithman (1982)
found that aortic rings from rats treated with
therapeutic concentrations of frusemide showed a
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significantly higher release of a PGI2-like substance
which was supressed by pre-treatment of the rats with
indomethacin or aspirin. However, frusemide did not
stimulate PGI2-like release from rat aortas in vitro
suggesting that it acts in vivo via secondary factors
present in plasma. Nevertheless, it was considered
relevant to examine the effects of loop diuretics on PG
production by homogenates of human aorta and saphenous
vein.
6.6.2 Results
The results for males and females were considered
separately. Patients were divided into those who were
taking a loop diuretic (frusemide or bumetanide) and
those who were not receiving this form of treatment.
Tables 6.6.1 and 6.6.2 show the mean (+/-s.e.m.)
production of PGs by homogenates of aorta and vein of
male and female patients.
- 284 -
Table 6.6.1
Mean (+/-s.e.m.) production of prostaglandins (PGs) by
homogenates of aorta (A) and saphenous vein (V) of male
subjects taking a loop diuretic.
Prostaglandin production (ng/mg wet wt.)





A 11.8 +/- 2.1 12.3 +/- 0.9
V 17.7 +/- 3.2 15.4 +/- 1.0
A 14.7 +/- 2.9 14.0 +/- 1.2
V 5.4 +/- 0.5 7.8 +/- 0.6
A 10.5 +/- 2.2 13.6 +/- 1.1
V 3.7 +/- 0.6 4.3 +/- 0.3
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Table 6.6.2
Mean (+/-s.e.m.) production of prostaglandins (PGs) by
homogenates of aorta (A) and saphenous vein (V) of female
subjects taking a loop diuretic.
Prostaglandin production (ng/mg wet wt.)
Loop diuretic No loop diuretic
n (9) (30)
6-Keto-PGF10C
A 8.0 +/- 1.1




A 17.0 +/- 4.7




A 11.6 +/- 1.9




It can be seen from Tables 6.6.1 and 6.6.2 that the use
of a loop diuretic does not affect the in vitro
production of 6-keto-PGF,, PGF2a or PGE2 by aorta or
saphenous vein of male and female patients.
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Section 6.7
The effects of calcium antagonists on PG production by
aorta and saphenous vein of male and female subjects.
6.7.1 Introduction
Calcium antagonists such as nifedipine and verapamil have
been widely used for angina pectoris although their
mechanism of action has not been fully elucidated. One
study by Srivistava and Awasthi (1983) has shown that
although nifedipine and verapamil actually reduced PGI2
release from rings of rat aorta in response to
stimulation with AA, they increased the formation of PGI2
by lung homogenates incubated with AA. In anaesthetised
dogs nifedipine produced a decrease in peripheral
vascular resistance but there was no significant change
in plasma 6-keto-PGF loc, PGEi or PGF20C. In contrast,
verapamil produced a decrease in peripheral vascular
resistance but significantly increased plasma levels of
6-keto-PGF !a , PGEi and PGF20C. Indomethacin reduced the
effects of verapamil on vascular resistance and plasma PG
concentration (Kai et al., 1982). Consequently, the
effects of calcium antagonists on PG production by




The mean (+/-s.e.m.) production of PGs by homogenates of
aorta and saphenous vein of male and female subjects
taking nifedipine or verapamil is shown in Tables 6.7.1
and 6.7.2 respectively.
Table 6.7.1
Mean (+/-s.e.m.) production of prostaglandins (PGs) by
homogenates of aorta (A) and saphenous vein (V) of male
subjects taking nifedipine (n=52) or verapamil (n= 2),
(Ca2 + antag.).
Prostaglandin production (ng/mg wet wt.)
Ca2+ antag. No Ca2+ antag.
n (54) (34)
A 10.8 +/- 1.0 * 14.5 +/- 1.5
6-Keto-PGF10c
V 14.4 +/- 1.2 17.9 +/- 1.6
A 13.7 +/- 1.3 15.4 +/- 1.9
PGF2K
V 6.4 +/- 0.5 8.5 +/- 1.1
A 12.2 +/- 1.2 14.2 + /- 1.8
PGE2
V 4.7 +/- 0.4 4.5 +/- 0.5




Mean (+/-s.e.m.) production of prostaglandins (PGs) by
homogenates of aorta (A) and saphenous vein (V) of female
subjects taking nifedipine (n=17) or verapamil (n= 3),
(Ca2+ antag.).
Prostaglandin production (ng/mg wet wt.)
Ca2+ antag. No Ca2+ antag.
n (20) (19)
6-Keto-PGF10c
A 11.2 +/- 1.5




A 17.0 +/- 3.1




A 13.2 +/- 2.2




The aorta from male patients taking a Ca2+ antag produced
significantly lesser (PC0.05) amounts of 6-keto-PGFtK
than the aorta from males not taking this drug (Table
6.7.1). There were no significant differences in the
production of 6-keto-PGF10C by vein, or by PGF2K and PGE2
by either aorta or vein between the two groups.
The Ca2+ antag. did not appear to have any effect on the




The results of the present study do not show any
significant differences in the production of 6-keto-PGFtK
by homogenates of aorta or vein of male subjects with
age. Also, there was no difference in 6-keto-PGFtK output
from rings of saphenous vein with age. There was a
significant decrease in the release of PGE2 from rings of
saphenous vein of males aged 61-70 compared to males of
41-50. 6-Keto-PGF!K production was significantly lower
by homogenates of saphenous vein of females aged 41-50
and 61-70 years than males in the same age groups but
females aged 41-50 and 61-70 produced greater amounts of
PGF2k from homogenised veins than the corresponding male
groups. Similarly, rings of saphenous vein from females
aged 61-70 years released significantly greater
amounts of PGF20C than males in the same age group. There
were no other sex differences observed in PG production
or release. Because there were only 2 males and 2 females
aged 70 years or more it was not possible to comment on
either age or sex differences in this small sample of
elderly patients compared to the other age groups.
This study has shown that homogenates of saphenous vein
from male ex-smokers or ex-smokers + smokers produce
significantly less 6-keto-PGF j a, PGF20C and PGE2 compared
to non-smokers. However, the basal release of
6-keto-PGF, K, PGF20C and PGE2 from rings of saphenous
vein, although lower in smokers or ex-smokers, did not
differ significantly to non-smokers, except for a
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significantly lower output of PGF2CC im male ex-smokers.
Interestingly, reduced PG production by vein was not seen
in female patients, although PG release from rings of
saphenous vein did appear to be lower in smokers. It is
not possible to say if this is a genuine difference in
the response of male and female vascular tissue to
cigarette smoke because the number of female subjects was
rather small.
Of the patients taking a ^-blocker only female subjects
showed any significant differences in PG production, the
aorta producing more 6-keto-PGF loc than the aorta from
females not taking a ^-blocker. The use of a /?-blocker
had no effect on the in vitro production of PGs by
vascular tissue of male subjects. Nitrates produced a
similar effect to fi-blockers with respect to PG
production. Males taking nitrates did not show any
significant difference in vascular PG production but the
saphenous vein from females taking nitrates produced
significantly greater amounts of 6-keto-PGFjK than
females who were not taking this treatment. The calcium
antagonist, nifedipine and the loop diuretic, frusemide
did not appear to have any marked effects on in vitro PG
production by aorta and vein of male or female subjects.
However, the production of 6-keto-PGF10C by the aorta of
males taking nifedipine was significantly less than that
of males not taking nifedipine. Other drugs known to
affect PG production such as NSAIDs and dipyridamole have
not been discussed here because the number of patients
taking these drugs (9 and 4 respectively) was too small
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for valid comparisons to be made. However, as there did
not appear to be a marked effect of either of these two
drugs on PG production by homogenates of aorta and





7.1.1 Profile of PG production by several blood vessels
from male and female rats.
Since the discovery of PGI2, and in particular the
ability of blood vessels to produce this potent
vasodilatory and antiaggregatory PG, it has been assumed
that PGI2 is the major and most important product of
arachidonic acid metabolism in all blood vessels. This
has led to the formulation of an hypothesis of a
TXA2/PGI2 balance controlling blood vessel homeostasis.
However, this view may be an over-simplification of the
involvement of arachidonic acid metabolites in the
control of blood vessel tone and platelet aggregation.
The initial experiments described in this thesis have
established that, contrary to the accepted view, PGI2 is
not the sole product of AA in blood vessels and it has
been demonstrated that aorta, vena cava, mesenteric
artery and femoral vein of male and female rats all
produce substantial amounts of PGE2 and PGF20C in addition
to PGI2 (measured as 6-keto-PGFtK). This was true for
homogenates of all 4 blood vessels, and also for the
perfused aorta and the perfused mesenteric arterial bed.
Indeed, homogenates of the vena cava, mesenteric artery
and femoral artery from male rats produced similar
amounts of 6—keto—PGF1K, PGF20C and PGE2 , and it was only
in the aorta that 6-keto~PGFlcc production was markedly
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greater than that of PGF20C and PGE2 . In the female, the
vena cava produced similar amounts of the 3 PGs, the
mesenteric and femoral arteries produced mainly
6-keto-PGF j of with less PGF20C and PGE2 , and, in contrast
to the situation in the male the aorta produced similar
amounts of 6—keto—PGF1K and PGF2Cf with less PGE2 . Also,
using the experimental procedures of perfusion of an
intact vessel and perfusion of an entire resistance bed,
6-keto-PGF loc was the PG released in greatest quantities
by the isolated, perfused aorta and the isolated,
perfused mesenteric vascular bed of both male and female
rats. These two preparations probably give a better
representation of the profile of the basal output of PGs
from a blood vessel than the use of rings or strips of
aorta which will reflect the release of PGs from not only
the endothelium but also the cut ends of the smooth
muscle layer. As the procedure of cutting the blood
vessel into rings will in itself cause PG formation, via
stimulation of PLA2, this type of preparation may not
give an accurate representation of the basal,
unstimulated release of PGs from vascular tissue.
Many studies in different species have shown that PGI2 is
the principal PG synthesised in large conduit type blood
vessels such as the aorta. In contrast, microvessels and
microvascular endothelial cells, such as from rabbit
myocardium or bovine cerebral cortex exhibit a very
different PG profile with PGE2 being the major PG
produced both under stimulated and basal conditions
(Gerritsen and Cheli, 1983; Gerritsen and Printz, 1981).
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Furthermore, PGI2 is not the only PG involved in the
modulation of contractility of blood vessels. In the
rabbit, exogenous PGI2 inhibited contractions induced by
NA in the coeliac artery but was without effect on the
aorta, extrapulmonary artery or femoral artery; PGE2 had
no effect on NA-induced contractions of the aorta,
inhibited those of the pulmonary and coeliac arteries,
and markedly potentiated those of the femoral artery;
PGF2cc significantly enhanced contractions of the femoral
artery, but the increased contractions of the other
vascular preparations were not significant (Foerstermann,
Herrting and Neufang, 1984). Salzman et al. (1980)
demonstrated similar effects of PGs on intrapulmonary
arteries with PGI2 having no consistent effect, PGF2K
slightly contracting the tissue and PGE2 always relaxing
the tissue. In the canine mesenteric artery strip, PGF2K
and PGE2 produced contraction of the tissue whereas PGEj
and PGI2 were equally potent at causing relaxation
(Hatano, Kohli, Goldberg and Fried, 1981). These findings
suggest that in certain blood vessels, PGs other than
PGI2 may be important modulators of vascular tone, and
indicate that not all changes in vascular tone following
cyclooxygenase inhibition should be interpreted as due
solely to the inhibition of PGI2 synthesis. It is
important, therefore, in studies of vascular PG
production that the fullest range of PGs is measured
whenever possible.
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7.1.2 Male and female differences in vascular PG production
The majority of studies on vascular PG production have
been carried out using male animals, although it has been
reported that PGI2 output from the rat aorta, and from
perfused lungs, is higher in male than in female rats
(Pomerantz et al., 1980; Maggi et al., 1980; Wey et al.,
1983; Bakhle and Zakrzewski, 1981).
In agreement with these authors the findings of the
present study also showed an increased output of
6-keto-PGFtK from the isolated, perfused aorta of male
compared to female rats. The total amount of
6-keto-PGF, K , PGF20C and PGE2 synthesised by homogenates
of aorta did not differ between male and female rats,
therefore the higher basal output of 6-keto-PGFjK from
the aorta of male rats cannot be due to a greater
concentration of PGH2 synthetase in the aorta of males
compared to females. However, there did appear to be a
slight shift in PG synthesis away from 6—keto—PGF1K
towards PGF20C in the female aorta and this may be
responsible for the lower output of 6-keto-PGFj^ from the
aorta of female rats. It is of interest that despite the
aorta from male and female rats having a similar capacity
to produce PGI2, it appears that the male aorta, in a
situation where the aorta is perfused in a pulsatile
manner to more closely simulate in vivo conditions, is
more active in releasing PGI2 than the female aorta.
6-Keto—PGF loc production was greater by vena cava and
lower by femoral artery of male compared to female rats.
The amounts of PGF2K and PGE2 produced by vena cava and
femoral artery of males and females were not
significantly different. The production of 6-keto-PGF 10c,
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PGF.^ and PGE2 by the mesenteric artery did not differ
between the sexes.
7.1.3 Vascular PG production at different times during
the oestrous cycle.
Oestrogen or a combination of oestrogen/progestagen
treatment has been reported to stimulate the output of
PGI2 from the aorta and vena cava of female rats
(Roncaglioni et al., 1979; Ali and Williams, 1983;
Karpati et al.,1980) and from rat aortic smooth muscle
cells in vitro (Chang et al., 1980). The reasons for the
increased output of PGI2 from the aorta of male rats and
the possible role of oestrogen in vascular arachidonic
acid metabolism have not been elucidated. Studies
presented in this thesis aimed to establish whether the
levels of oestrogen and progesterone produced during the
female rats' natural cycle could affect aortic PG
synthesis. The two periods of the oestrous cycle
investigated in this study were 10:00 h on the day of
pro-oestrus, i.e. 4h after a peak of oestradiol and when
progesterone levels are still low, and 02:00 h on the day
of oestrus, i.e. 4 h after a peak of progesterone and
when plasma oestradiol levels are declining. These times
were chosen to ensure that if there were differing
effects of oestrogen and progesterone on PG synthesis,
then sufficient time had elapsed for there to be fresh
protein synthesis.
There was no significant difference in PG production by
homogenates of the aorta or the vena cava at these two
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times during the oestrous cycle. Ali and Williams,
(1983) found that PGI2 release from rings of aorta was
lowest at oestrus and significantly greater at
pro-oestrus, met-oestrus and di-oestrus and showing a
similar fluctuation to the amounts of PGI2 released by
the myometrium. Isolated lungs from rats at different
stages of the oestrous cycle when perfused with [14C] AA
were found to produce more 6-keto-PGF1K at pro-oestrus
than at any other stage of the cycle (Bakhle and
Zakrzewski, 1981). The majority of work on the effects of
the oestrous cycle on PG production has understandably
been carried out using uterine tissue, and it is
interesting that the observations made using isolated
lungs are in agreement with several workers reporting
that the PG-synthesising ability of the uterus is
greatest at pro-oestrus (Thaler-Dao, Saintot, Ramonatxo,
Chavis and Crastes de Paulet, 1982) and in conflict with
the findings of other workers that the capacity for
uterine PG synthesis is greatest at oestrus (Poyser and
Scott, 1980; Ham, Cirillo, Zanetti, and Kuehl, 1975).
However, measurements have largely been made only once or
twice daily during the cycle and the study of Brown and
Poyser (1985) has shown the importance of measuring more
frequently than this (every 4 hours) to determine the
times of maximum PG production in the uterus. PG
production by homogenates of the uterus was maximal at
02:00 h on the day of oestrus. A similar protocol of
4-hourly measurements of PG-synthesising capacity during
the oestrous cycle, adopted for the study of blood vessel
tissue, would possibly be required to reveal an effect,
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if any, of endogenous oestrogen and/or progesterone on
vascular PG production.
7.1.4 Effects of oestrogen and progesterone treatment on
vascular PG production.
Since there were no significant differences in vascular
PG production at the two times of the cycle studied here,
the effects of short-term treatment with oestrogen and
progesterone in an acute ovariectomy model were
investigated. There were no significant differences in
the production of any one PG by either the aorta or vena
cava of oestrogen- and progesterone- treated rats
compared to control, ovariectomised rats. However the
procedure of ovariectomy in itself appears to have had a
significant effect on vascular PG production. Comparing
intact Day 1 or Day 4 rats to ovariectomised control or
treated rats, there was a significant increase in
6-keto-PGFja production by aorta of ovariectomised rats,
and a significant increase in PGE2 production by vena
cava from ovariectomised compared to intact rats. These
findings are in agreement with those of Wey et al.,
(1983) who found that neonatal ovariectomy increased the
capacity of the aorta for 6-keto-PGFtK synthesis, and
Pomerantz et al., (1981) who found that ovariectomy of
rats at 3 weeks of age increased aortic synthesis of
6-keto-PGF t (x as an adult. Deprivation of ovarian steroid
hormones may therefore have an inhibitory effect on
vascular PGs but the effect is a long-term, as opposed to
a short-term, effect on PG production, as short-term
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treatment with steroids did not
ovariectomy.
reverse the effects of
7.2 Vascular PG production in hypertensive rats.
Homogenates of aorta from normotensive and hypertensive
male rats synthesised mainly 6—keto—PGF loc with less PGE2
and PGF2CC, whereas homogenates of vena cava synthesised
6-keto-PGF1K and PGF2CC in similar quantities, with less
PGE2. There was no difference in 6—keto—PGF1K or PGE2
synthesis in homogenates of aorta or vena cava in
normotensive compared to GH rats. However, PGF2a
production was significantly greater by homogenates of
aorta, and tended to be greater in homogenates of vena
cava from normotensive than GH male rats. The synthetic
capacity of the adventitia for PG production was low in
both GH and normotensive rats and the 3 PGs were produced
in similar amounts, suggesting that PG production by the
adventitia is of little importance in the regulation of
blood vessel tone. The smooth muscle layer however, was
almost as active as the endothelium in its ability to
produce PGs when the results were expressed as production
by the total layer. The total amounts of 6-keto-PGFtw
synthesised by the separate layers were in the order of
smooth muscle > adventitia > endothelial cells except in
male hypertensive rats where 6-keto-PGFtK synthesis by
the adventitia and endothelial cells was similar. The
total amounts of PGF2K and PGE2 synthesised were also in
the order of smooth muscle > adventitia > endothelial
cells. However, the endothelium constitutes approximately
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2% of the total aortic tissue meaning that the synthetic
capacity for 6-keto-PGFtK, PGF2a and PGE2 is 3-30 fold
higher in the endothelial cells than in the adventitia or
smooth muscle of all groups of rats. This is in agreement
with the findings of Moncada et al. (1977), using
separated layers of rabbit aorta, where PGI2 generation
was highest at the intimal surface and progressively
decreased towards the adventitial surface.
Notwithstanding, the production of PGs may be an
important function of smooth muscle in vivo.
The observation of greatest interest was the finding that
the smooth muscle layer of hypertensive males produced
significantly more PGF2K than the smooth muscle layer
from normotensives. This finding of the difference in
the metabolism of AA in the aorta of hypertensive rats
has not been reported before. There was a concomitant
decrease in the production of 6-keto-PGFiK in the smooth
muscle layer from GH male rats. The endothelial cell
layer from GH rats also produced significantly greater
amounts of PGF20C then normotensives but as PGE2
production was at the same time decreased, it is not
possible to discount that the increased amount of PGF2K
measured was due to increased activity of
9-PGE2-ketoreductase in GH rats, thus increasing
conversion of PGE2 to PGF20C. There was no difference in
the output of 6-keto-PGFja or PGE2 from the isolated
aorta between the two groups of male rats. However, the
release of PGF2K from the aorta of GH rats was markedly
increased (3-fold) compared to normotensives and this was
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possibly a reflection of the increased synthetic capacity
of the aortic smooth muscle and endothelium from
hypertensives to produce PGF20C.
The capacity of the smooth muscle and endothelial cell
layers for 6-keto-PGF loc and PGE2 synthesis was
significantly lower in hypertensive than in normotensive
female rats, yet the basal release of 6-keto-PGF t, PGF2CC
and PGE2 from the perfused aorta were all higher in the
hypertensive state. Although GH females were similar to
GH males in releasing greater amounts of PGF20C from the
aorta it is possible that the concomitant increase in
PGI2 and PGE2 output compensates for the increase in
PGF2cc, assuming they can all affect the smooth muscle
layer.
Similar to the observations made using homogenates of
aorta, 6-keto-PGFtK release from the intact aorta was not
different between normotensive and GH rats. This is not
in agreement with the findings of Okuma et al., (1980)
and Pace-Asciak et al. (1978) using aortic rings from
SHE, or of Botha et al., (1980) using aortic strips from
the GH strain of hypertensive rats. However, the
spontaneous release of PGI2 from aortic rings or strips
is probably due to the metabolism of arachidonic acid
released by PLA2 from the damaged cells, and therefore
may reflect the ability of the damaged tissue to
synthesise PGI2, rather than the true basal rate of
synthesis. If the increased output of PGI2 in the
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hypertensive state were a compensatory measure to
alleviate the increased peripheral resistance
characteristic of hypertension, as suggested by some
authors, it seems inappropriate that such an obviously
ineffective measure would be adopted by the body!
Conversely, the increased PGI2 output observed in the
vasculature of hypertensive rats could be secondary to
the mechanical effect of a raised blood pressure (as
discussed in the General Introduction).
However, unlike the majority of work on blood vessels
from hypertensive rats, an increase in either the
production or basal release of PGI2 (measured as
6-keto-PGF!K) was not observed from the vessels of GH
rats. However, the most marked difference between the
two groups of male rats was the increased production of
PGF2cc by:- (i) homogenates of whole aorta, (i i)
homogenates of smooth muscle, (iii) the endothelial cell
suspensions, and the increased basal output of PGF2CC from
the perfused aorta and mesenteric arterial bed of
hypertensives compared to normotensives. The increased
production of PGF2K by homogenates of aorta from male
hypertensive rats was not due to its decreased
metabolism, conversion of PGF20C to its
13,14-dihydro-15-keto-PGF2K and 15—keto—PGF2 K metabolites
being similar in normotensive and GH rats. Female
hypertensive rats however, showed a decreased production
of both 6—keto—PGF 1<x and PGF2CC by the smooth muscle and
endothelial cell layers but an increased production of
PGE2 compared to normotensives. In contrast to the
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synthetic capacity of homogenates, the basal output of
PGF20C was greater by the perfused aorta and mesenteric
bed of hypertensive than normotensive females.
Since the discovery of PGI2 and its being 'labelled' as
the major and most important product of AA metabolism in
blood vessels, PGF20C and PGE2 have either been ignored or
deemed unimportant. Yet, both of these PG's have potent
effects on blood pressure. In the rat and dog PGF20C is
pressor; intra-arterial administration of PGF2a increases
vascular resistance, reportedly through a selective
venoconstrictor action (DuCharme and Weeks, 1967;
DuCharme et al., 1968). In the micro-circulation of the
cat (pial vessels), topical administration of PGF20C
produces significant arterial constriction (Welch et al.,
1974), and in the rat, arteriolar constrictor responses
to PGF20C have been observed in the mesocaecum (Vignera et
al., 1969) and cremaster muscle (Ellis and Hutchins,
1974).
The observation that PGF2K release was greater from the
mesenteric bed of hypertensive male and female rats
compared to their normotensive controls is of
considerable interest in relation to the potent
vasoconstrictor actions of PGF2K. In the dog, PGF2CC is a
potent mesenteric vasoconstrictor (Chapnick et al.,
1978). It also enhances the vasoconstrictor response
following nerve stimulation (Hedquist, 1976) and there
are reports that All induces the release of PGF2CC from
the canine kidney (Dunn, Liard and Dray, 1978). Thus,
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although there was no actual stimulation of PGF20C release
in the mesenteric bed of hypertensive rats after NA and
All, the observation that PGF20C was always present in
higher amounts in these animals may be of relevance to
the greater pressor response found in these animals.
7.2.1 Effects of NA and All on PG release from the
mesenteric arterial bed.
In agreement with previous studies, NA stimulated PGI2
output and, to a lesser extent, PGE2 output from the
mesenteric arterial bed of normotensive and hypertensive
male rats (Pipili and Poyser, 1982; Desjardins-Giasson et
al., 1982). The present study has shown that NA will
stimulate also the release of PGI2 and, to a lesser
extent, PGE2 from normotensive and GH female rats. The
potent vasodepressor actions of PGE2 are well documented
but the effects of PGE2 are not universally vasodepressor
in different vascular beds of the rat. In the splenic
vasculature and cremaster muscle, PGE2 produces
vasodilation (Malik, 1979; Messina et al., 1974) but the
situation in the kidney is less clear. Inhibition of PG
synthesis produced vasoconstriction, suggesting that an
influence of vasodilator PGs had been reduced (Dusing et
al., 1977), but direct administration of PGE2 into the
rat kidney increased vascular tone (Malik and McGiff,
1975; Gerber and Neis, 1979). In the rat mesenteric
arterial bed and hind limb, PGE2 potentiates and PGI2
attenuates the pressor response to NA whereas, in the
splenic artery, PGI2 and PGE2 both attenuate the effect
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of NA (Kondo, Okuno, Suzuki and Saruta, 1980). In
contrast, PGE2 attenuates the pressor response of NA in
the mesenteric arterial bed (Malik, Ryan and McGiff,
1976). PGE2 is believed to act by reducing the amount of
transmitter released, whereas PGI2 does not act in this
way and probably has a direct action on myogenic tone.
In vivo, the systolic and diastolic blood pressure
responses to NA were significantly potentiated in
anaesthetised rats treated with aspirin or indomethacin.
The infusion of PGI2 counteracted this aspirin or
indomethacin induced potentiation of blood pressure
responses to NA (Fischetti, Carmignani, Marchetti,
Ranelletti and Caprino, 1980)
In agreement with previous studies, All increased the
release of PGI2, and to a lesser extent, PGE2 from the
mesenteric arterial bed of normotensive male rats
(Dusting et al., 1981; Nolan et al., 1981;
Desjardins-Giasson et al., 1982). In contrast, All failed
to increase PGI2 or PGE2 output from the mesenteric bed
of hypertensive male rats and the pressor response to All
was higher in the mesenteric bed of hypertensive compared
to normotensive male rats. The importance of this finding
in relation to hypertension remains to be established.
The results from the female rats make interpretation of
these findings more difficult, as the higher dose of All
stimulated PGI2 output in female hypertensive rats, and
tended to stimulate PGI2 output in female normotensive





Studies using cyclooxygenase inhibitors in rabbits and
sheep have indicated that the pressor effect of All is
normally attenuated by PGs released in response to All
treatment (Blumberg et al., 1977; Beilby, Coghlan,
Denton, Graham, Humphrey, Scoggins and Whitworth, 1981;
Rave and Nasjletti, 1983). In All-induced hypertension in
the rat, systolic blood pressure was positively
correlated with both plasma 6-keto-PGFtK concentration
and the amount of 6—keto—PGF loc released from rings of
aorta (Diz, Baer and Nasjletti, 1983). Therefore, the
results from male hypertensive rats are suggestive of an
involvement of the lack of vascular PGI2 in response to
All being causal in the raised blood pressure
characteristic of these rats. The results of this study
have demonstrated that when there was a stimulation of PG
release by either NA or All, it was the concentration of
6-keto-PGFiK in the perfusion fluid which increased
whereas PGE2 and PGF2C( did not change significantly,
except for a significant stimulation of PGE2 output in
normotensive males by All.
It remains to be established if the conversion of PGI2 to
the longer acting 6-keto-PGEj is important for the
actions of PGI2 in vivo. It would be extremely
interesting to measure either the conversion of PGI2 to
6-keto-PGEt by liver and platelets, or the actual levels
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of 6-keto-PGEt present in the liver and plasma of
hypertensive rats to determine whether the increased, or
similar levels of PGI2 in the hypertensive state in the
face of an elevated blood pressure is due to the absence
of conversion of PGI2 to 6-keto-PGE!.
7.2.2 Effects of diet and sodium intake on vascular PG
production.
Although PGE2 and PGF20C have frequently not been measured
in studies of vascular PG production, there is some
evidence from the literature that the output of these two
PGs, particularly PGF20(, is altered in humans with
essential hypertension and in rat models of hypertension.
The release of PGE2 from renal medullary tissue of SHR
was found to be raised during the pre-hypertensive and
early hypertensive stages, but decreased later with the
further development of hypertension. The release of PGF20(
from renal tissue of SHR also tended to be higher than
controls, but this difference was not significant (Ozawa,
Kan, Konishi, Kitayima and Matsomura, 1982). The output
of PGF2C( from the kidney is higher than normal in humans
with essential hypertension (Weber et al., 1979) and is
raised even higher if the patients are given an acute
sodium load (Neri Serneri, Castellani, Scarti, Trotta,
Sciagra and Masotti, 1985). In the SHR an increased renal
PGF2k formation was found even before overt hypertension
had developed (Ahnfelt-Rohne and Arrigoni-Martelli,
1978). PGE2 output however, did not change. These
observations made using the kidney from hypertensive rats
and the findings made using the aorta in the present
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study, support the idea that an alteration in the pathway
of PG formation from PGE2 to PGF20C may lead to an
increase in blood pressure, and that it is the ratio of
these PGs that is critical for blood pressure control
rather than the absolute amounts of vasodilator PGs.
Further support for this hypothesis has come from studies
of dietary fatty acid manipulation. Compared with a
linoleic acid-rich diet, a linoleic acid-deficient diet
produced an increase in the blood pressure of
normotensive salt-loaded rats. This increase in blood
pressure was associated with a reduction in renal and
aortic PGE2 formation, with little change in the
formation of PGF20C, thus leading to an increase in the
PGF2cc:PGE2 ratio (Hoffman, Taube, Ponicke, Zehl, Beitz,
Forster, Somoa, Orbetzova and Davidova, 1982). The enzyme
9-PGE2-ketoreductase is responsible for the conversion of
PGE2 into PGF20( and it is possible that it is the
increased activity of this enzyme that is causing the
shift in PG production away from PGE2 towards PGF20C
(Ziboh et al, 1977). After salt-loading, Weber et al.,
(1977) and Scherer, Siess and Weber (1977) found an
increased activity of the 9-PGE2-ketoreductase in the
kidney of rabbits. It appears that there is a marked
stimulation of this enzyme when the two treatments,
1inoleic-acid deficiency and salt-loading are
administered concomitantly. Interestingly, blood pressure
could be reduced in linoleic acid deficient salt-loaded
animals by injection of gold salts, which selectively
inhibit the synthesis of PGF20C and stimulate that of PGE2
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(Hoffman and Forster, 1981; Stone, Kather and Gipson,
1975). In a similar study, a linoleic acid-deficient
diet was again found to produce an increase in the blood
pressure of normotensive rats and a decrease in the
release of PGI2 from isolated aorta and a secondary rise
in plasma TXA2 (measured as TXB2) concentration (Duesing,
Scherhag, Glaenzer, Budde and Kramer, 1983). Conversely,
dietary deprivation of linoleic acid in SHR induced a
reduction in blood pressure compared to SHR fed a high
linoleic acid diet (Mogenson and Box, 1982).
A high sodium chloride diet produced a sustained and
significant increase in PGI2 formation (measured as
urinary 2,3—dinor-6-keto-PGF,K) in the Dahl
salt-resistant strain of rats, which remained
normotensive. Salt-loading in the Dahl salt-sensitive
rats however, produced a slight decrease in PGI2
production and a gradual increase in the blood pressure
of these rats (Falardeau and Martineau, 1983). In the
mesenteric arterial bed of rabbits, chronic sodium
loading caused a significantly smaller release of PGI2
following All stimulation, and vasoconstrictor responses
to All were greater in the high sodium group (Miyamori,
Yasuhara, Ikeda, Koshida, Takeda, Morise, Takimoto and
Takeda, 1983).
7.2.3 Possible alteration in vascular AA metabolism in
hypertension.
The vasodepressor actions of AA are enhanced in both SHR
and IK, 1C hypertensive rats (Dusting, Di Nicolantonio,
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Drysdale and Doyle, 1981; Dusting* Dickens, Di
Nicolantonio and Doyle, 1984). The increased efficiency
of the CO pathway in these 2 models of hypertension
perhaps results from a more fundamental defect in AA
metabolism. This could be a defect in the liberation of
AA from membrane phospholipids, or possibly reduced
incorporation of AA in these stores. The observation that
increasing linoleic acid, the precursor of AA, in the
diet reduces blood pressure is in agreement with the
hypothesis that AA in membrane phospholipids may be
reduced in the hypertensive rat. In agreement with this
hypothesis is the observation that daily s.c. injections
of AA significantly retarded the development of
hypertension in SHR, but did not alter the normal
age-related increase in blood pressure of normotensive
WKY rats (Bayorh, Zukowska-Grojec, Ezra, Feuerstein and
Kopin, 1983). There is very little information in the
literature on the fatty acid content of blood vessels,
although it has been shown that supplementation of
cultured bovine and human endothelial cells with linoleic
acid actually reduced the AA content of phospholipids,
leading to a decrease in PGI2 production (Kaduce, Spector
and Bar, 1982; Spector, Hoak, Fry, Stoll, Tanke and
Kaduce, 1981). These findings suggest that endothelial
cells are not able to convert linoleic acid to AA and
that the mechanism of the protective effect of a linoleic
acid diet on the development of hypertension requires
further study. It remains to be established whether the
AA content of endothelial cell and smooth muscle cell
phospholipids is deficient in hypertensive rats compared
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to normotensive rats, and if this is the case, whether
the deficiency is due to a fault in the uptake mechanism
for AA.
The majority of studies regarding hypertension and
vascular PG production have been carried out on the
2-series of PGs. An alternative suggestion for the
involvement of PGs in the aetiology of hypertension is
suggested by the work of Tan and Mutrow (1976). These
authors found an impairment in the renal production of
PGE j in SHR; PGEj synthesis increased spontaneously in
the control WKY strain at about 4 months of age but there
was no such increase in the kidney of SHR. In the
isolated mesenteric vascular bed of SHR, low
concentrations of zinc chloride (Zn) potentiated pressor
responses to NA in SHR and normotensive WKY, but at
higher concentrations Zn inhibited responses to NA in
WKY, but not in SHR. (Mtabaji, Kihara and Yamori,
1985). Since the effects of Zn may be mediated via
release of dihomo-gamma-linolenic acid (DHLA; the
precursor of the 1- series PGs) and PGEt has biphasic
effects on vascular reactivity, enhancing at low doses
and depressing vascular reactivity at higher doses, it is
possible that Zn is acting through the release of DHLA
and its subsequent conversion to PGEt (physiological
concentrations of PGEt are generally vasodepressive).
Significant quantities of dihomo-gamma-linolenic acid
have been found in cultured human endothelial cells
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(Rastogi and Nordoy, 1980; Spector, Hoak, Fry, Denning,
Stoll and Smith, 1980; Marcus, Broekman, Weksler, Jaffe,
Safier, Ullman, Islam and Tack-Goldman, 1981) so
theoretically PGEt can be synthesised by these cells. It
has been shown that basal levels of human platelet PGEs
and PGE2 are very low but that the amount of PGE , is
about 4 xs higher than PGE2 (Lagarde, Guichardant and
Dechavanne, 1981). This suggests that although it is
generally accepted that the 2-series PGs predominate over
the 1-series PGs due to the much greater levels of AA in
membrane phospholipids compared to DHLA, it is possible
that under normal conditions PGEt is released tonically
by both blood vessel wall and platelets to maintain
vascular tone and normal blood flow, and it is only when
a stimulus such as injury is present that the more potent
anti-aggregatory PG, PGI2 is released. If this is the
case, more studies are required to establish if there is
a more generalised reduction in PGEt production
throughout the vasculature of hypertensive rats, not just
in the kidney, and also if possible to determine the
plasma and urinary concentrations of PGEt in essentially
hypertensive patients. Indeed, it was suggested a number
of years ago that DHLA might have potential as an
antithrombotic agent. DHLA supplementation in human
volunteers produced an increase in the proportion of DHLA
relative to AA in plasma and platelets, decreased plasma
heparin-neutralising activity and caused an inhibition of
ADP-induced aggregation (Kernoff, Willis, Stone, Davies
and McNicol, 1977). Unfortunately work in this area has
largely ceased since the advent of PGI2, and PGE,'s
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contribution to vascular homeostasis may have been
underrated.
7.3 Vascular PG production in aged rats.
Consistent measurements of systolic blood pressure were
obtained from old male rats and it was established that
the blood pressures of these old rats were significantly
greater than that of young male rats. Previous studies
have used either genetically hypertensive rats or an
experimental model of hypertension to investigate the
possible role of vascular PGs in the aetiology of
hypertension. This study has used a normal strain of rats
which, because of their advanced age, had a significantly
raised blood pressure compared to their young
counterparts. The old rats therefore, provided a model
for studying the effects of a naturally elevated blood
pressure on vascular PG production.
The most striking difference in PG production by the
aorta of old compared to young male rats was the marked
increase in the production of all 3 PGs by homogenates of
smooth muscle from old male rats. The increase in
6-keto-PGFjK production was 6-fold, the increase in PGE2
production was 3-fold, but the greatest increase was in
PGF20C production which was 8-fold. The profile of PG
production by the endothelium of old rats was also
considerably different to that of young male rats. There
was a change in the 6-keto-PGF, K : PGF20C ratio from 3.9 :
1.0 in the endothelium of young rats to 1.3 : 1.0 in the
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endothelium of old male rats. PGE2 production was not
different between the two groups. Thus, the profile of PG
production by smooth muscle and endothelium from old rats
was changed in favour of PGF2(X. In contrast, old female
rats although showing an increased production of
6-keto-PGF j K and PGE2 , showed no difference in PGF20C
production by homogenates of smooth muscle compared to
young females. The endothelial cell layer from old
females produced more PGE2 and less PGF20C than the
endothelium from young females, whereas 6—keto—PGF 1<x
production did not differ between the two groups.
However, the basal output of 6-keto-PGF10C from the
isolated, perfused aorta did not change significantly
with the increase in age in male or female rats, and in
fact tended to be higher in the aged rats. The output of
PGF20C, but not PGE2 , from the perfused aorta was
significantly higher in old male and female, compared to
young male and female rats. Similar to the situation in
the young rats, old female rats released lower amounts of
6-keto-PGFiK compared to old male rats. Paradoxically,
despite there being no difference in the production of
PGF20C by homogenates of the smooth muscle and endothelial
cell layers, there was a significant increase in the
release of PGF2K from the isolated, perfused aorta of old
compared to young female rats.
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7.3.1 Effects of NA and All on PG release from the
mesenteric bed of aged rats.
The basal output of all 3 PGs tended to be higher from
the mesenteric arterial bed of old male and female
compared to young male and female rats and this was
significant for 6-keto-PGF1K and PGE2 in old male rats.
The outputs of all 3 PGs also tended to be higher in old
males than old females and this was significant, for
6-keto-PGF t o,., at the start of the perfusion experiment.
The lower dose of NA (0.1 jig) and All (0.1 jig)
significantly increased 6-keto-PGFla output from the
mesenteric arterial bed ofold male rats, but not of old
female rats. This was similar to the situation in young
male and female rats. However, the higher doses of NA and
All (1.0 jig) increased 6-keto-PGF tK release from both old
male and old female rats. NA and All, at either dose, had
no significant effect on PGE2 or PGF2(X output from the
perfused mesenteric bed of old male and female rats. NA
and All both produced an increase in the perfusion
pressure of the mesenteric bed, with NA producing the
greater increases. The NA-induced changes in perfusion
pressure (expressed as a percentage) were significantly
greater, at both doses, in old compared to young male
rats. There was no significant difference in the pressor
response to All when comparing young and old female rats.
There is very little information in the literature on PG
formation by the vasculature of aged animals. Two
previous studies, one using normotensive rats and the
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other one using SHR have shown that PGI2 generation by
homogenates of aorta and by intact aorta increases up to
20 weeks of age (Panganamala et al., 1981; Pace-Asciak
and Carrara, 1979). In a study on genetically obese rats,
PGI2 release from aortic rings was greater in rats of
14-16 months compared to rats of 6-8 months of age
(Landgrof-Leurs, Loy, Christea, Weber, Seiss, Herberg and
Landgrof, 1981). However, another study showed that there
was no difference in the release of PGI2 from the aorta
of 15 month and 3 month old male rats (Suzuki, Kobayashi,
Hayawaka and Wado, 1985). In vitro, Chang et al., (1980)
found that cultured smooth muscle cells from old rats
produced less PGI2 than those from young animals.
However, a later study by the same authors, Chang et al.,
(1983), showed that PGI2 release from aortic rings of
mature (12 months) rats is increased compared to young (2
month) rats, but is significantly decreased in senescent
(24 months) rats compared to young rats. So the rats used
in the present study are comparable to the mature rats
used in the study of Chang et al., (1983) and show a
similar trend in producing greater amounts of
6-keto-PGFtK from the aorta than young male rats. It is
not possible to comment on the increased production of
PGF20C by the aorta of old male rats in the present study
as this PG was not measured by the previous authors.
Thus, the evidence to date suggests that PGI2 production
by the aorta of the rat increases from an early age until
it reaches a peak at about 'middle-age' whence it
declines towards senescence. The mechanism of this
bell-shaped curve of vascular PGI2 generation with age
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remains to be established. It is possible that the amount
of PGI2 released from a blood vessel is a function of the
mechanical effect of an increase in blood pressure with
increasing age.
7.3.2 Possible effects of a reduction in anti-oxidant
state with age.
Lipid peroxidation induced by free radical formation is
known to occur in vitamin E deficiency, in the ageing
process and possibly also the hyper1ipidaemia of
atherosclerosis (Slater, 1972). It is well known that
lipid peroxides are perhaps the most selective and
effective inhibitors of PGI2 formation by blood vessel
microsomes or by fresh vascular tissue (Bunting et al.,
1976; Salmon et al., 1978). It is possible therefore,
that if there is a potent inhibitory effect of lipid
peroxides on PGI2 synthetase, the endoperoxide PGH2 might
be redirected into the pathways for PGF20C and PGE2
synthesis. The accumulation of lipids in atherosclerotic
plaques could contribute to the formation of lipid
peroxides. Furthermore it has been shown that there is a
positive correlation between the apparent increased
levels of lipid peroxides and the severity of
atherosclerotic lesions (Glavind, Hartmann, Clemmesen,
Jessen and Dam, 1952). High serum levels of low-density
lipoproteins (LDL) contribute to the process of
endothelial injury and they may also be mitogenic and
contribute to the formation of the atherosclerotic
plaque. Moreover, LDL has been found to inhibit PGI2
synthesis by human endothelial cells in culture (Nordoy,
- 318 -
Svensson, Wiebe and Hoak, 1978). Conversely,
high-density lipoproteins (HDL) have been correlated in
epidemiological studies with a decreased incidence and
progression of atherosclerotic disease and this has been
suggested to be due to their ability to transport
cholesterol away from aortic smooth muscle cells in
culture, indicating their possible action in vivo. A
negative correlation was found between the activity of
the PGI2 synthetase and the amount of LDL cholesterol;
the reverse was true for HDL cholesterol (Beitz and
Forster, 1981). Interestingly, these authors found that
LDL cholesterol had less of an inhibitory effect, and HDL
cholesterol a greater stimulatory effect on porcine aorta
PGI2 synthetase, from female compared to male subjects
(Beitz and Forster, 1981). These results suggest that the
difference in the risk of cardiovascular disease and
thrombosis between men and women despite similar plasma
concentrations of lipoproteins (Gordon, Castelli,
Hjortland, Kannel and Dawber, 1977) may be related to a
differential effect of the lipoproteins isolated from
women and men on blood vessel PGI2 synthetase.
Further support for the involvement of lipid peroxides in
PG metabolism comes from the results of studies on
vitamin E and selenium, two components of the antioxidant
potential of plasma and tissues. Vitamin E inhibits
lipid peroxidation, whereas selenium acts indirectly as
an antioxidant through its incorporation into the enzyme,
selenium-dependent glutathione peroxidase
(GSH-peroxidase). This enzyme catalyses the reduction of
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lipid hydroperoxides formed from PUFAs and thus has an
important role in the detoxification and protection of
cell membranes against oxidative damage. The formation
of PGI2 by rat or rabbit aorta has been shown to decrease
when vitamin E is low or absent from the diet (Chan and
Leith, 1981; Karpen, Merola, Trewyn, Cornwell and
Panganamala, 1981; Chan, Pritchard and Choy, 1983). One
could speculate that a decrease in vitamin E levels with
age could be responsible for the decrease in blood vessel
PGI2 production via increased production of lipid
hydroperoxides exerting an inhibitory effect on PGI2
synthetase. Unfortunately, because of the large overlap
in the values of human vitamin E levels measured in
different age groups by different workers, it is not
possible to say whether vitamin E levels decrease with
age or not (for review see Farrell, 1980).
7.4 Human vascular PG production.
The patients used in this study of human vascular PG
production were taking a large and varied range of
medications making the analysis of the effects on PG
production rather complex. However, the use of the
different drugs was distributed randomly amongst the age
groups and amongst smokers, ex-smokers and non-smokers,
so these parameters should not have affected the results
regarding drug treatment and vice versa. The effects of
different drug treatments had no effect on the production
of PGF2cc or PGE2 by homogenates of aorta or saphenous
vein, and had rather varied and inconsistent effects on
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6—keto—PGF 10( production by homogenates of male and female
aorta and saphenous vein.
7.4.1 Male and female differences in vascular PG production
The profile of PG production by blood vessels of female
subjects was slightly different from that of the males.
As was observed for males, the aorta from females
produced similar amounts of the three PGs. The profile
of PG production by the saphenous vein of females was
more complex with differences being found in different
age groups. In the 41-50 age group, PGF20C was the major
PG produced with lesser amounts of 6-keto-PGF10C and PGE2 ;
in the 51-60 age group, 6—keto—PGF lc< was the major PG
produced with lesser amounts of PGF20C and PGE2 ; and in
the 61-70 age group, PGF2K was the major PG produced with
lesser amounts of 6-keto-PGF,a and PGE2. These
differences in the profile of PG production reflected
significant differences in 6-keto-PGFjK production with
age; the veins of women aged 51-60 produced significantly
more (P<0.01) 6—keto—PGF lcc and significantly less
(P<0.01) PGF20c compared to the veins of women aged 41-50
or 61-70 years of age. There was a change in the
6-keto-PGFto PGF2K ratio from 2.07 : 1.0 in the 51-60
age group to 0.34 : 1.0 and 0.45 : 1.0 in the 41-50 and
61-70 age groups respectively. PGE2 production did not
vary significantly with age. There were no significant
differences in the production of the 3 PGs by homogenates
of aorta with age.
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Comparing males and females in the same age group there
was no significant sex difference in the aortic
production of 6-keto-PGF loc, PGF20( or PGE2 . There were
significant differences however, in the production of
6-keto-PGFjK, with females in the 41-50 age group
producing smaller (P<0.01) amounts of 6-keto-PGFjK from
vein homogenates than males in the same age group. But,
females in the 41-50 and 61-70 age groups produced
significantly (P<0.01) more PGF2K from vein homogenates
than males in the same age groups. There was no
significant difference in the production of PGE2 by veins
of males compared to females.
7.4.2 Effects of age on vascular PG production.
There were no significant differences in PG production by
homogenates of aorta and vein when comparing the age
groups although there did appear to be a trend towards
increased production of 6-keto-PGF!a by aorta and vein
with increased age. There was also a trend towards
decreased production of both PGF2K and PGE2 by the aorta,
but not by the vein with increasing age.
6-Keto-PGFj« was the major PG released in all age groups
of male subjects followed by lesser and approximately
equal amounts of PGF2K and PGE2. There was a decline in
the release of all 3 PGs in the 61-70 compared to the
41-50 years age group; this was not significant for
6-keto-PGF i« or PGF20( but was significant (P<0.05) for
PGE2 . 6-Keto-PGF j oc was also the major PG released by
- 322 -
saphenous vein of females with lesser and similar amounts
of PGF2K and PGE2. Because of the small number of female
subjects it was not possible to determine if there were
any age differences in PG production. The only sex
difference apparent in the release of PGs was in the
61-70 years age group where the vein from females
released significantly (P<0.05) greater amounts of PGF20t
than the males.
The results of the present study do not show any
significant differences in the production of 6-keto-PGFta
by aorta or vein of male subjects with age which is in
agreement with the findings of Ylikorkala et al. (1982)
where plasma 6-keto-PGFja levels did not change over the
same age range as studied here. Because there were only 2
males in the 71-80 age group in this study it is not
possible to say if the reduced production of 6-keto-PGFtK
and PGF20t by aorta and vein was a definite trend. There
was a significant (PC0.05) decrease in the release of
PGE2 from venous rings of males aged 61-70 compared to
males of 41-50 years. Because there were only 2 males and
2 females aged 70 years or more it was not possible to
comment on these results with reference to the findings
of Ylikorkala et al. (1982), where plasma 6-keto-PGFxK
levels were higher in females over 70 years compared to
males of the same age. However, the plasma levels of
6-keto-PGFjK measured in the former study by RIA (80-120
pg/ml) are considerably higher than the values obtained
using GC-MS and the validity of the results obtained by
RIA could be questioned.
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It must be remembered in considering the results of these
experiments that these patients have both essential
hypertension and coronary heart disease and are not a
normal population. Mehta, Mehta and Horalek, (1983) found
that patients with coronary artery disease showed
abnormally high plasma levels of TXB2 and considerably
lower levels of 6-keto-PGF4K in response to exercise
compared to healthy controls, although resting plasma
TXB2 and 6-keto-PGF1K levels were comparable in the two
groups of subjects. Using RIA, Uehara, Ishii, Ikeda,
Atarashi, Takeda and Murao, (1983) found that essentially
hypertensive patients had significantly lower plasma
6-keto-PGFiK levels than controls and that there was a
significant negative correlation between 6-keto-PGF,K
levels and systolic, diastolic and mean blood pressures
in both hypertensive and control subjects.
These results suggest that PGI2 may be important in the
control of blood pressure in humans and that a deficiency
both in basal levels and in the response to NA (Ishii et
al., 1982) could be important in the pathogenesis of
hypertension in humans. The findings of the present study
are largely in agreement with those of Hanley and May
(1985); segments of saphenous vein from patients
undergoing surgery for varicose veins did not show any
significant difference in the basal output of PGI2 with
respect to age, sex or smoking habits. It is unfortunate
that the saphenous vein is the blood vessel most commonly
available to researchers for the study of human vascular
PG production as it is atypical in its response to PGI2,
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which causes vasoconstriction rather than vasodilation,
as it does in the majority of blood vessels studied
(Levy, 1978). This vessel therefore, being atypical in
its response to PGI2, may not be typical of the rest of
the human vasculature in its ability to synthesise PGs.
7.4.3 Effects of smoking on vascular PG production.
This study has shown that homogenates of saphenous vein
from smokers and ex-smokers produced 20% less
6-keto-PGF1K than those from non-smokers, although this
reduction was significant only for ex-smokers. There was
also a significant reduction in the production of PGF20C
by homogenates of saphenous vein from ex-smokers and a
significant reduction in the production of PGE2 by
smokers compared to non-smokers. Rings of saphenous vein
from smokers or ex-smokers also released smaller amounts
of the 3 PGs than non-smokers but this was significant
only for PGF20C. Interestingly, reduced PG production by
saphenous vein was not seen in female patients, although
PG release from venous rings did appear to be greater in
non-smokers. It is not possible to say if this is a
genuine difference in the response of male and female
vascular tissue to cigarette smoke because the number of
female subjects was rather small. Thus, overall, smoking
appears to cause an inhibition in the capacity of the
saphenous vein to produce PGs and it is interesting to
note that this inhibitory effect is apparent in the
vessels of males who had not smoked, in the majority of
cases, for over a year. More work is required to
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establish the cause of this long-term inhibitory effect
of cigarette smoke on blood vessel AA metabolism, and the
component or components of smoke which are responsible
for this potentially detrimental influence on blood
vessel homeostasis.
PGI2 production by cultured endothelial cells from
umbilical veins of mothers who smoked was markedly
reduced compared to endothelial cells from matched
mothers who did not smoke. Interestingly, the
endothelial cells from mild (< 15/day) and heavy (>
15/day) smokers were significantly less able to grow and
reach confluency than cells from non-smokers (Busacca,
Balconi, Pietra, Vergara-Dauden, De Gaetano and Dejana,
1984). However, cord blood platelet aggregation and
thromboxane production, in response to ADP and collagen,
were not significantly different in infants born to
mothers who smoked compared to infants born to mothers
who did not (Ahlsten, Ewald, Kindahl and Tuvemo, 1985).
Wennmalm and Alster (1983) have proposed that the
inhibitory effect of cigarette smoke on PGI2 production
is due to the presence of nicotine. Nicotine, in vitro,
dose-dependently inhibited the amount of PGI2-like
activity released from rings of rabbit aorta. In further
studies involving the incubation of slices of rat aorta
with [14C]-AA in the presence of nicotine, it was found
that nicotine competitively inhibited the formation of
[14C]-6-keto-PGFjK. The formation from [14C]-PGH2 was not
affected, indicating that the inhibitory effect of
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nicotine was on the cyclooxygenase rather than PGI2
synthetase (Wennmalm and Alster, 1983). Extending these
studies, Wennmalm (1983) established that although
vascular PGI2 formation was inhibited by nicotine, TXA2
formation by platelets was not affected, thus pushing the
system further in the pro-aggregatory direction. In an
acute study, the smoking of nicotine-containing
cigarettes, but not of nicotine-free cigarettes,
decreased urinary 6—keto—PGF 1({ in smokers but not in
non-smokers (Nadler, Velasco and Horton, 1983). Other
authors have failed to find an effect of nicotine on
vascular PGI2 production. In the pre-labelled ([14C] AA)
isolated, perfused rabbit ear nicotine failed to affect
the basal release of AA or PGs, but strongly inhibited
the histamine-stimulated release of PGI2 and PGE2 (Juan,
1981). Incubation of cultured umbilical vein endothelial
cells with cigarette smoke condensate impaired basal and
phorbol myristate acetate stimulated PGI2 release, but
these effects could not be attributed to nicotine or
cadmium. Furthermore, the production of PGI2 from
exogenous AA was not affected by cigarette smoke
condensate, suggesting that the inhibitory effects were
not at the level of cylcooxygenase or PG synthetase
(Reinders, Brinkman, Mourik and van de Groot, 1986).
Cigarette smoke extracts also inhibited PGI2 synthesis by
human artery, rabbit and rat aorta and lung but the
inhibitory effect was not due to nicotine (Jeremy,
Mikhailidis and Dandona, 1985). Similarly, nicotine had
no effect on the metabolism of exogenous AA or PGE2 in
isolated, perfused hamster and rat lungs (Mannisto,
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Puustinen and Uotila, 1984). Another major component of
cigarette smoke, carbon monoxide, had no significant
effect on the metabolism or distribution of [14C] AA in
hamster lung (Mannisto, Puustinen and Uotila, 1984).
Furthermore, neither nicotine nor pretreatment with
carbon monoxide decreased PGI2 production by rat aortic
rings, and neither compound had a direct effect on
ADP-induced aggregability of human PRP (Hartiala,
Simberg, Uotila, 1982). In the present study, the
depression in the production of all 3 PGs by saphenous
vein of males who had smoked or were currently smoking
compared to non-smokers does support the hypothesis that
some factor from cigarette smoke, possibly nicotine,
supresses cyclooxygenase activity. Thus it remains to be
established which factor, or combination of factors, from
the 3000 different compounds present in cigarette smoke
are responsible for the effects of smoking on vascular PG
synthesis.
Of interest, particularly to the advocates of the dangers
of passive smoking (ie the effects of smoke from
cigarette smokers on non-smokers) is the finding that in
a model of passive smoking, rats inhaling sidestream
smoke, there was a dose-related increase in platelet TXA2
production and a maximum decrease in aortic PGI2
synthesis at the lowest level of sidestream smoke (which
has 3xs more carbon monoxide and nicotine than mainstream
smoke). The decrease in aortic PGI2 synthesis was more
sensitive to both mainstream and sidestream smoke than
the increase in platelet TXA2 (Lubawy and Valentovic,
1985).
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7.4.4 Effects of different drug treatments on vascular
PG production.
Of the drugs being taken only calcium antagonists
(nifedipine and verapamil) affected the production of
6-keto-PGFtK in male patients, increasing 6-keto-PGFtK
production by homogenates of aorta but not of saphenous
vein. In female patients 6-keto-PGF,K production was
increased in homogenates of aorta by ^-adrenoceptor
blocking agents, and increased in homogenates of
saphenous vein by nitrate vasodilators and thiazide
diuretics. 6-Keto-PGF loc production by homogenates of
aorta and saphenous vein was not affected by the loop
diuretics (frusemide and bumetanide) and did not appear
to be markedly affected by the NSAIDs although because
there were only 9 patients taking these agents it was not
possible to determine significance in this instance.
The observation that p-adrenoceptor drugs increased
6-keto-PGFjK production by homogenates of female aorta
agrees with the findings of Srivistava et al. (1983) who
found that labetalol increased the synthesis of PGI2 from
exogenous labelled AA in rat aorta and also enhanced the
synthesis of PGI2 from endogenous AA. Brandt, Seppala,
Nowak and Vapaatalo (1984) found that an i.v. dose of
propranolol in human subjects increased plasma
6-keto-PGF!K and PGE2 but 2 other /-blockers, practolol
and atenolol were without effect on plasma 6-keto-PGFj^
or PGE2. This observation may be of relevance to this
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study as a large number of the patients were taking
atenolol.
Nitrates produced a similar effect to ^-blockers with
respect to PG production. Males taking nitrates did not
show any significant difference in vascular PG production
but the saphenous vein from females taking nitrates
produced significantly (P<0.05) greater amounts of
6-keto-PGFtK than females who were not taking this
treatment. Glyceryl trinitrate (GTN) has been shown to
stimulate the production of 6-keto-PGF,K in vitro from
cultured umbilical endothelial cells (McEvoy, Patel,
Evans and Felton, 1983). At therapeutic concentrations,
GTN increased the release of 6-keto-PGF,K from human
saphenous and umbilical vein after stimulation with AA
(Mehta, Mehta, Roberts, Faro, Ostrowski and Brigmon,
1983). Another more recent study (De Caterina, Dorso,
Tack-Goldman and Weksler, 1985) showed that the basal
release of 6-keto-PGFt« from umbilical vein endothelial
cells and fragments of saphenous vein was not altered by
incubation with GTN, isosorbide mononitrate and
isosorbide dinitrate. However, using patients with
ischaemic heart disease Rolland et al., (1984) observed
that right atrial administration of isosorbide dinitrate




This study has highlighted some differences in vascular
PG production between normotensive and hypertensive rats
and has shown that there are several important
differences between the sexes. However, no difference
was observed in PG production by the aorta and vena cava
of female rats during the oestrous cycle or after
short-term ovariectomy and 2 days of oestrogen and
progesterone treatment. Further study is required to
establish the reason for these observed differences in PG
production in female rats.
The observation of greatest interest was that the
vascular capacity for the synthesis of the
vasoconstrictor, PGF2K, was greater in hypertensive than
in normotensive rats of both sexes and this was reflected
in a greater output of PGF2K from the aorta and
mesenteric bed. Regarding stimulated PG release, All
caused a significant increase in 6—keto—PGF1K release in
normotensive but not in GH rats. There was a greater
pressor response to All in the mesenteric bed from GH
rats and the absence of any increase in PGI2 release
after All may reflect a deficiency in this proposed
aspect of the control of vascular tone in the GH male
rat. However, the results from females do not agree with
this hypothesis since All stimulated 6—keto—PGF!K output
in female GH rats. The reason for this difference in
response to All in male and female rats requires further
study.
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Increase in age produced a marked stimulation in
6-keto-PGFla production by smooth muscle homogenates,
with the greater stimulation being found in male rats.
However, the basal output of 6-keto-PGF loc from the
perfused aorta did not change significantly with age, but
did tend to be greater in old male and female rats. Thus
the present study does not support the hypothesis that
the increased incidence of vascular disorders with age is
associated with a decrease in vascular PGI2 production.
Similar to the situation observed in hypertensive rats,
the production of PGF2o; by homogenates, and PGF20C output
from perfused aorta and mesenteric bed were significantly
greater in old compared to young rats. The responses to
NA and All in the mesenteric bed did not differ markedly
between old and young rats. Whether the increase in blood
pressure with age, and in the genetically hypertensive
rat, is connected with increased vascular PGF2K
production merits further investigation.
In the human study, 6-keto-PGF 4 a , PGF20( and PGE2
production by homogenates of aorta and saphenous vein
were largely unaffected by the age or sex of the
subjects. 6-Keto-PGF10C production by horaogenates of
saphenous vein was lower in male, but not female, smokers
and ex-smokers, although this was significant only for
ex-smokers. However, the basal outputs of PGs,
particularly 6-keto-PGFjK from the saphenous vein were
not affected markedly by age, sex or smoking habits.
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